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1 Introduction 
1.1 Alzheimer’s disease 
1.1.1 A century of Alzheimer’s disease 
Alzheimer’s  disease  [AD]  is  a  brain  disorder  named  after  the  German 
physician  “Dr.  Alios  Alzheimer”.  In  November  1906,  Alois  Alzheimer 
presented the case of his patient “Frau Auguste D.,” a 51-year-old woman 
brought to see him in 1901 by her family. Auguste had developed memory 
disorder,  hallucinations,  delusions  and  language  deficits.  Her  case 
deteriorated,  and  within  a  few  years  she  was  bed-ridden.  After  Auguste’s 
death in 1906, Dr. Alzheimer performed a brain autopsy and observed histo-
pathological changes which are recognized till today as typical characteristic 
features of AD. 
 
Figure 1-1 
Dr. Alois Alzheimer [1864-1915] 
Within 6 months Dr. Alzheimer presented his findings at the 37
th reunion of 
Southwest German psychiatrists meeting in Tuebingen. Sarcastic as it may 
sound,  due  to  its  “lower  importance”  only  the  title  of  Dr.  Alzheimer’s Introduction 
 
  7 
presentation was announced, with a statement between brackets declaring that 
the lecture “was inappropriate for a short presentation”. 
 
Figure 1-2 
The 11
th contribution in the Southwest German psychiatrist meeting in 
Tuebingen  
Dr. Alzheimer’s contribution in the Tuebingen meeting was briefly announced and was regarded 
unsuitable for an oral presentation. 
Although  the  disease  entered  in  1907  the  medical  literature,  the  term 
“Alzheimer’s disease” was coined by Emil Kraepelin in 1910. The importance 
of AD has increased since then and has become a major concern in the last 
decades due to its high incidence. 
            
Figure 1-3 
Auguste D [left] and Dr. Emil Kraepelin [right].Introduction 
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1.1.2 Prevalence 
Alzheimer’s disease is the most common cause of dementia which accounts 
for 60 % to 80 % of all cases. 
Dementia  is  a  clinical  syndrome  of  loss  or  decline  in  memory  and  other 
cognitive abilities. In 2005, it was estimated that there are 24 million people 
with dementia worldwide (Ferri et al. 2005). By 2040, it is anticipated that 
this figure will have increased to 81 million.  
According to the latest studies in 2005 it can be calculated that the estimated 
number  of  people  with  dementia  living  in  the  European  Union  is 
approximately 5.3 million. The estimated number of people with dementia in 
Germany  in  2005  was  1,010,245.  This  represents  1.22  %  of  the  total 
population, which is slightly higher than the EU average of 1.14 % (Ferri et 
al.  2005).  Moreover,  one  must  take  into  consideration  that  these  figures 
under-estimate  the  number  of  people  with  dementia  in  Germany,  as  it  is 
impossible to obtain sufficiently detailed population statistics of the number 
of people in Germany over the age of 94. 
A  very  recent  report  [2008]  about  AD in  the  USA shows  alerting  figures 
concerning this disease. Around 5.2 million people have AD in the USA and 
statistically calculated every 71 seconds someone in America develops AD. 
Women are more likely to develop AD than men. The reason behind this is 
most  probably  because  on  average  basis  women  live  longer  than  men, 
therefore their longer life expectancy increases the time during which they 
could develop AD.  
Despite  the  striving  of  researchers  in  finding  answers  to  diagnosis  and 
treatment of AD, one has to face the facts that the number of patients with AD 
are  unfortunately  growing  rapidly.  The  good  news  is  that  the  number  of Introduction 
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people  developing  AD  is  increasing  because  their  life  span  is  increasing, 
thanks to medicine, social and environmental conditions! 
1.1.3 Diagnosis 
Diagnosis of  AD  is complex and  can’t be  easily  distinguished  from  other 
forms  of  dementia.  The  National  Institute  of  Neurological  and 
Communicative  Disorders  and  Stroke,  and  the  Alzheimer's  Disease  and 
Related Disorders Association proposed the NINCDS-ADRDA Criteria for 
clinical diagnosis of AD in 1984. Lately, after the emergence of distinctive 
and reliable biomarkers of AD, revised diagnostic criteria for AD have been 
suggested in order to update the current criteria (Dubois et al. 2007). 
The degree of cognitive impairment can be quantified by means of cognitive 
tests. The mini-mental status examination [MMSE], the global deterioration 
scale [GDS] and the Alzheimer’s disease assessment scale [ADAS] are such 
examples of cognitive tests.  
Macroscopically AD is characterized by reduced brain weight, hippocampal 
and cortical atrophy and enlarged ventricles. A succession of neuropathologic 
diagnostic criteria for AD has been established over the past 20 years. In 1997 
a committee formed under the auspices of the national institute of aging and 
the Reagen institute, published new diagnostic criteria that included cortical 
densities  of  both  neuritic  plaques  and  neurofibrillary  tangles  (Hyman  and 
Trojanowski  1997).  The  spreading  of  AD  pathology  begins  in  the  [trans] 
entorhinal  area  of  the  basal  mediotemporal  cortex,  progressing  to  the 
hippocampus and finally to the entire neocortex with relative preservation of 
the  occipital  area  striata  (Braak  and  Braak  1991).  Hence,  the  definitive 
diagnosis of AD requires a microscopic examination of the cerebral cortex. 
Cortical  biopsy  can  provide  an  ultimate  diagnosis  but  it’s  not  a  routine 
procedure, therefore a definite AD diagnosis is obtained only post-mortem. 
 Introduction 
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Figure 1-4 
Normal brain [left] vs. Alzheimer brain [right] 
Brain from patient with AD [right] demonstrating significant cortical atrophy, widening of the sulci 
and narrowing of the gyri. Frontal and temporal lobes are more affected than the occipital lobe. 
 
Figure 1-5 
A section from normal brain [left] and one from Alzheimer’s patient [right] 
Note how much smaller is the brain on the right. The hippocampus is noticeably smaller [arrow]. 
However, it would be much more useful to be able to diagnose AD as early as 
possible [definitely not post-mortem]!  
 Present  diagnostic  measures  have  become  more  accurate  and  one  can 
nowadays  diagnose  AD,  but  unfortunately  not  before  symptoms  start 
appearing. This is not really beneficial if treatment is pathologically targeted Introduction 
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and not symptomatic treatment, since it is well known that the pathological 
processes in AD begin decades before the first symptoms appear.  
Therefore, researches in the field of AD diagnosis are extensive and still on 
going.  Measuring  biomarkers  like  amyloid  beta  [Aß]  peptide  and 
phosphorylated tau in CSF, using MRI and CT scans to determine atrophy, or 
18-F-deoxy-glucose positron emission tomography [FDG-PET] for measuring 
the impaired metabolism in AD, are all helpful methods in distinguishing AD 
from other types of dementia. Moreover, the use of Pittsburgh compound B in 
PET scans is useful in detecting regions with Aß. But unfortunately none of 
these diagnostic tools is utterly 100% reliable, for example measuring atrophy 
alone is not really helpful because it can occur during aging or due to another 
form of dementia. FDG-PET scans are quite promising but still a qualitative 
method and the cost and limited availability of PET scanners will constrain 
their widespread use.  
Maybe trying to combine 2 or more of the diagnostic methods, for example 
measuring both biomarkers in CSF and performing simultaneously MRI scans 
can lead to a more sensitive or accurate judgment. 
 
Figure 1-6 
Metabolic reductions on FDG-PET 
FDG-PET scans in a 71-year-old cognitively normal woman at baseline (1989) and over 9 years. 
During this period the patient declined to MCI and later was diagnosed with AD, confirmed at 
autopsy. For each observation a coronal PET scan is depicted at the level of the entorhinal cortex 
and  anterior  hippocampus.  Arrows  point  to  the  inferior  surface  of  the  entorhinal  cortex  with 
progressively darker colors on the PET scans, which indicates progressive reductions in glucose 
metabolism. Introduction 
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1.1.4 Risk Factors 
Early onset AD is not very common and occurs below the age of 60. The 
majority of early onset AD is caused by rare genetic variations found in a 
small  number  of  families  worldwide  recognized  as  familial  AD  and  can 
develop sometimes in individuals as young as 30. However, the most common 
form is the sporadic form, which represents approximately 90 % of AD cases. 
Unfortunately, the causes of the sporadic form of AD are not yet known. The 
risk  factors  which  seem  to  play  a  major  role  in  both  types  are  discussed 
below. 
1.1.4.1 Sporadic AD 
For the widespread late onset sporadic AD, age is by far the most common 
risk factor (Gao et al. 1998). During aging, cells in the human brain, like cells 
in other organ systems, experience cellular changes such as oxidative stress, 
mitochondrial  dysfunction,  metabolic  impairment,  DNA  damage  and 
apoptosis (Mattson 2006).  
Changes  in  neurotransmitter  and  neurotrophic  factor  signaling  pathways 
which are amplified in neurodegenerative diseases are also a consequence of 
aging. Although the abovementioned mechanisms seem to connect aging to 
AD, the exact means and the order of events are still obscure. 
Other  non-genetic  risk  factors  besides  aging  are  environmental  factors, 
including aspects of diet and lifestyle. For instance patients with more varied 
activities, including intellectual, physical,  recreational  and social  activities, 
are less likely to develop AD (Friedland et al. 2001). Also low calorie diets 
and  increased  consumption  of  omega  3  fatty  acids  have  been  linked  to  a 
decreased  risk  of  developing  AD.  The  role  of  other  diseases  such  as 
hypertension,  hyperlipidemia,  type  2  diabetes  mellitus  and 
hyperhomocysteinemia  in  increasing  the  risk  for  developing  AD  is  still 
debatable. Other medical risk factors include head trauma, clinical depression, Introduction 
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and some medications such as vitamin E or NSAIDs may reduce the risk of 
acquiring dementia. (Ownby et al. 2006; Patterson et al. 2008; Mattson 2006). 
The  only  well  established  genetic  factor  that  can  increase  a  person's 
susceptibility for sporadic AD is Apolipoprotein E [APOE]. APOE belongs to 
the low density lipoprotein receptor gene family, and it is suggested that it 
could provide a system for lipid transport and cholesterol homeostasis in the 
brain (Pitas et al. 1987). There are three different isoforms of APOE gene 
[APOE-ε2, APOE-ε3 and APOE-ε4]. Increased risk is linked with inheritance 
of the APOE-ε4 allele has helped explain some of the variations in age of 
onset of Alzheimer's disease based on whether people have inherited zero, 
one, or two copies of the ε 4 allele from their parents. The more APOE-ε4 
alleles  inherited,  the  lower  the  age  of  disease  onset  (Corder  et  al. 
1993;Saunders  et  al.  1993).  The  exact  mechanism  is  unidentified,  but  Aß 
deposits  are  more  abundant  in  ε  4-positive  than  in  ε  4-negative  cases 
(Schmechel et al. 1993). In addition, APOE4 is associated with a number of 
other  factors that  may  contribute  to  AD  pathology,  including  low  glucose 
usage, mitochondrial abnormalities, and cytoskeletal dysfunction (Mahley et 
al. 2006). 
1.1.4.2 Familial AD 
Although  familial  AD  [FAD]  is  very  rare  its  importance  should  not  be 
underestimated. Fact is without the familial cases we would have been far 
behind in our knowledge about AD. FAD is associated with an autosomal 
dominant pattern of inheritance, with three major genes whose mutations are 
known to contribute to the disease. In the mid 80’s, as Mann et al observed 
that  individuals  with  Down’s  syndrome  develop  the  clinical  and 
neuropathological features of AD, studies on the amyloid precursor protein 
[APP]  as  a  genetic  determinant  of  AD  began  (Mann  et  al.  1985).  Since 
Down’s syndrome is characterized by the presence of an extra copy of genetic 
material on chromosome 21, the involvement of this chromosome in AD was Introduction 
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then considered. A few years later the gene encoding for APP was identified 
and its mutations as a leading cause of hereditary AD (Kang et al. 1987). The 
different APP mutations were given their names according to the families 
where  they  were  discovered,  for  example  the  Swedish  mutation  was  first 
discovered in 2 Swedish families by Lannfelt and his coworkers (Mullan et al. 
1992).  The  APP  mutations  are  clustered  near  the  α-,  β-,  or  γ-secretase 
cleavage sites, having a direct effect on APP processing [see figure 1-7]. The 
discovery of these mutations led to the development of transgenic cell and 
animal models that were essential for many thriving findings in the field of 
AD. 
 
Figure 1-7 
Amyloid precursor protein 
Amyloid precursor protein showing the sites where FAD mutations occur [illustrated in red]. The 
Swedish and London mutations are clustered near the ß-secretase and γ-secretase respectively.  
In the current study a cell model over expressing the Swedish double mutation 
and a transgenic animal model expressing both the Swedish double and the 
London  mutations  were  utilized.  The  Swedish  APP  double  mutation 
[KM670/671NL] promotes the processing of APP by the ß-secretase causing 
a  massive  increase  in  total  Aß  levels  (Citron  et  al.  1992).  In  the  London 
mutation the total amount of Aß doesn’t change , however the proportion of Introduction 
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Aß 42 increases by 50–90 % (Suzuki et al. 1994). Thus the London mutation 
shifts the balance of γ-secretase cleavage slightly toward the 42 over the 40 
cleavage site. 
Although the APP mutations were the first identified in FAD, it is believed 
that they are responsible for only 5-20 % of all FAD cases. On the other hand 
mutations in presenilin 1 [PS1] gene found on chromosome 14 are assumed to 
be  accountable  for  approximately  85  %  FAD.  Homologue  to  PS1  are 
mutations in presenilin 2 [PS2] localized on chromosome 1, and they are very 
rare.  Research  conducted  on  PS  mutations  revealed  that  they  specifically 
promote Aß 42 generation from APP (Turner 2006). 
1.1.5 Neuropathology 
After the death of Auguste D in April 1906 [refer to section 1.1.1], her brain 
was sent to Munich for analysis. Alzheimer’s use of the silver staining method 
helped him identify the neuropathalogical characteristics of AD, the neuritic 
plaques  and  neurofibrillary  tangles.  Whereas  plaques  have  been  reported 
before in an elderly patient with epilepsy, Alzheimer was the first to describe 
the tangle pathology. He also attempted to illustrate the tangles as he saw 
them during his investigation [see figure 1-8]. Interestingly, after 100 years 
these 2 hallmarks remain the only pathological evidence for the postmortem 
definite diagnosis of AD. Of course the molecular composition of the plaques 
and tangles were at that time unidentified. After the recognition of the cross-ß 
structure of the extracellular plaques and the paired helical structure of the 
tangles in the 60’s (KIDD 1963;Terry et al. 1964), it took another 20 years of 
research before their major components were revealed. Ever since tau was 
identified  as  the  major  tangle  component  and  Aβ  as  the  major  plaque 
constituent a modern era of research began in AD. 
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Figure 1-8 
Neurofibrillary tangles 
The similarity between Dr. Alzheimer’s drawings of the neurofibrillary tangles [left] 100 years ago, 
and  a  recent  confocal  microscopy  picture  of  the  tangles  (Helbecque  et  al.  2003)  [right]  is 
demonstrated above. 
1.1.5.1 Neurofibrillary tangles  
The intracellular tangles arranged in paired helical filaments are made of full 
length, hyperphosphorylated tau, a protein involved in microtubule assembly 
and stabilization. Hyperphosphorylation of tau is common to all diseases with 
tau filaments and may be required for toxicity. Since filamentous tau deposits 
are  found  in  a  number  of  other  neurodegenerative  diseases,  including 
progressive supranuclear palsy, corticobasal degeneration and Pick’s disease, 
its  importance  in  AD  was  always  doubted.  However,  the  findings  that 
mutations in the tau gene leads to inherited “fronto-temporal-dementia and 
parkinsonism  linked  to  chromosome  17”  [FTDP-17]  enlightened  the 
importance of tau and its role in AD.  
In the human brain, six tau isoforms are produced from a single gene through 
alternative mRNA splicing (Goedert et al. 1989). They fall into two groups on 
the  basis  of  numbers  of  microtubule-binding  repeats,  with  three  isoforms 
having three repeats each and three isoforms having four repeats each. In the 
normal  brain,  a  correct  ratio  of three-repeat  to  four-repeat tau  isoforms  is 
essential  for  preventing  neurodegeneration  and  dementia.  Most  missense 
mutations  in  tau  reduce  the  ability  of  tau  to  interact  with  microtubules Introduction 
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(Hasegawa et al. 1998), and some also promote aggregation into filaments. 
Mutations lead to the relative overproduction of four-repeat tau, (Hutton et al. 
1998;Spillantini et al. 1998;D'Souza et al. 1999) therefore altering its ratio to 
the three-repeat form. 
It appears likely that a reduced ability to interact with microtubules and/ or 
alteration of the ratios of the different tau isoforms is necessary for initiating 
toxic function that can cause neurodegeneration. 
Although the amyloid cascade hypothesis which accentuates the importance 
of Aß as the initiator of AD is highly supported, one should not undervalue 
tau and its role in AD. Introduction 
 
  18 
1.1.5.2 Amyloid plaques 
The Plaque filaments found in AD and other diseases are extracellular and 
have the molecular fine structure of amyloid. This term refers to filaments 
with  a  diameter  of  around  10  nm  that  have  a  cross-beta  structure  and 
characteristic  binding  properties  to  the  congo-red  dye.  The  emphasis  on 
amyloidal research directly led in 1984 to the discovery of Aß peptides, the 
39- 43 residue peptides now known to be the major protein constituent of 
amyloid plaques in AD and cerebrovascular amyloid deposits (Glenner and 
Wong 1984). 
A few years later amyloid precursor protein gene was identified (Kang et al. 
1987)  and  Yanker  et  al  demonstrated  that  Aß  could  be  toxic  to  cultured 
neurons (Yankner et al. 1989). Progressed research in this field emphasized 
the role and toxicity of Aß peptide leading to the proposal of the amyloid 
cascade hypothesis. This hypothesis briefly states that accumulation of Aß 
aggregates  causes  synaptic  dysfunction  and  biochemical  changes.  These 
changes  modify  the  tau  protein  into  insoluble  paired  helical  filaments. 
Together  these  events  cause  progressive  neuronal  loss  associated  with 
multiple neurotransmitter deficiencies and cognitive failure. 
 
Figure 1-9 
Plaques and tangles in AD tissue Introduction 
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1.1.6 Amyloid beta: first the making… 
Shortly after the elucidation of the amino acid sequence of the Aß peptide, the 
neuronal isoform of its precursor protein APP695 was cloned (Kang et al. 
1987). The other 2 isoforms 770 and 751,which are mainly expressed in non-
neuronal cells, were characterized a year later (Kitaguchi et al. 1988;Ponte et 
al. 1988;Tanzi et al. 1988). According to the isoform the molecular weight of 
APP  ranges  between  110  and  140  kDa.  Full-length  APP  contains  a  large 
extracellular domain [corresponding to approximately 88% of the total protein 
mass for the main neuronal isoform], a single transmembrane region and a 
small cytoplasmic tail. The physiological function of APP is still not clear, 
however it is suggested that APP acts as a contact receptor due to its role in 
adhesion of neurons to glia cells and tissue maintenance (Gralle and Ferreira 
2007).  
APP can be cleaved by 2 alternative pathways, either the non-amyloidogenic 
pathway by the action of α-secretase or the amyloidogenic pathways by β-
secretase  yielding  Aß  [figure  1-10].The  α-secretase  pathway  forms  an 
extracellular  soluble  N-terminus  [APPα]  (Hooper  et  al.  1997),  and  a 
membrane bound c- terminal fragment [C-83], and the ß-secretase leads to the 
formation of extracellular soluble APPß and C-99. According to the position 
where the γ-secretase cleaves the C-99 fragment either the Aß 40 is formed or 
the longer form Aß 42. Introduction 
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Figure 1-10 
APP cleavage pathways 
Amyloidogenic splicing of APP by beta and gamma secretases leading to the formation of Aß 
[left], and the non-amyloidogenic pathway cleaving the APP in the Aß region by alpha-secretase 
and gamma-secretase [right]. The Aß region is illustrated in red. Introduction 
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1.1.6.1 Alpha secretase 
Alpha secretase [α-secretase] cleavage occurs at the lys 16-leu 17 bond within 
the  Aß  domain,  preventing  the  formation  and  deposition  of  Aß.  To  date, 
mainly 2 proteins have been identified to have α-secretase activity, known as 
ADAM 17 and ADAM 10. Both ADAM 17 [also known as tumor necrosis 
factor  alpha  converting  enzyme  =  TACE]  and  ADAM  10  are  membrane 
bound  metalloprotienases  belonging  to  the  adamlysin  family  of  proteins 
(Blobel 1997;Hooper and Turner 2002;Slack et al. 2001). Although the main 
function of TACE is to cleave the TNF- alpha precursor to release TNF-alpha 
from cells, its α-secretase activities have been seen in cultured cells in vitro 
but its ex vivo role is still questionable. For example, disruption of the TACE 
gene  abolished  the  augmented  secretion  of  sAPP  in  mouse  fibroblasts  in 
response to phorbol ester (Buxbaum et al. 1998). However basal formation 
and  secretion  of  sAPPα  was  unaffected  in  the  cells  derived  from  TACE 
knockout mice (Parvathy et al. 1998). 
The second enzyme, ADAM 10 has shown α-secretase activity in different 
cell systems in vitro (Lammich et al. 1999) and also in vivo. In a transgenic 
mouse  model  for  human  APP,  over-expression  of  ADAM  10  enhanced 
cognitive functions, reduced the formation of Aß 40 and Aß 42, and prevented 
their deposition in plaques. Whereas the catalytically inactive ADAM 10 led 
to an enhancement of the number and size of amyloid plaques in the brains of 
double-transgenic  mice  (Postina  et  al.  2004).  Interestingly,  a  significant 
decrease  of  platelet  ADAM  10  levels  has  been  observed  in  AD  patients 
together with a similar decrease in sAPPα in both thrombin-activated platelets 
and CSF (Colciaghi et al. 2002). 
Although both ADAM 10 and ADAM 17 have shown in several cell models 
their  α-secretase  activities,  the  evidence  present  seems  to  be  in  favor  of 
ADAM 10 more than ADAM 17. Another study highlighting the effect of 
ADAM 10 showed that in situ hybridization revealed overlapping expression Introduction 
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of APP and ADAM 10 but not ADAM 17 in both mouse and human brains 
(Marcinkiewicz and Seidah 2000). 
As mentioned above the α-secretase pathway leads to formation of sAPPα and 
a  C-terminal  stub  [C-83].  Further  processing  of  the  C-83  fragment  by  γ-
secretase  yields  truncated  fragments  of  about  3  kDa  [p3],  preventing  the 
formation of Aß. sAPPα was reported to modulate synaptic transmission and 
is  neuroprotective  against  ischemic  and  excitotoxic  injury  (Mattson  et  al. 
1993;Morimoto et al. 1998;Smith-Swintosky and Mattson 1994). It is quite 
remarkable that the α-secretase pathway not only prevents formation of the 
toxic Aß, but leads to the formation of neuroprotective products. 
1.1.6.2 Beta secretase 
The beta secretase [ß-secretase] cleavage of APP occurs less frequent than α-
secretase splicing, but it is much more critical. Similar to the α-secretases, 2 
enzymes having ß-secretase activity are identified till now. These are known 
as BACE-1 and BACE-2 [beta site APP cleavage enzyme (Huse and Doms 
2000;Nunan and Small 2000). 
BACE-1 is expressed at very high levels in pancreas, at moderate levels in 
brain, and at low levels in most peripheral tissues (Vassar et al. 1999;Yan et 
al.  1999).  Surprisingly  the  ß-secretase  activity  is  high  in  brain  only,  and 
almost undetectable in pancreas (Sinha et al. 1999). BACE-1 exists mainly at 
the Trans golgi network and endosomal system and to a lower extent in the 
ER and on the cell surface (Capell et al. 2000;Haniu et al. 2000;Huse et al. 
2000). BACE-1 over-expression in cell models led to the increase of the ß-
secretase cleavage products including Aß 40 and Aß 42 (Vassar et al. 1999). 
Also  in  a  transgenic  mouse  line  expressing  human  BACE-1,  the 
amyloidogenic processing of APP is increased and levels of Aß 40/42 are 
elevated (Bodendorf et al. 2002). Knocking out the BACE-1 gene completely 
impairs the ß-secretase cleavage of APP and abolishes the generation of Aß Introduction 
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(Cai et al. 2001) showing no phenotypic alterations in the mice (Luo et al. 
2001). 
In humans several studies indicated the importance of ß-secretase in AD. In 
the  cortex  from  AD  patients  a  2.7-fold  increase  in  protein  expression  of 
BACE was observed and also the C-99 fragment was shown to be double that 
present  in  non-demented  controls  (Holsinger  et  al.  2002).  Moreover 
Fukumoto et al were able to show that the activity of ß-secretase increases in 
the  temporal  cortex  by  aging  in  non-demented  humans  (Fukumoto  et  al. 
2003).  It  seems  from  the  above  evidence  that  BACE-1  is  involved  in  the 
amyloidogenic processing of APP and plays a major role in AD. 
Despite the fact that BACE-2 is 55% identical to BACE-1 and shows similar 
substrate specificity (Farzan et al. 2000), it is not highly expressed in the brain 
(Bennett  et  al.  2000)  and  on  the  contrary  to  BACE-1  there  is  no  direct 
evidence linking it to AD pathology. 
1.1.6.3 Gamma secretase 
Due to the complexity of the gamma secretase [γ-secretase] complex it was 
identified step-wise, one component after the other. Starting with the evidence 
that γ-secretase is an aspartyl protease and that presenilin is critical for γ -
secretase activity, led to the discovery that presenilin itself was an aspartyl 
protease, and therefore a part of the γ -secretase complex. Further studies 
revealed nicastrin, a presenilin-interacting protein found by co-isolation upon 
immunoaffinity  purification  (Yu  et  al.  2000).  Since  over-expression  of 
presenilin and nicastrin still did not result in increased γ-secretase activity, it 
was clear that other associated proteins were yet to be discovered. Finally 
Aph-1  and  Pen-2,  which  encode  proteins  of  seven  and  two  predicted 
transmembrane domains respectively (Francis et al. 2002;Goutte et al. 2002), 
were discovered and the picture of γ-secretase was complete! 
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The c-fragments C-83 and C-99 which are the products of α- and ß-secretases 
respectively can be further cleaved by the γ-secretase. The scission of the C-
83 stub is harmless and  yields p3  fragment  and  APP intracellular domain 
[AICD].The exact role of AICD remains ambiguous, some studies report that 
it can alter gene expression and lead to increased apoptosis (Kim et al. 2003) 
and other studies indicate that AICD is important for mitochondrial function 
(Hamid et al. 2007). Moreover, Ma et al reported that AICD correlates with 
enhanced memory and synaptic plasticity (Ma et al. 2007). 
On the other hand the cleavage of the C-99 fragment leads to the formation of 
AICD in addition to variable Aß fragments [Aß 38, 40 or 42] according to the 
position of the cut. The precise site of scission has an important influence on 
the self-aggregating potential and resulting pathogenicity of Aß, as only the 
Aß 42 peptide has a strong propensity to oligomerize in vivo. 
1.1.6.4 Amyloid beta…“the peptide from Hell” 
In  1907,  shortly  after  Alzheimer’s  report,  Oskar  Fischer  published  his 
observations  of  plaques  and  tangles  in  more  typical  late  onset  “senile” 
dementia.  He  speculated  that  the  plaques  found  in  12  of  16  post-mortem 
brains from elderly subjects with dementia which were absent in age-matched 
non  demented  subjects,  resulted  from  deposition  of  a  foreign,  presumably 
infectious, agent (Gouras et al. 2005). Demandingly, Fischer studied these 
depositions extensively until he concluded that the plaques are not a result of 
infection  and  most  probably  they  are  derived  from  degenerating  neuronal 
processes.  In  1911,  Alzheimer  described  in  a  more  detailed  report  the 
phenomenon  of  AD,  and  acknowledged  Fischer  for  his  efforts  in 
characterizing  the  plaques  by  describing  them  as  “Fischer’s  Plaques”. 
Interestingly  Alzheimer  summarized  the  different  views  of  their  origin 
without providing his interpretation, probably due to his knowledge that the 
tools to answer this question are still not available. Introduction 
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73 years later these tools became available, and a breakthrough occurred in 
this field of research as Aß was identified, isolated and characterized as the 
constituent of the amyloid plaques. Glenner et al were able to isolate and 
characterize Aß in the vasculature of AD brains in 1984 (Glenner and Wong 
1984). Numerous investigations kept on proving the toxicity of Aß and led to 
the well known “amyloid hypothesis” stating that Aß aggregation is the cause 
and not an effect of AD (Hardy and Selkoe 2002). Until then it was assumed 
that secreted Aß gradually increase in the extracellular space, aggregating into 
amyloid plaques which causes neuronal toxicity (Yankner et al. 1989).  
Intraneuronal or intracellular Aß was first discovered in 1994 (Wertkin et al. 
1993;Lee et al. 1998), here again this was also due to the development of 
immunohistochemical equipment. Cell biological studies reported that Aß is 
generated in the ER (Cook et al. 1997), Golgi apparatus (Xu et al. 1997) and 
endosomal-lysosomal  system  (Koo  and  Squazzo  1994).  Present  evidence 
correlates the toxicity of intracellular Aß to AD and cytotoxicity rather than 
extracellular Aß. Since initially it was thought that extracellular Aß present in 
plaques  is  toxic,  primarily  studies  focused  on  Aß  fibrils  (Lorenzo  and 
Yankner  1994).  However  nowadays  lower  order  Aß  assemblies  such  as 
oligomers are believed to be the more toxic form and are highly linked to AD 
(Walsh et al. 2002;Cleary et al. 2005) . 
Aß consists of 39-43 amino acids, the most common forms are Aß 40 and Aß 
42,  which  is  known  to  self-assemble  and  form  different  aggregates,  from 
monomers,  to  oligomers,  protofibrils  and  finally  fibrils.  The  mechanism 
behind this aggregation is still vague. Most researchers tend to lean towards 
the theory that it is a seeded process that requires a nucleus rather than a linear 
one (Finder and Glockshuber 2007). The formation of the nucleus which is 
the  rate  limiting  step  is  followed  by  assimilation  of  more  Aß  oligomers 
leading to the formation of the fibrils. For the explanation of the transition of 
Aß monomers to oligomers, different assumptions exist. What seems to be Introduction 
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definite  is  that  high-order  insoluble  oligomers  acquire  a  ß-sheet  structure, 
which  appears  to  be  responsible  for  initiating  aggregate  formation.  The 
question  which  arises  is  in  which  stage  Aß  reconfigures  to  the  ß-sheet 
structure?  One  model  considers  that  Aß  monomers  exist  in  equilibrium 
between α-helical and ß-sheet conformation, and that only the ß-sheet fraction 
is capable of self-aggregating and thereby shifting the equilibrium (Finder and 
Glockshuber  2007).  This  theory  is  supported  by  the  finding  that  dimers, 
tetramers and octomers of Aß with ß-sheet structures occur as early-assembly 
intermediates  (Mastrangelo  et  al.  2006).  The  second  proposal  is  that  the 
alpha-helical  monomers  aggregate  to  oligomers,  and  then  the  oligomers 
transform their structure to ß-sheet conformation. This is based on the finding 
that  an  α-helical,  oligomeric  intermediate  accumulates  during  fibrillization 
(Kirkitadze et al. 2001), and that soluble low molecular weight oligomers 
have been identified (Walsh et al. 1999). 
Leaving aside how the ß-sheet structure oligomers are formed, they seem to 
be the nucleus that grows by seeding forming protofibrils and finally fibrils. 
According to the latest findings the lower order Aß oligomers seem to be the 
most neurotoxic species. Cognitive impairment and synaptic loss have been 
shown to correlate with the amount of soluble oligomers in AD patients and 
the formation of soluble oligomers is elevated in AD brain tissue (Finder and 
Glockshuber 2007). 
In vitro and in vivo experiments have shown that Aß can cause several cellular 
and  synaptic  dysfunctions,  such  as  oxidative  stress,  mitochondrial 
impairment, apoptosis and inflammation (Haass and Selkoe 2007;Nakagawa 
et al. 2000). From the 2 most common forms Aß 40 and Aß 42, Aß 42 is 
especially apparent within the neurons, and more prone to aggregation (Finder 
and Glockshuber 2007). Oligomeric Aβ 42 is far more toxic than monomeric 
Aβ 42 and, in carefully controlled experiments, is more toxic than fibrillar Aβ 
42 (Dahlgren et al. 2002). Introduction 
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In cerebrospinal fluid Aß 42 is increased in the first stages in sporadic AD but 
then declines with disease progression (Jensen et al. 1999). This can indicate 
that initially elevated Aß 42 leads to its aggregation and deposition, and this 
deposition of Aß 42 results later in a decline of its levels in CSF and plasma. 
Fact is, Aß is not only present in AD patients but also accumulation of Aß is 
observed in non-demented controls especially with aging (Fukumoto et al. 
2003) .Thus Aß is generated constitutively and this raises the possibility that 
Aß  has  a normal  physiological  function.  The  exact  role of Aß  is  still  not 
known but neuronal excitation increased with Aß (Gouras et al. 2005). Both 
Aβ 40 and Aβ 42 modulate potassium channels in neurons. However, Aβ 40 
but not Aβ 42, is able to counteract the effects of secretase inhibitors, drawing 
further distinction between the two forms (Plant et al. 2003). 
Person  to  person  variability  in  absolute  levels  of  Aß  [40  or  42]  makes  it 
difficult to draw conclusions about disease progression. However, recently the 
importance of the ratio Aß 42/40 has gained more and more attention, and a 
reduction of the ratio correlates with the onset and progression of AD. This 
was shown in CSF and plasma levels of AD patients (Findeis 2007). Another 
study showed also the importance of this ratio in a transgenic mice model; by 
demonstrating that  over  expressing  Aß  40  was  able  to  prevent  the  Aß 42 
linked amyloid deposition and premature death. These results seem to indicate 
that a shift towards the shorter form of Aß, or a decrease in Aß 42/40 ratio 
seems to be protective and beneficial. 
Concluding,  Aß  appears  to  be  present  in  physiological  amounts  and  most 
probably  has  a  potential  normal  function.  However  increase  in  the  longer 
form of Aß aggregates, mainly oligomers, or the ratio Aß 42/40 seems to be 
deleterious, and can cause neurotoxicity. Still to be answered is the question 
whether  this  non-physiological  toxic  Aß  is  due  to  an  increase  in  the 
production of  Aß,  decrease  in  the  degradation of  Aß,  an  increase  of  self-Introduction 
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assembly and formation of ß-sheet structures or a combination of more than 
one? 
1.1.7 Amyloid beta…first the making…then the breaking… 
Although the pathway of Aß production has been extensively studied since 
the discovery of Aß, only recently the catabolism of Aß has started to gain 
attention.  Understanding  the  mechanisms  behind  Aß  degradation  and  the 
enzymes involved, could be an important therapeutic tool in the future for 
eliminating Aß levels in brains of AD patients. 
A few enzymes have been reported with the capability to break down Aß, the 
first to be identified was the “insulin degrading enzyme” [IDE]. A year later 
neprilysin [NEP] was reported to metabolize Aß in vitro, and later on in vivo. 
Other  members  of  the  NEP  family  such  as  endothelin-converting  enzyme 
[ECE]  were  examined  for  their  ability  to  degrade  Aß  and  proved  their 
efficacy. Introduction 
 
  29 
The biological features of proteases known to cleave Aß are summarized in 
the table below 
Common 
Name 
Other 
names 
class  Sub-cellular 
location 
Other substrates 
Neprilysin 
CD10, 
CALLA, 
EC 3.4.24.15 
NEP 
M 
Cellular & intracellular 
membrane including 
presynaptic membrane 
Enkephalin,  cholecystokinin, 
neuropeptide  Y,  substance  P, 
opiod  peptides,  atrial 
natriuretic peptides, bombesin-
like  peptides,  chemotatic 
peptides,  adrenocorticotropin 
hormone (ACTH) 
Insulin  degrading 
enzyme 
EC 3.4.24.56 
Insulysin, IDE  M 
Cytosol,  cellular,  and 
intracellular  membrane 
extracellular space 
Insulin,  glucagon,  atrial 
natriuretic  factor,  β-endorphin 
amylin,  APP  intracellular 
domain 
TGFα 
 
Endothelin-
converting enzyme 
EC 3.4.24.71 
ECE  M  Trans-Golgi network 
Cell surface 
Big  endothelin,  substance  P, 
bradykinin, oxidized insulin B 
chain 
Angiotensin-
converting enzyme 
EC 3.4.15.1; 
ACE; 
dipeptidyl 
carboxypeptida
-se 
M 
plasma membranes 
perinuclear region 
 
Angitensin-I,  enkaphalins, 
bradykinin 
 
Table 1.1 
Biological features of Aβ degrading enzymes 
Summary of the major enzymes known to cleave Aβ peptide (Wang et al. 2006) 
1.1.7.1 Neprilysin [NEP] 
NEP  gene  is  located  on  chromosome  3q21-q27,  and  is  composed  of  750 
amino acids with an approximate molecular weight of 86 kDa (Malfroy et al. 
1988). It consists of a short N-terminal cytoplasmic tail, a membrane spanning 
domain,  and  a  large  c-terminal  extracellular  catalytic  domain.  NEP  is 
expressed  in  a  variety  of  tissues  including  the  brain.  In  the  brain  NEP  is 
mainly  expressed  in  areas  susceptible  to  Aß  deposition  such  as  the 
hippocampus. 
In 1995, NEP was linked to Aß degradation by Howell et al (Howell et al. 
1995). Further investigations proved the in vivo capability of Aß cleavage by 
NEP. Worth mentioning was the study by Iwata et al showing that Aß 42 is Introduction 
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degraded by NEP in the hippocampus of rats, this process was blocked by 
NEP inhibitor leading to accumulation of Aß and plaque formation (Iwata et 
al. 2000). Subsequently, the same authors reported that the levels of Aß 40 
and Aß 42 were elevated in NEP knockout mice (Iwata et al. 2001). 
Others  were  able  to  demonstrate  the  ability  of  NEP  to  degrade  not  only 
monomeric form of Aß but also the oligomeric form (Kanemitsu et al. 2003). 
Quantitative analysis showed that NEP mRNA was significantly lower in AD 
(Caccamo et al. 2005;Yasojima et al. 2001), and an inverse relationship was 
observed with both Aß plaques and Aß levels (Wang et al. 2006). 
From the aforementioned evidence NEP appears to contribute to the normal 
metabolism and accumulation of Aß in AD. 
1.1.7.2 Insulin degrading enzyme IDE 
IDE gene was mapped to chromosome 10q23-q25, consisting of 1019 amino 
acids.  The  Aß  degrading  property  of  IDE  was  first  described  in  1994  by 
Kurochekin et al (Kurochkin and Goto 1994). IDE is expressed in several 
tissues, such as liver, skeletal muscles and brain, and is primarily located in 
the  cytosol  (Wang  et  al.  2006).  Anatomical  data  was  first  provided  in 
suggesting  that  IDE  is  associated  with  neuropathlogical  hallmarks  of  AD 
(Bernstein  et  al.  1999).  Immunostaining  revealed  the  presence  of  IDE  in 
cortical and sub cortical neurons, senile plaques and microvessels (Morelli et 
al. 2004). Reduced mRNA levels and activity of IDE in the hippocampus of 
cases  at  high  risk  of  developing  AD  and  in  APOE4  carriers  (Zhao  et  al. 
2007;Cook  et  al.  2003)  supported  the  hypothesis  that  IDE  activity  may 
contribute to Aß accumulation in AD patients.  
Additionally,  animal  studies  suggest  a  role  of  IDE  in  Aß  degradation. 
Transgenic  mice  over  expressing  IDE  demonstrated  reduced  levels  of  Aß 
accumulation and prevented amyloid plaque formation (Leissring et al. 2003). 
On the other hand IDE knockout mice demonstrated increased Aß load and Introduction 
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the AICD (Miller et al. 2003;Farris et al. 2003). Another study also reported 
the ability of IDE to degrade AICD, suggesting that IDE is not specific to 
insulin and Aß only (Edbauer et al. 2002). 
Although  the  above  evidence  suggests  the  involvement  of  IDE  in  Aß 
metabolism,  however  the  proof  for  a  genetic  association  remains 
controversial. As an example, one of the most recent studies concluded that 
there is no association of IDE haplotypes with the risk of developing dementia 
(Marlowe et al. 2006). Nevertheless, one can’t overlook the strong in vivo 
data present linking IDE activity and Aß, and from a therapeutic point of view 
up-regulation or increasing activity of IDE remains a viable prospect. 
1.1.7.3 Endothelin converting enzyme [ECE] 
ECE is a transmembrane metalloprotease that catalyzes the conversion of the 
inactive precursor pro-endothelin to its potent vasoactive peptide endothelin. 
The  most  abundant  form,  ECE-1  is  encoded  by  the  gene  located  on  the 
chromosome  1p36,  and  consists  of  758  amino  acids.  In  addition  to  pro-
endothelin,  ECE  has  been  reported  to  hydrolyze  other  peptides  such  as 
bradykinin, substance P and neurotensin in vitro [see table 1.1]. ECE-1 is a 
member of the NEP family, and has shown 37 % homology to NEP (Sansom 
et al. 1998). Given this information and the fact that ECE-1 is non-specific in 
its substrate repertoire as mentioned above, it is not surprising that ECE-1 was 
examined as a potential Aß-degrading enzyme. The ability of ECE-1 to cleave 
Aß  was  first  noticed  by  Eckmann  et  al,  when  they  observed  that 
phosphoramidon caused an increase of Aß accumulation in a cell line that 
expressed ECE, but not in another cell model devoid of ECE (Eckman et al. 
2001). Recombinant soluble ECE-1 was demonstrated to hydrolyze Aß 40 and 
Aß 42 in vitro at multiple cleavage sites [see diagram 1-11]. Since ECE-1 
devoid mice do not survive, heterozygous mice showing a 27 % decrease in 
ECE-1 activity were investigated for their Aß levels and they exhibited higher 
levels of Aß (Eckman et al. 2003). Introduction 
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ECE-2 which is relatively less studied isoform, has recently gained attention 
as an Aß degrading enzyme. ECE-2 is mainly localized in the brain; however 
its overall expression is only 1-2 % as much as the more abundant form ECE-
1 (Wang et al. 2006). ECE-2 knockout mice develop increased amounts of Aß 
40 and Aß 42 (Eckman et al. 2006). Interestingly, a recent microarray study 
of gene expression patterns demonstrated that ECE-2 was down-regulated in 
AD patients (Weeraratna et al. 2007). Therefore, it seems that ECEs play a 
role in Aß metabolism, ECE-2 role is less apparent, but this could be due to 
the fact that it was not extensively studied like ECE-1, owing to its scarcity. 
 
Figure 1-11 
Aß cleavage sites by NEP, ECE-1 and IDE Introduction 
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1.1.8 Role of oxidative and nitrosative stress in AD 
Reactive oxygen species [ROS] include both radicals such as oxygen ions and 
non-radicals  such  as  peroxides.  Under  physiological  conditions  ROS  are 
produced  as  natural  byproducts  of  aerobic  mitochondrial  respiration.  They 
play  a  physiological  role  in  enzymatic  reactions,  cell  signaling  and 
neurotransmission. But unfortunately ROS can also cause deleterious effects 
on tissues when they exceed physiological amounts. This phenomenon known 
as oxidative stress, describes a situation where there is an imbalance between 
production and detoxification of ROS. Various cellular defense mechanisms 
such as anti-oxidant enzymes and vitamins serve to prevent the accumulation 
of ROS. However, in many cases such defense mechanisms are overburdened 
and oxidative stress leads to lipid peroxidation, DNA damage and finally cell 
death. 
Aging  and  many  aging-related  diseases  which  include  neurodegenerative 
diseases  and  Alzheimer’s  disease  have  been  associated  with  excessive 
formation  of  ROS.  The  high  vulnerability  of  the  brain  to  oxidative  stress 
could be explained by high metabolic rate [consumes about 20 % of oxygen 
uptake] its high unsaturated lipid to volume ratio and its reduced capacity for 
cellular regeneration compared with other organs. 
The importance of net mitochondrial ROS production and its link to aging can 
be supported by the observations that enhancing mitochondrial antioxidant 
defenses  can  increase  longevity.  It  has  been  recently  shown  that  over-
expression  of  catalase  experimentally  targeted  to  mitochondria  increased 
lifespan  in  an  already  long-lived  mouse  strain  (Schriner  et  al.  2005). 
Moreover,  a  study  of  gene  expression  in  the  human  brain  suggested  that 
oxidative damage plays a major role in the cognitive decline that accompanies 
aging (Lu et al. 2004). Introduction 
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Since oxidative stress has been associated with aging, and the fact that aging 
is  by  far  the  greatest  risk  factor  for  sporadic  AD,  it  was  assumed  that 
oxidative stress could be connected to AD. In light of this postulation many 
researchers directed their work towards this hypothesis. Nowadays, there is 
extensive  literature  supporting  a  role  for  mitochondrial  dysfunction  and 
oxidative  damage  in  the  pathogenesis  of  AD  (Nunomura  et  al.  2001). 
Deficiencies  in  mitochondrial  proteins  that  could  contribute  to  ROS 
production  have  been  detected  in  brains  from  AD  patients  (Kish  et  al. 
1999;Maurer et al. 2000;Chandrasekaran et al. 1997). Electrophilic aldehydes 
such as malondialdehyde and free 4-hydroxy-2-nonenal [HNE] are elevated in 
AD brain tissue (Markesbery and Lovell 1998;Sayre et al. 1997;Williams et 
al.  2006).  These  aldehydes  react  with  cellular  nucleophiles  such  as  DNA, 
proteins and lipids. Supporting this finding, glutathione transferase which is 
the enzyme responsible for clearance of HNE is decreased in several regions 
in AD brain including the hippocampus (Lovell et al. 1998). Another anti-
oxidant  enzymes,  thioredoxin  is  also  decreased  in  AD  amygdala  and 
hippocampus/ parahippocampal gyrus (Lovell et al. 2000). On the contrary 
SOD  displays  elevated  expression  levels  in  AD  brains  compared  to  age 
matched controls (Marcus et al. 2006;Schuessel et al. 2006). This could be 
explained as a compensatory mechanism against free radical damage in AD 
patients. 
So the fact is oxidative stress and AD are related, the question that arises is 
how? The exact mechanisms are not known but here again Aß seems to play a 
role  in  this  matter.  Studies  reported  that  Aß  can  increase  ROS  levels 
(Butterfield  et  al.  1999)  and  that  oxidative  stress  leads  to  intracellular 
accumulation of Aß (Misonou et al. 2000). Further on, transgenic PC12 cells 
with APP mutations, that lead to increased Aß production, show increased 
oxidative  stress  (Marques  et  al.  2003a)  and  in  transgenic  mice  models Introduction 
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oxidative damage and lipid peroxidation was shown to precede Aß deposition 
(Pratico et al. 2001). 
Not  only  oxidative  stress  but  also  nitrosative  stress  is  implicated  in  AD. 
Physiologically Nitric oxide synthese [NOS] in neurons [nNOS, type INOS] 
and endothelial cells (eNOS, type III NOS) produce nanomolar amounts of 
NO for short periods in response to transient increases in intracellular Ca
+2, 
which  is  essential  for  neurotransmission.  The  brain  produces  more  Nitric 
oxide [NO] for signal transduction than the rest of the body combined, and its 
synthesis  is  induced  by  excitatory  stimuli.  Under  various  pathological 
conditions large amounts of NO are produced in the brain as a result of the 
induced  expression  of  iNOS,  excessive  NO  can  exert  various  deleterious 
roles. It appears that both neuronal and glial NOS may play a role in the 
pathogenesis  of  AD  and  peroxynitrite  formation.  Increased  expression  of 
nNOS  was  reported  in  neurons  with  neurofibrillary  tangles  in  the 
hippocampus  and  enthorinal  cortex  of  AD  patients  as  well  as  in  reactive 
astrocytes  near  amyloid  plaques  (Simic  et  al.  2000;Thorns  et  al.  1998). 
Moreover, increased nitrotyrosine levels were demonstrated in hippocampus, 
neocortical regions, ventricular fluid and CSF of AD patients (Hensley et al. 
1998;Smith et al. 1997). Importantly, the high levels of 3 nitrotyrosine in 
cerebrospinal fluid correlated with the decrease in cognitive function in AD 
patients (Tohgi et al. 1999).The role of Aß on NO levels has also been tested. 
Chronic  intra-cerebroventricular  infusion  of  Aß  can  also  cause  ROS  and 
peroxynitrite  formation  and  subsequent  tyrosine  nitration  of  proteins 
(Sarchielli  et  al.  2003).  Also  stimulation  of  cortical  neurons  with  Aß  42 
increased NO release and decrease cellular viability (Law et al. 2001).  
Therefore multiple evidence suggest that both oxidative and nitrosative stress 
play a role in neurodegenerative diseases including AD. Although the exact 
mechanisms behind their role are still debatable, Aß seems to be involved 
somehow. Introduction 
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1.1.9 Mitochondrial dysfunction and AD 
The  role  of  mitochondria  in  aging  and  neurodegenerative  diseases  has 
received much more attention in the last decade. Due to the present evidence 
nowadays,  mitochondrial  dysfunction  is  believed  to  play  a  pivotal  role  in 
aging and AD. 
Simply,  mitochondria  are  double-membranous,  self-replicating  organelles 
with a circular genome of 16.5 kb DNA (Chen and Chan 2005). They are 
essential for cell viability and functioning. Mitochondria contain their own 
mitochondrial DNA and machinery for transcription, translation, and protein 
assembly. The mitochondrial DNA codes for 13 polypeptides that are part of 
the mitochondrial electron-transport chain, which is involved in the oxidative 
phosphorylation that generates adenosine triphosphate [ATP]. The production 
of ATP [energy] is the major function of the mitochondria and this is why 
they  are  known  as  power  house  of  the  cell.  Oxidative  phosphorylation 
operates through five protein complexes embedded in the inner membrane of 
the  mitochondria  known  as  respiratory  chain  complexes  [see  figure  1-12]. 
Since neuronal functions and synaptic neurotransmission require vast amounts 
of  energy,  mitochondria  occupy  an  essential  task  by  generating  ATP  and 
maintaining calcium homeostasis (Nicholls and Budd 2000;Kann and Kovacs 
2007).  Therefore,  impairment  in  mitochondrial  vital  functions  may  have 
serious and deleterious consequences on neuronal physiology. Introduction 
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Figure 1-12 
Diagram showing mitochondria and the respiratory chain 
Researchers  have  in  the  last  few  years  found  many  evidences  linking 
mitochondrial  dysfunction  to  AD.  Baloyannis  reviewed  the  morphologic 
alterations  of  the  mitochondria  in  22  brains  of  AD  patients,  and  reported 
disruption of the cristae and/or osmiophilic inclusions (Baloyannis 2006). 
Morphometric  studies  of  the  mitochondria  in  AD  revealed  a  significant 
reduction in mitochondria density in endothelial cells as well as in fibroblasts 
obtained from patients with AD (Stewart et al. 1992).This observation was 
also seen in mitochondria from Frontal and temporal cortex of AD patients 
(Hirai et al. 2001). 
Not only morphological changes in AD mitochondria were noticed but more 
importantly functional changes. Positron emission tomography [PET] showed 
decrease  energy  metabolism  in  AD  brains  (Azari  et  al.  1993;Grady  et  al. 
1988). Tricarboxylic acid cycle [TCA], which takes place in the mitochondria, Introduction 
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is the main pathway for oxidation of glucose in the brain. Deficiency in the 
two  key  enzymes  of  the  rate-limiting  step  of  the  TCA  cycle,  Pyruvate 
dehydrogenese  [PDHC]  and  alpha  -ketoglutarate  dehydrogenase  complex, 
[KGDHC] has been documented in AD cases by multiple groups, suggesting 
defects in glucose metabolism in the AD brains (Gibson et al. 2000;Sorbi et 
al.  1983).  Normally,  electrons  from  the  TCA  are  transported  across  the 
respiratory  chain  in  order  to  produce  ATP.  Deficiency  of  cytochrome-c-
oxidase [COX] [complex IV of the respiratory chain] in different AD brain 
regions  has  been  reported  (Bosetti  et  al.  2002;Mutisya  et  al.  1994).  So  it 
seems  that  COX  and  most  probably  PDHC  and  KGDHC  activities  are 
decreased in AD patients, the exact mechanism of their deactivation is not 
known but interestingly it has been reported that Aß inhibits both COX and 
KGDHC in isolated brain mitochondria (Casley et al. 2002). 
Aß seems also to have other toxic effects on the mitochondria in cell and 
animal models. Previous studies showed that in the presence of Ca
+2 Aß 40 
and  Aß25–35  induce  the  opening  of  Permeability  transition  pore  [PTP] 
(Mancuso et al. 2006;Mancuso et al. 2003). PTP induction, a phenomenon 
characterized  by  a  sudden  increase  in  the  permeability  of  the  inner 
mitochondrial  membrane,  plays  a  key  role  in  apoptotic  cell  death  by 
facilitating the release of apoptogenic factors. 
The  toxic  effects  of  Aß  on  the  mitochondria  were  observed  in  transgenic 
animal models as well, for example Keil et al demonstrated a decrease in 
mitochondrial membrane potential and ATP levels in APP-transgenic mouse 
when compared  to littermate  non-transgenic  mice.  Accumulation of  Aß in 
Tg2576  AD  transgenic  mice  and  mouse  neuroblastoma  cells  expressing 
human  APP  correlated  with  high  levels  of  H2O2,  impaired  cytochrome-
oxidase  activity,  and  increased  carbonylation  of  mitochondrial  proteins 
(Manczak et al. 2006). Introduction 
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Anandatheerthavarada  et  al  linked  amyloid  to  the  mitochondrion.  These 
authors  showed,  for  the  first  time,  that  APP  is  targeted  to  neuronal 
mitochondria. They showed in a transgenic mouse model of AD [Tg2576] 
that over-expresses Swedish APP, accumulation of incompletely translocated 
full-length  APP  in  the  mitochondrial  compartment  of  the  cortex  and 
hippocampus known to be affected in AD (Anandatheerthavarada et al. 2003). 
The same group then extended their results in human AD brains. They found 
that  non-glycosylated  full-length  and  C-terminally–truncated  APP  was 
associated with mitochondria in samples from the brains of individuals with 
AD, but not with mitochondria in samples from non-demented subjects (Devi 
et al. 2006). However, the frontal cortex, hippocampus, and amygdala showed 
the highest accumulation of APP in the mitochondria of all three categories of 
AD brains. Triple-labeling immuno-histochemistry of AD brains revealed the 
accumulation of APP in the mitochondria of cholinergic neurons of all stages 
of AD brains. 
In  order  to  study  more  extensively  the  effect  of  mitochondria  in  AD  the 
cytoplasmic hybrid (“cybrid”) technique, first described in 1989 (King and 
Attardi  1989),  has  been  applied.  In  this  technique,  mitochondria/  mtDNA 
from human AD and control platelets is transferred to cultivable cells depleted 
of  endogenous  mtDNA.  Interestingly  the  AD  cybrids  showed  elevated 
secretion  of  Aß,  they  also  confirmed  the  COX  deficiency  found  in  the 
mitochondria of  AD  patients.  AD  cybrids  also show  elevated  spontaneous 
death  with  apoptotic  nuclear  morphology  and  decrease  in  mitochondrial 
membrane  potential  (Khan  et  al.  2000).  Moreover,  increased  caspase-3 
activity and elevated cleavage of caspase substrate were previously reported 
(Khan et al. 2000;Onyango et al. 2005).  
Wrapping up this section, mitochondrial dysfunction is always involved in 
AD,  whether  present  in  post-mortem  AD  tissue,  transgenic  cell  or  animal 
models or AD cybrids. Additionally, Aβ the major pathologic hallmark for Introduction 
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AD plays a key role in mitochondrial impairment. However which starts first, 
Aβ aggregation or mitochondrial dysfunction in this viscous cycle is still an 
unanswered question. Introduction 
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1.1.10 Therapeutic interventions 
After 100 years of AD discovery the absence of treatment with a major impact 
is  quite  disappointing.  The  drugs  approved  are  mainly  for  symptomatic 
treatments, and this is related to the fact that the pathways that cause AD are 
still not fully declared. Although multiple drugs have now been approved, 
their  expected  benefits  are  marginal.  However,  the  causes  behind  AD  are 
being slowly identified and new treatments in the pipeline which are aimed at 
these mechanisms are being developed. 
In this section a short overview of the current approved drugs for AD is given, 
followed  by  the  new  therapeutic  interventions  under  development  or  in 
clinical trials. 
1.1.10.1 Acetylcholinesterase inhibitors 
Post-mortem findings in the early 1970s such as reduced acetylcholine [Ach] 
release and presynaptic cholinergic deficits in brains of AD patients led to the 
development of the cholinergic hypothesis of AD. The ‘cholinergic deficit 
hypothesis’  was  the  dominant  theory  in  AD  in  the  early  1980s.  This 
hypothesis  states  that  degeneration  of  cholinergic  neurons  in  the  basal 
forebrain nuclei causes disturbances in presynaptic cholinergic terminals in 
the hippocampus and neocortex, which is important for memory disturbances 
and  other  cognitive  symptoms  (Terry,  Jr.  and  Buccafusco  2003).  It  was 
anticipated  that  restoring  the  cholinergic  balance  by  inhibition  of  Ach 
breakdown would improve cognitive functions and retard the progression of 
AD. The 2 Cholinesterases, namely, acetyl cholinesterase [AchE] and butyryl 
cholinesterase [BuChE] control the availability of Ach in the synapses.  
In  1993,  the  FDA  approved  the  first  drug  for  the  treatment  of  AD,  the 
cholinesterase inhibitor  [ChEI]  tacrine,  which  was soon  followed  by  other 
ChEIs:  donepezil  [1996],  rivastigmine  [2000]  and  galantamine  [2001].  All 
ChEIs interfere with the degrading of Ach by blocking AchE. Donepezil and Introduction 
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galantamine are selective AchE inhibitors while rivastigmine inhibits AchE 
and  BuChE  with  similar  affinity.  Theoretically,  this  dual  action  could  be 
valuable  because  in  AD,  BuChE  levels  tend  to  be  higher  compared  with 
AchE, which decreases in the course of the disease process (Lane et al. 2006). 
In  addition  to  inhibiting  AchE,  galantamine  allosterically  modulates 
presynaptic nicotinic receptors.  
The efficiency of these drugs has been studied in more than 30 randomized 
double-blind clinical trials, most of which indicate the symptomatic treatment 
influence of AchEI. In a 2006 Cochrane review, it was concluded that the 
acetyl cholinesterase inhibitors donepezil, rivastigmine, and galantamine are 
efficacious in mild to moderate AD (Birks 2006). Overall, they are safe drugs, 
but  exhibiting  predominant  gastrointestinal  side-effects  including  nausea, 
vomiting, and diarrhea. The incidence of side-effects can usually be reduced 
by starting treatment with a low dose, which is escalated slowly. However 
caution should be taken in prescribing AchEI to patients with cardiovascular 
diseases, GIT problems, or Asthma. 
1.1.10.2 Memantine 
Memantine, a low to moderate affinity, uncompetitive NMDA [N-methyl-D-
aspartate]  receptor  antagonist,  was  approved  in  2003  for  AD  treatment. 
Glutamatergic dysfunction can lead to an excessive influx of calcium ions 
through NMDA receptors, leading to neuronal death. Such “excitotoxicity” 
has been implicated in AD (Danysz et al. 2000). Memantine is thought to 
block  selectively  the  effects  associated  with  abnormal  transmission  of  the 
neurotransmitter glutamate, without preventing the physiological transmission 
associated with normal functioning (Wilcock 2003). 
Memantine treatment of patients with moderate-to-severe AD has been shown 
to  confer  significant  benefits  on  cognition  whether  alone  or  when 
administered concomitantly with other ChEI (Gauthier et al. 2005;Reisberg et Introduction 
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al. 2003;Tariot et al. 2004). The efficacy of memantine in patients with mild-
to moderate AD is debatable, and the latest Cochrane review concluded that 
there  are  no  data  to  lend  support  to  the  notion  that  memantine  has  any 
beneficial effect in mild stages (Areosa and Sherriff 2003). Due to the scarcity 
of trials, the assessment of memantine as a disease modifying drug is difficult. 
However, memantine is well tolerated, with few adverse events, and may be a 
useful  therapeutic  adjunct  in  patients  with  moderate  to  severe  disease, 
typically defined as an MMSE less than 15 points (Areosa and Sherriff 2003). 
1.1.10.3 Piracetam 
N
CH2
CONH2
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Figure 1-13 
Chemical structure of the compound piracetam 
Piracetam [2-oxo-pyrrolidine carboxylic acid] was first synthesized in 1964 at 
the pharmaceutical company UCB. Piracetam is popularly referred to as a 
“smart drug”, or scientifically rephrased a Nootropic [“mind-related”] drug. 
This name was first assigned to Piracetam due to its unique pharmacological 
actions  which  include  facilitating  inter-hemispheric  transfer  and  enhancing 
cerebral resistance to cognitive impairments induced by hypoxia and aging 
(Giurgea  et  al.  1983).  It  is  prescribed  for  the  treatment  of  cognitive 
impairments, cerebral insufficiencies and cortical myoclonus. 
Several  clinical  trials  have  shown  the  efficacy  of  piracetam  for  cognitive 
impairments. In 2001 Tsolaki et al reported that the efficacy of piracetam is 
comparable  with  AchE  inhibitors  (Tsolaki  et  al.  2001).  A  meta-analysis Introduction 
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including 19 trials concluded that piracetam was effective in patients with 
cognitive impairment (Waegemans et al. 2002).  
The  mechanisms  lying  behind  the  actions  of  piracetam  are  not  fully 
elucidated. It has been reported that piracetam can restore changes that occur 
in  brain  membrane  fluidity  during  aging,  and  elevates  both  muscarinic 
cholinergic  and  NMDA  receptor  density  in  rodents  (Cohen  and  Muller 
1993;Pilch and Muller 1988). Moreover, mitochondrial protective properties 
have been also described for piracetam (Keil et al. 2006). 
1.1.10.4 Ginkgo Biloba extract 
An extract of Ginkgo biloba leaves was first registered as a medication by Dr. 
Willmar Schwabe GmbH & Co in France under the trademark Tanakan by 
IPSEN.  Several  different  Ginkgo  extracts  exist  nowadays  in  the  European 
market as well as in the US as dietary supplement. In Germany it’s a highly 
prescribed medication and since the early 1990s, Ginkgo biloba leaf extracts 
are  becoming  one  of  the  most  popularly  used  supplements  for  memory 
enhancement in the US. 
The fact that Ginkgo extracts constitute several active compounds such as 
flavonoids  and  terpenoids,  gives  it  its  unique  toti-potent  properties.  A 
standardized leaf extract [EGb 761
®] was reported as an anti-oxidant, anti-
apoptotic, gene regulator and comprises other mechanisms of action, unlike 
synthetic drugs,  which provide a single target  for  a  single  receptor  as the 
mechanism of action. 
Concerning  its  clinical  efficacy  a  vast  number  of  clinical  trials  and  meta-
analysis are present, but unfortunately major differences in the experimental 
parameters makes it quite challenging trying to reach a reasonable conclusion. 
In light of the present studies Ginkgo has been reported as a safe drug, and 
shows potential in enhancing cognition and function in patients with dementia 
[for further details on Ginkgo extract refer to section 1.2]. Introduction 
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1.1.11 Novel therapeutic strategies 
Due to the modest benefits acquired from currently existing AD therapies, 
scientists are striving to develop more potent AD drugs. A number of new 
compounds with different targets are being tested for their safety and efficacy 
in clinical trials. Reducing Aß production is one goal and under development 
are several drugs targeting secretases. 
1.1.11.1 Targeting secretases: Gamma secretase 
As already mentioned, γ-secretase is involved in the last step of APP cleavage 
to yield either Aß 40 or Aß 42 [see section 1.1.4.5]. Unfortunately, besides 
APP,  γ-secretase has  other substrates including  the transmembrane protein 
notch receptor-1. Notch is necessary for growth and development and notch 
related side effects of γ-secretase inhibition [e.g. severe gastrointestinal and 
haemopoetic  side  effects,  neurodegeneration]  have  been  hindering  the 
development of clinically valuable γ-secretase inhibitors so far. 
Nevertheless, γ-secretase inhibitors have been developed that do not affect 
notch signaling and have shown good tolerability in phase I studies (Petit et 
al.  2001;Siemers  et  al.  2005).  A  well  tolerated  compound,  LY450139, 
reduced the amount of Aß in the plasma, but not in the CSF (Siemers et al. 
2006).  Designing  new-generation  γ-secretase  inhibitors  that  selectively 
decrease  APP  cleavage  without  affecting  other  targets  is  a  cumbersome 
process.  One  approach  targets  the  substrate-docking  site  of  γ-secretase  to 
selectively  interfere with  APP binding  (Wolfe  2006).  Another  approach is 
modulating  γ-secretase  instead  of  inhibiting  it,  for  example  shifting  the 
cleavage towards more production of Aß 40 in preference to Aß 42. Some 
NSAIDS  [non-steriodal  anti-inflammatory  drugs]  have  this  property  by 
allosterically modulating γ-secretase and are now in phase III clinical trials 
(Eriksen  et  al.  2003;Lleo  et  al.  2004).  Tarenflurbil,  the  most  promising 
candidate, was not very successful in a phase II clinical trial. The primary Introduction 
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analysis failed where there was no overall effect on the primary outcomes. 
But planned analyses suggested that there was evidence of a favourable effect 
of treatment on activities of daily living and global function in the subgroup 
of patients with mild AD (Wilcock et al. 2008). 
1.1.11.2 Targeting secretases: Beta secretase inhibitors 
Another method of decreasing Aß generation involves inhibiting ß-secretase 
[BACE], which is essential for the cleavage of APP to produce Aß. Keeping 
in mind that BACE has fewer substrates compared to γ-secretase and that 
knockout mice seem to have a normal phenotype (Luo et al. 2001), one would 
expect that the development of such compounds is safer and more promising. 
However  the  hampering  reasons  here  are  structural,  development  of  small 
molecules able to pass the BBB, which is quite complicated (Citron 2004). 
NSAIDs  seem  to  play  a  role  here  as  well,  showing  the  ability  to  inhibit 
BACE1  by  activating  the  PPAR-  γ  [peroxisome  proliferated  activated 
receptor- γ] (Sastre et al. 2006). Further studies need to be done in this field in 
order to overcome the structural complexity and to assure effectiveness and 
safety. 
1.1.11.3 Aß clearance 
Increasing Aß clearance through Aß immunization or Aß degrading enzymes 
could be feasible. The Aß clearance by the Aß-degrading enzymes has been 
thoroughly discussed before [see section 1.1.6], left to be said is that no phase 
II or III studies have been published on the effects of enhancing enzymatic 
degradation in AD patients.  
1.1.11.4 Immunotherapy 
As for promoting Aß clearance by immunization, this approach appears to be 
quite promising. In a phase II trial active immunization with Aß plus adjuvant 
appeared  to  reduce  amyloid  deposits  in  some  brain  regions  and  improve 
certain  cognitive  measures  in  patients  who  developed  antibodies. Introduction 
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Unfortunately, the trial was discontinued due to the development of 18 cases 
[6%]  of  meningoencephalitis,  which  was  most  likely  an  immune  response 
complication mediated by T helper cells (Gilman et al. 2005). 
In order to circumvent this problem, new vaccines which lack the amino acid 
parts thought to be responsible for the T-cell response, but preserving the 
beneficial antibodies against Aß are under development. 
An  alternative  immunotherapeutic  strategy,  avoiding  T-cell  response,  is 
passive  immunization.  Unpublished  data  from  a  phase  II  study  of  the 
humanized monoclonal antibody bapineuzumab demonstrated that there was 
no improvement in cognition and functional ability (Burns 2009). 
Another  approach  is  targeting  Aß  aggregation.  The  only  Aß  aggregation 
inhibitor reaching phase III is the synthetic glycosaminoglycan 3-amino-1- 
propaneosulfonic  acid  [3APS,  tramiprosate,  Alzhemed].  It  is  designed  to 
prevent conformational transitions that lead to the assembly of the neurotoxic 
oligomers  and  subsequently  protofibrils  and  fibrils.  A  phase  II  trial  using 
3APS demonstrated a significant decrease in mean CSF Aß 42 concentration 
vs.  baseline,  but  no  significant  differences  in  the  cognitive  and  clinical 
assessments  between  the  3APS  and  placebo  groups  was  noticed  after  3 
months of treatment. However, the disappointing results from the US phase 
III trial in the year 2007 led to discontinuation of the European phase III trial 
(McLaurin et al. 2006;Gervais et al. 2007). 
Several other drugs not targeted at Aß are being examined for their efficacy. 
These  include  mainly  statins,  anti-oxidants,  anti-inflammatory  drugs, 
estrogens, nerve growth factor [NGF] mimics and anti-tau drugs. An old anti-
histmainic drug, dimebon, has shown promising results in a clinical trial for 
patients with mild-to-moderate AD (Doody et al. 2008). Interestingly, one of 
the possible discussed mechanisms of action is mitochondrial protection by Introduction 
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preventing opening of mitochondrial pores induced by neurotoxins (Bachurin 
et al. 2003). 
Concluding, there seems to be consensus that multiple drugs will be required 
for the treatment of AD, and more or less individually tailored drugs should 
be  indicated.  This  creates  imposing  challenges  for  both  researchers  and 
pharmaceutical industries in developing such drugs. Introduction 
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1.2 Ginkgo Biloba 
The Ginkgo tree is a living fossil, representing the family Ginkgoaceae. It is 
the only surviving member of this family dating back to hundreds of millions 
of  years.  Scientists  thought  that the  Ginkgo  tree  became  extinct,  until the 
German  physician  Engelbert  Kaempfer  discovered  its  presence  in  Japan. 
Ginkgo seeds were brought to Europe from Japan by Kaempfer in the early 
1700's and to the USA later that century. 
 
 
 
Figure 1-14 
Ginkgo biloba tree Introduction 
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The seed of the Ginkgo tree has a silvery shine [see photo below] and the 
name Ginkgo is thought to originate from the Japanese word Ginkyō meaning 
silver apricot. As for the term biloba it is a Latin word meaning 2 lobes, 
describing the shape of the leaves. They are leathery with a wax layer and a 
deep vertical slit dividing the leaf into 2 lobes and giving it its characteristic 
form.  
 
    
Figure 1-15 
Ginkgo biloba seeds and leaves 
The Ginkgo biloba seeds appearing like a small apricot with a silvery shine [left] and the typical 
leaves with a slit dividing it into 2 lobes [left] Introduction 
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1.2.1 Medicinal History  
The seeds of Ginkgo biloba were first described in the Chinese medicine for 
over 5000 years. The use of seeds was described for digestion and for the 
treatment of asthma, coughs, irritability of the bladder, blenorrhoa and uterine 
fluxes. As for the use of the leaves, this was mentioned later as an aid for 
blood circulation, for the lungs, for skin treatment, head sores and freckles. 
The  first  publication  concerning  the  internal  use  of  the  leaves  of  Ginkgo 
biloba  for  medicinal  purposes  dates back  to 1505  A.D,  where  it  was  first 
mentioned to be used for the treatment of diarrhea. 
Dr. Willmar Schwabe a German physician-pharmacist introduced extracts of 
Ginkgo biloba leaves into medicinal practice in 1965. The extract of Ginkgo 
biloba leaves was first registered as a medication by Dr. Willmar Schwabe 
GmbH & Co. in Germany with the trade name Tebonin. Co-developed by Dr. 
Willmar Schwabe Company, IPSEN and INTERSAN the extract obtained the 
code name “EGb 761
®”. 
 
Figure 1-16 
Dr. Willmar Schwabe [1840-1917] 
Dr. Willmar Schwabe Pharmaceuticals was found in 1866. Introduction 
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1.2.2 Production of EGb 761
® 
1.2.2.1 Harvesting and cultivation 
The leaves for EGb 761
® are harvested with a modified cotton-picker and air-
dried to contain about 70-75 % moisture before drying and approximately 10 
% after drying. Dried leaves from the plantations in Bordeaux, South Carolina 
and the Far East are analyzed for the contents of the active constituents. It is 
notable  to  mention  the  fact  that  the  amounts  of  active  constituents  differ 
dramatically according to the season of harvesting. 
1.2.2.2 Extraction and standardization 
Like any other plant extract, toxic substances which can cause allergies or 
other disturbances have to be removed. In the case of Ginkgo biloba these 
toxic substances are mainly alkylphenol compounds. A patented invention by 
Schwabe in 1994 provided an extract of Ginkgo leaves that is substantially 
free from the alkyl phenols and containing all the ginkgolides and the flavonol 
glycosides present essentially in the leaves. From 100 kg Ginkgo leaves only 
2.5 kg of extract are obtained. 
To  ensure  a  standardized  extraction  the  Ginkgo  leaves  are  harvested  in 
summer or autumn while they are still green followed by an 18-step extraction 
procedure. According to the German federal health authority the composition 
of the extract is as follows: 
“A dry extract from the dried leaves of Ginkgo biloba Linne manufactured 
using  acetone/water  and  subsequent  purification  steps  without  additionally 
mixing  concentrations  or  isolated  active  ingredients.  The  extract  is 
characterized  by  22-27  %  flavonol  glycosides,  determined  as  quercetin, 
kaempferol  including  isorhamnetin,  5-7  %  terpene  lactones,  of  each 
approximately  2.8-3.4  %  consist  of  ginkgolide  A,  B  and  C,  as  well  as 
approximately 2.6-3.2 % bilobalide and below 5 ppm ginkgolic acids. 
To insure consistent quality a standardized procedure is always preformed.  Introduction 
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Figure 1-17 
Extraction and standardization process for preparation of EGb 761
® 
Scheme demonstrating the extraction procedure for preparation of EGb 761
® from Ginkgo biloba 
leaves. 
Active components/ condensed 
 Polyphenolic compounds 
Total extract 
EGb761 
Water soluble components 
Ginkgo biloba leaves 
Extraction with acetone/ water 
Enrichment of active components 
Removal of strongly lipophilic components 
Removal of condensed polyphenolic compounds Introduction 
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1.2.3 Chemical composition 
1.2.3.1 Flavonoids 
The flavonoids present in EGb 761
® are exclusively flavonol-o-glycosides i.e. 
combinations of the phenolic aglycon with sugars in different positions of the 
flavonol moiety. The chemical structures of the flavonoids in EGb 761
® are 
illustrated below. 
 
Figure 1-18 
Chemical structure of flavonoid constituents 
Flavonol-O-glycosides, with a glycosidic linkage normally located in position 3 or 7 of a phenolic 
aglycon [quercetin, kaempferol or isorhamnetin] and the carbohydrate moiety usually being D-
glucose, L-rhamnose or glucorhamnose. 
 Introduction 
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1.2.3.2 Terpeniods 
The  terpeniods  present  in  EGb  761
®  are  Ginkgolides  and  Bilobalide.  The 
Ginkgolides  that  are  present  in  the  EGb  761
®  extract  are  diterpenes, 
Biloblaide  is  a  pentanorditerpene.  These  particular  terpenes  are  found 
exclusively in Ginkgo biloba and they possess three lactone functions and a 
tertiary butyl group. 
1.2.3.3 Ginkgolides 
In 1967 four Ginkgolides were identified namely Ginkgolides A, B, C and M. 
Recently  Ginkgolide  J  was  identified  as  a  constituent  in  EGb  761
®. 
Ginkgolides A, B and C account for about 3.1 % of EGb 761
®. Ginkgolides A 
and C are present in the highest amounts each representing ≥1 %, Ginkgolide 
B is ≤1% and Ginkgolide J ≤0.5 %. Ginkgolide M was only found in the roots 
of the Ginkgo tree, therefore it is not present in the leaf extract EGb 761
® 
(Defeudis 1998). 
1.2.3.4 Bilobalide 
Bilobaide  accounts  for  about  2.9  %  of  EGb  761
®.  Bilobalide  is  a 
pentanorditerpene and it was first isolated by Major in 1967 (Defeudis 1998). Introduction 
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Figure 1-19  
Chemical structure of terpene constituents of Ginkgo biloba  
Ginkgolides  A,  B,  C  and  J  have  been  isolated  from  the  leaves  and  are  present in  EGb  761
®, 
Ginkgolide M is found only in the roots. Bilobalide accounts for about 3.1 % of EGb 761
®. Introduction 
 
  57 
1.2.3.5 Organic acids 
Organic acids represent about 5-10 % of EGb 761
®.These include vanillic 
acid, protocatechuic acid, acetic acid, schikimic acid, p-hydroxybenzoic acid 
and  in lower  amounts kynurenic  acid  and  ascorbic  acid.  These substances 
increase the solubility of the extract by increasing its acidity. Ginkgolic acid, 
which is toxic, is non-detectable in the EGb 761
® extract. 
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Figure 1-20 
Chemical structures of acids present in EGb 761
® 
Acetic acid, shikimic acid, 4-hydroxybenzoic acid, protocatechouic acid [3, 4 dihydroxybenzoic 
acid], vanillic acid [3-methoxy-4-hydroxybenzoic acid] and 6-hydroxykynurenic acid. These acids 
are present in amounts >0.5 %. Introduction 
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1.2.4 Pharmacokinetics 
1.2.4.1 EGb 761
® 
Determining the pharmacokinetic properties of EGb 761
® is quite difficult due 
to the  presence  of  several  active  constituents  in the  extract.  However, the 
examining of the pharmacokinetic properties was already addressed in 1986. 
Moreau et al preformed their study on rats using radioactive EGb 761
®. At 
least 60 % of the radioactivity was absorbed and was broadly distributed. In 
the  brain  radioactivity  was  detected  in  particular  in  the  hypothalamus, 
striatum and hippocampus. 
1.2.4.2 Flavonoids 
The pharmacokinetics of the flavonoid glycosides present in the EGb 761
® 
was thoroughly investigated. The glycosides are absorbed but also quickly 
metabolized. Therefore detection of glycosides and aglycons is not possible 
but  their  metabolites  could  be  detected  in  plasma  indicating  their 
bioavailability. This was seen by Pietta et al in a 15 days treatment study on 
rats  using  EGb  761
®  (Pietta  et  al.  1995)  and  confirmed  in  other  human 
studies. In human plasma, only quercetin glucuronides, but no free quercetin, 
could be detected after administration of quercetin plant extract to 12 healthy 
volunteers in a four-way crossover study (Graefe et al. 2001). Another study 
using  C57BL6  mice  measured  the  plasma  concentrations  of  quercetin, 
kaempferol and isorhamnetin after administration of 36 mg/kg body weight 
EGb  761
®.  The  plasma  concentrations  of  quercetin,  kaempferol  and 
isorhamnetin  were  12,  7  and  49.6  ng/ml  respectively  in  the  Ginkgo-
supplemented  group  compared  to  the  control  group  [4.8  and  3.2  ng/ml, 
respectively; isorhamnetin was not detectable] (Watanabe et al. 2001). 
 
 Introduction 
 
  59 
1.2.4.3 Ginkgolides 
In an attempt to find the bioavailability of the ginkgolides and Bilobalide 
[BB] several pharmacokinetic studies were preformed and are described in the 
literature. The first pharmacokinetic study described in the literature was in 
1995 by Fourtillan et al. In this study on human volunteers both oral and I.V 
EGb 761
® were administered and the authors concluded that ginkgolides A 
[GA] and B [GB] are highly bioavailabe but C [GC] was not bioavailable. 
The relative bioavailability of GA, GB and BB was demonstrated to differ in 
the plasma after a single oral dose of 120 mg Ginkgo biloba according to the 
pharmaceutical preparation applied (Kressmann et al. 2002). 
Measuring the pharmacokinetic parameters in rats after oral administration of 
EGb 761
® the plasma concentrations were BB> GA> GB, and GC was not 
detectable (Biber 2003). Other studies confirmed the bioavailability of GA, 
GB and BB (Mauri et al. 2001). Only very recently, Xie et al were able to 
report pharmacokinetic data for GC by a novel method after I.V injection of 
Ginkgo biloba leaf extract at a dose of 8 mg/kg (Xie et al. 2008).  
The  only  study  showing  distribution  of  GB  in  the  brain  was  recently 
published (Chen et al. 2007). Chen et al were able to demonstrate that 60 
minutes after I.V administration of 12 mg/kg GB to rats, the concentration of 
GB in the brain was 148.9 ng/ ml, and after 6 hours GB was not detectable 
anymore. 
 Introduction 
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1.2.5 Medicinal properties of Ginkgo biloba 
Ginkgo biloba fruits and seeds have been used in Chinese traditional medicine 
with indications for the treatment of asthma, bronchitis and skin diseases. The 
use of Ginkgo biloba leaves came later into practice, where the internal use of 
Ginkgo leaves was first published in a text by Liu Wen-Tai. Modern Chinese 
pharmacopeias  introduced  the  leaves  of  Ginkgo  biloba  for  treating 
dysfunctions of heart and lungs (Defeudis 1998). In folk medicine Ginkgo can 
be  used  to  induce  labor,  for  the  treatment  of  bronchitis,  chronic  rhinitis, 
arthritis and edema. However, these indications have no scientific background 
and  are  not  supported  by  research  or  clinical  data.  Surprisingly,  the 
indications of Ginkgo nowadays were not identified in folk medicine. 
According to the WHO monograph for medicinal plants, standardized Ginkgo 
biloba leaves extracts have been used for symptomatic treatment of mild to 
moderate cerebrovascular insufficiency, different forms of dementia with the 
following  symptoms:  memory  deficit,  disturbance  in  concentration, 
depressive  emotional  condition,  dizziness,  tinnitus,  and  headache. 
Standardized  extracts  are  also  used  in  peripheral  arterial  occlusive disease 
such as intermittent claudication, Raynaud disease, acrocyanosis, and post-
phlebitis  syndrome,  and  to  treat  inner  ear  disorders  such  as  tinnitus  and 
vertigo of vascular and involutive origin. 
Nowadays,  the  standardized  extract  of  Ginkgo  biloba  leaves  EGb  761
®  is 
becoming one of the most popular herbal medicine and dietary supplements 
consumed in Europe and the US. Since the major therapeutic indications for 
EGb  761
®  are  associated  with  age-related  memory  impairments,  more 
attention will be given here to the research in this field. Earlier, in vivo or ex 
vivo research using EGb 761
® was more extensively studied, but recently the 
trend is moving towards cellular and molecular mechanisms of action of EGb 
761
® and its constituents. Introduction 
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1.2.6 Pharmacological effects 
The pharmacological effects of EGb 761
® and its constituents that most likely 
play a role in the treatment of memory deficits and Alzheimer’s disease are 
discussed below.  
1.2.6.1 Free radical scavenging effect 
The important role of oxidative stress and ROS in aging and AD has been 
previously discussed in section 1.1.8. One of the highly proposed mechanisms 
of action of EGb 761
® is its free radical scavenging effect. Several researchers 
have linked the neuroprotective effect of EGb 761
® to its anti-oxidative effect. 
Previous  studies  have  highlighted  the  potential  of  EGb  761
®  and  its 
components as scavengers of free radicals such as OH
., O2
- and NO in both in 
vitro acellular and cellular studies, as well as in vivo studies (Defeudis 1998).  
For instance, Smith and Luo have demonstrated that a pre-treatment with EGb 
761
®  significantly  lowered  ROS  levels  both  in  a  cellular  model  stably 
expressing an AD associated double mutation and in C.elegans AD model 
(Smith  and  Luo  2003).  EGb  761
®  and  α-tocopherol  exhibited  similar 
inhibitory effects in vitro on lipid peroxidation in rat brain synaptosomes and 
human lymphocytes (Sram et al. 1993). 
In  post-mortem  tissue  from  AD  patients’  it  was  shown  that  EGb  761
® 
prevented  lipid  peroxidation  induced  by  the  pro-oxidant  system  H2O2/Fe
2+ 
(Ramassamy  et  al.  1999).  Moreover,  intracellular  and  mitochondrial  ROS 
decreased when hippocampal neurons were treated for 24 hours with EGb 
761
® (Bastianetto et al. 2000a). 
Not only in vitro studies linked the anti-oxidative effects of EGb 761
® to its 
neuroprotective effects, but a number of in vivo studies supported this fact. 
Treating rats with 50 or 100 mg/kg body weight for 12 weeks resulted in 
decrease  of  lipid  peroxidation  in  the  cerebral  cortex,  and  only  the  higher Introduction 
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concentration  [100  mg/kg  body  weight]  was  able  to  decrease  lipid 
peroxidation in the hippocampus (Sram et al. 1993). 
Another  in  vivo  study  by  Holgado  et  al  in  1995  showed  very  interesting 
results after treating 4 and 33 months old rats with 100 mg/kg body weight 
EGb 761
® daily for 3 months. In the younger rats EGb 761
® was able to 
decrease  the  rates  of  O2
-  with  no  effect  on  superoxide  dismutase  [SOD], 
catalase  and  glutathione  peroxidase.  However  in  the  older  rats  EGb  761
® 
treatment was able to decrease the rate of O2
- generation as well as increase 
the scavenging activities of the 3 mentioned enzymes. Other results were also 
able to confirm the ability of EGb 761
® to increase the activities of anti-
oxidant enzymes, for example glutathione in mouse liver (Sasaki et al. 2002) 
as well as SOD and catalase (Bridi et al. 2001) in rats.  
A more recent study showed that both Ginkgo biloba extract and vitamin E 
reduced the oxidative stress resulting from senile plaques in vivo as monitored 
with intracranial imaging (Garcia-Alloza et al. 2006). 
With all the above mentioned evidence it seems that the anti-oxidant property 
of EGb 761
® plays a significant role in its therapeutic effects, the question that 
arises  is  clearly  which  of  EGb  761
®  constituents  is  responsible  for  these 
effects. 
Many  researchers  have  addressed  this  question  and  the  majority  links  the 
radical scavenging activity of EGb 761
® to the flavonoid fraction. This is 
partly due to their chemical structure. 
In  acellular  models  and  test-tube  reactions  EGb  761
®  scavenges  hydroxyl 
radicals and superoxide radicals efficiently, while the terpenoid fractions fails 
(Pietri et al. 1997). 
Ramassamy et al were able to show that the flavonoid fraction of EGb 761
® 
has  higher  ability  to  prevent  oxidative-induced  damages  than  the  terpene 
fraction (Ramassamy et al. 1993). In another study, the anti-lipoperoxidative Introduction 
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effect  of  the  terpenoids  and  the  flavonoids  were  determined  in  isolated 
hepatocytes and the terpenoid fraction showed no effect while the flavoniods 
were  effective  (Joyeux  et  al.  1995).  Moreover,  the  flavonoid  fraction  [CP 
205], but not the terpenoid constituents [CP 160 and BN 52021], was also 
able  to  decrease  the  Aß-induced  ROS  production  in  hippocampal  cells 
(Bastianetto et al. 2000a). 
Although many studies assert the anti-oxidative effect of EGb 761
® to the 
flavonoids, it seems that the terpenoid fraction also play a role here. 
In an acellular model it was shown that BB, GB, GC and GJ but not GA have 
radical scavenging activities (Scholtyssek et al. 1997) when using DMSO as a 
solvent instead of water.  
In  vitro,  Zhou  et  al  were  also  able  to  show  that  BB  can  protect  neurons 
against oxidative stress (Zhou and Zhu 2000). Some studies showed that the 
flavonoid fraction alone was not able to exert the same effect as the whole 
extract.  For  example,  the  H2O2-induced  toxicity  in  hippocampal  cells  was 
attenuated by a co-treatment with EGb 761
®; however the flavonoid fraction 
CP 205 was not effective (Bastianetto et al. 2000a). 
Therefore, the primary assumption that the anti-oxidative properties of EGb 
761
® are only due to the presence of its flavonoid fraction is imprecise. 
Concluding, it seems that EGb 761
® has indeed free radical scavenging and 
anti-oxidant  properties,  regardless  of  the  exact  constituents  that  are 
implicated.  It  appears  that  the  flavonoid  fraction  exert  a  direct  radical 
scavenging activity which could be partly explained by its chemical structure, 
and  that  the  terpenoids  seem  to  somehow  decrease  the  generation  of  free 
radicals. 
Although EGb 761
® is known to act as a vasodilator, and can influence the 
endothelial nitric oxide synthase induced NO production (Li et al. 2001), it is 
suggested that excessive NO production stimulated by inducible nitric oxide Introduction 
 
  64 
synthase  could  be  controlled  by  EGb  761
®.  The  deleterious  effects  of 
excessive  NO  have  also  been  previously  discussed  [section  1.1.8]  and 
fortunately EGb 761
® shows not only anti-oxidative properties but also can 
protect cells from nitrosative stress. In 1994, EGb 761
® was described as an 
NO scavenger in acellular system (Marcocci et al. 1994). Later on other in 
vitro  studies  showed  the  ability  of  EGb  761
®  to  protect  cells  against  NO 
damage  in  PC-12  cells  and  hippocampal  neurons  (Eckert  et  al. 
2005;Bastianetto et al. 2000b). 
As for the EGb 761
® constituents, in PC 12 cells BB was able to inhibit the 
NO induced toxicity, on the other hand in hippocampal neurons the flavonoid 
fraction  was  most  effective  and  the  terpenoid  and  GB  were  not  effective 
(Song et al. 2000;Bastianetto et al. 2000b). 
To sum up EGb 761
® and its components are capable of scavenging reactive 
oxygen  species  and  reactive  nitrogen  species,  preventing  their  damage  on 
cells. Which constituent/ constituents play a part here is highly debatable. In 
order to reach such conclusions all components should be evaluated under the 
same  conditions.  Meaning  the  method  used,  cell  model,  experimental 
procedures and all influencing factors should be identical. 
1.2.6.2 Mitochondrial protection and anti-apoptotic effects 
Mitochondrial dysfunction has been lately associated with the aging process 
as well as with neurodegenerative diseases as described in section 1.1.9. The 
role  of  EGb  761
®  in  protecting  the  mitochondria  is  receiving  much  more 
attention  lately.  Previously  the  effect  of  EGb  761
®  on  cells  was  mainly 
attributed to its radical scavenging activity, but recently studies are pointing 
out to a direct effect on the mitochondria. Some of these direct effects, such as 
stabilization of mitochondrial membrane potential, ATP levels and protection 
against complexes inhibitors were shown in PC12 cells (Eckert et al. 2005). Introduction 
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Also  in vivo protection  was observed,  for  instance age-related decrease  in 
respiratory functions and morphological changes of both brain and liver rat 
mitochondria were prevented by treatment with EGb 761
® [100 mg/kg body 
weight] (Sastre et al. 1998). EGb 761
® treatment also modulated synaptic and 
mitochondrial plasticity in rats with vitamin E deficiency (Bertoni-Freddari et 
al. 2002). 
Not only direct mitochondrial effects were described for EGb 761
®, but also 
anti-apoptotic  effects.  It  was  able  to  prevent  serum  deprivation  and 
staurosporine-induced  mitochondrial  damage  and  attenuated  cytochrome  C 
and DNA fragmentation (Smith et al. 2002;Massieu et al. 2004). The ratio of 
the pro-apototic protein Bax to the anti-apoptotic protein Bcl-2 was decreased 
by EGb 761
® in all brain regions in senescence-accelerated mice (Lu et al. 
2006). Up regulation and down regulation of Bcl-2 and Bax respectively was 
previously  reported (Smith  et  al. 2002;Zhou  and  Zhu 2000).  Additionally, 
EGb 761
® was able to decrease the activities of both caspases 3 and 9, where 
activation of the caspase cascade is known to lead to apoptosis and cell death 
(Eckert et al. 2005;Luo et al. 2002). 
Here  again  just  like  the  anti-oxidative  effect,  many  tried  to  link  the 
mitochondrial  protective  effects  of  EGb  761
®  to  one  or  more  of  its 
components. In contrast to the free radical scavenging effect, the terpenoid 
fraction is highly associated to the mitochondrial protection properties of EGb 
761
®  and  BB  being  the  most  nominated  candidate.  In  vitro  BB  inhibited 
hypoxia-induced  decreases  in  ATP  content  in  endothelial  cells,  protected 
complexes  1  and  3  against  complex  inhibitors  and  was  able  to  increase 
complex 1 activity in liver mitochondria (Janssens et al. 1999;Janssens et al. 
1995).  BB  also  reduced  ROS-induced  elevation  of  Bax  and  activation  of 
caspase-3 effectively in PC 12 cells. 
Ex vivo, the respiratory control ratio of liver mitochondria was increased in 
rats treated with BB (Janssens et al. 1995). Another 2 in vitro studies carried Introduction 
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out on most of the terpenoids showed discrepancies, one study indicated that 
BB was the most potent anti-apoptotic constituent (Ahlemeyer et al. 1999) , 
where  as  another  study  revealed  that  GB,  but  not  BB,  was  effective  in 
opposing apoptosis (Rapin et al. 1998). However, the study by Ahlemeyer et 
al  indicated  also  the  anti-apoptotic  effects  of  GJ  and  GB.  Moreover,  GB 
inhibited apoptosis induced by 6-hydroxydopamine [6-OHDA] and decreased 
the activity of caspase-3 in PC 12 cells (Meng et al. 2007). 
From the above studies it appears indeed that the terpeniods of EGb 761
® all 
except maybe GA (Ahlemeyer et al. 1999), show mitochondrial protection 
and anti-apoptotic properties in vitro. Depending on the cell model used and 
the  methodologies  it  is  still  ambiguous  which  of  the  terpenoids  is  most 
effective, BB, or GB or is it a synergistic action of two or more terpeniods.  
But  it  would  be  too  simple  to  exclude  the  flavonoid  fraction  from  the 
mitochondrial protective effects! So just to complicate things, there is also 
evidence that the total flavonoid component of EGb 761
® and a mixture of 
flavonoids  and  terpenes  protected  cerebellar  granule  cells  from  apoptosis 
induced by hydroxyl radicals. Surprisingly, total terpenes of EGb 761
® did not 
protect against apoptosis in the same study (Xin et al. 2000)! 
1.2.6.3 Neurotransmitter systems 
Neurotransmitter systems regulate CNS activities. Aging is associated with 
changes in neurotransmitter systems. In rodents, aging is highly associated 
with  the  decrease  in  the  number  of  neurotransmitter  receptors.  While  in 
humans  data  are  more  complicated,  nevertheless  neurotransmitter  receptor 
changes  have  also  been  noticed  in  post-mortem  tissue  from  AD  patients 
(Mash et al. 1985). 
Interestingly, EGb 761
® is able to increase the maximum number of receptor 
binding  sites  [B  max]  and  the  receptor  density  of  a  number  of 
neurotransmitters (Defeudis 1998) in aging models. This effect of EGb 761
® Introduction 
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has been shown in ex vivo studies demonstrating that it has the ability of 
increasing  the  B  max  of  muscarinic,  serotoninergic  and  alpha  adrenergic 
receptors (Taylor 1986;Huguet and Tarrade 1992;Huguet et al. 1994).  
A  dramatic  degeneration  of  the  cholinergic  system  especially  in  the 
hippocampus and cerebral cortex is a well known characteristic for AD and 
cognitive decline. For example, it was previously reported that the number of 
muscarinic receptors of rats subjected to cholinergic denervation is decreased 
(Mash et al. 1985). Also the muscarinic receptor binding was found to be 
lower in the brains of aging rodents (Defeudis 1998). These findings were 
confirmed in post-mortem tissue form AD patients (Mash et al. 1985). 
Relevant to these findings, the effect of EGb 761
® on the cholinergic system 
has been extensively studied. EGb 761
® was shown to increase the B-max of 
high affinity choline uptake in vitro in hippocampal synaptosomes as well as 
ex vivo after treatment of old rats with EGb 761
® for 30 days (Kristofikova 
and Klaschka 1997). This implies that treatment with EGb 761
® might cause 
activation  of  cholinergic  nerve  terminals.  Taking  into  account  that  high 
affinity choline uptake is decreased during aging (Defeudis 1998), the former 
results  suggest  that  EGb  761
®  can  cause  deceleration  of  brain 
neurodegenerative processes.  
Some  of  the  constituents  of  EGb  761
®  have  also  shown  effects  on  the 
neurotransmitter systems. An in vitro study on hippocampal slices, showed 
that  BB  prevented  hypoxia  and  NMDA-induced  release  of  choline  and 
activation  of  phospholipase  A2  (Klein  et  al.  1997;Weichel  et  al.  1999). 
Enhanced 5-HT uptake in synaptosomes from mouse cortex was related to the 
flavonoid fraction and not the terpeniods (Ramassamy et al. 1992). 
These  effects  of  EGb  761
®  on  neurotransmitter  systems  especially  the 
cholinergic system could be involved in the positive effects of the extract on 
aging, cognition and dementia. Introduction 
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1.2.6.4 Receptors: Platelet activating factor receptor 
Platelet activating factor [PAF] receptor is a member of G-protein coupled 
receptors. Specific PAF receptors have been identified in the CNS, localized 
in  both  synaptic  endings  and  intracellular  membranes  (Marcheselli  et  al. 
1990). PAF is an alkyl phosphoglyceride produced by a variety of cells. PAF 
is  involved  in  numerous  disorders  including  acute  allergy,  inflammation, 
asthma, and ischemic injury. It also appears to augment neurotransmission 
involving  excitatory  amino  acids.  It  was  previously  reported  that  PAF 
enhances  excitatory  synaptic  transmission  in  cultured  rat  hippocampal 
neurons (Clark et al. 1992). Some of the actions related to PAF are its ability 
to  induce  intracellular  Ca
2+  mobilization,  long  term  potentiation  and 
modulation of apoptosis (Maclennan et al. 2002). Most of these actions were 
shown to be antagonized by the most potent PAF antagonist GB.  
One of the earliest mechanisms described for GB was its ability to act as a 
PAF  receptor  antagonist  (Braquet  et  al.  1985).  Several  other  studies  have 
come  to  show  that  all  terpeniods  act  as  PAF  antagonist  in  vitro  but  with 
different  affinities  (Koch  2005).  Stromgaard  et  al  reported  that  the  most 
potent terpenoid was GB with a Ki value of 0.56 µM, while GA was slightly 
less potent. GC and GJ are significantly less potent and BB had Ki value 
larger than 50 µM (Stromgaard et al. 2002). Although the exact mechanisms 
of PAF in the CNS are still not clear, there is no doubt that this mechanism of 
action is specific only for the terpenoids and no other constituents in EGb 
761
® (Steinke et al. 1993). Introduction 
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1.2.6.5 Receptors: Glycine receptor 
Glycine receptors belong to the pentameric nicotinic acetylcholine receptor 
super family. Glycine receptors are known to mediate synaptic inhibition in 
spinal  cord,  brainstem  and  also  in  higher  brain  regions  such  as  the 
hippocampus  and  developing  cortex  (Betz  and  Laube  2006).  The 
neuropharmacology and functional importance of glycine receptors in higher 
brain  regions  is  unfortunately  not  well  characterized  (Chattipakorn  and 
McMahon 2002). Recently GB has been reported to inhibit glycine receptor 
mediated  currents  in  acutely  isolated  hippocampal  pyramidal  neurons 
(Kondratskaya  et  al.  2002)  and  cortical  slices  (Ivic  et  al.  2003)  in  a 
noncompetitive fashion. It was also reported that GB and GC are significantly 
more potent than GA and GJ (Ivic et al. 2003;Chatterjee et al. 2003). Introduction 
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1.2.6.6 Amyloid precursor protein and Amyloid beta 
We have already highlighted the toxicity of amyloid beta and the role it plays 
in AD [1.1.6]. In this section we will concentrate on the effects of EGb 761
® 
on Aß-induced toxicity. 
Quite a few in vitro studies showed the toxicity of Aß in in vitro models and 
the ability of EGb 761
® to hinder its effect. Aß–induced increase in ROS, 
apoptosis,  glucose  uptake,  decrease  mitochondrial  membrane  potential  and 
decrease in neurogenesis (Yao et al. 2001;Bastianetto et al. 2000a;Tchantchou 
et al. 2007) were all attenuated by EGb 761
® extract.  
What is more interesting is that EGb 761
® is not only able to protect against 
Aß induced toxicities but also shows a direct effect on Aß production and 
aggregation.  Interestingly,  patients  who  received  Ginkgo  for  more  than  2 
years had significantly lower levels of Aß 42 in plasma (Blasko et al. 2005). 
Furthermore, in vivo studies reported that EGb 761
® was able to direct the 
APP  metabolism  towards  the  non-amyloidogenic  alpha  secretase  pathway 
without affecting APP levels and another study showed decrease in both the 
amount  of  Aß  and  APP  (Colciaghi  et  al.  2004;Yao  et  al.  2004).  On  the 
contrary, treating transgenic mice with EGb 761
® showed unaltered Aß levels 
although spatial learning and memory were enhanced (Stackman et al. 2003). 
The  toxicity  of  Aß  varies  tremendously  depending  on  its  form.  Aß  self-
assembles  into  oligomeric  structures,  protofibrils  and  fibrils which  are  the 
main constituents of amyloid plaques. Aß monomers have little or no toxic 
effects; it is the aggregates which are highly toxic. Therefore mechanisms 
which try to prevent aggregation of Aß could be of therapeutic relevance. 
Interestingly,  in  vitro  studies  were  able  to  demonstrate  that  EGb  761
® 
decreased Aß fibrillogenesis (Luo et al. 2002;Longpre et al. 2006). Moreover, 
Luo et al together with others were able to show that EGb 761
® inhibits the Introduction 
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formation of the toxic oligomers or the so called ADDLs (Luo et al. 2002;Yao 
et al. 2001) in cell models. 
These findings were confirmed in vivo, after treating 12 months old tg mice 
for 1 month with EGb 761
®, levels of the 21 kDa oligomer was found to be 
reduced (Tchantchou et al. 2007).  
From  the  above-mentioned  evidence  one  may  state  that  EGb  761
®  is 
protective against Aß-induced cell toxicity and alters either production and/or 
aggregation  of  Aß.  Trying  to  relate  these  effects  to  a  certain  component 
showed inconsistency. 
Aß induced cell toxicity and fibril formation were decreased by the flavonoid 
fraction and not the terpenoids (Bastianetto and Quirion 2002;Longpre et al. 
2006).  Moreover,  a  very  recent  study  illustrated  several  mechanisms  of 
myricetin  [a  flavonoid  constituent  of  EGb  761
®]  against  Aß-induced 
neurotoxicity. They were able to show that myricetin prevented Aß induced 
apoptosis, caspase 3 activation and also activated and up-regulated α-secretase 
and inhibited ß-secretase (Shimmyo et al. 2008). Quite the opposite is seen in 
other studies  were myricetin  and quercetin show  no  effect on  Aß-induced 
toxicity and on the other hand GA and GB are protective (Bate et al. 2004). 
Therefore, the role of the terpenoids here can not be left out. GJ, GA, and GB 
are capable of blocking the Aß 42 induced damage to synaptic plasticity in 
cell culture, with GJ showing the highest effects (Vitolo et al. 2009). On the 
contrary GC and BB exhibited no effects here. In transgenic C. elegans GA 
was the most effective against Aß-toxicity and to some extent GJ, but both 
were able to decrease the formation of Aß oligomers (Wu et al. 2006).  
It appears quite complicated in this matter to try to assert these effects to one 
of  the  components  of  EGb  761
®,  the  discrepancies  seen  are  due  to  the 
methodologies used or the research models. Another factor which has to be Introduction 
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taken  into  consideration  is  the  fact  that  all  the  tests  carried  out  with  the 
constituents are in vitro and their in vivo significance is still questionable!  
1.2.6.7 Gene Expression 
The gene-regulatory actions of EGb 761
® has been addressed and proposed as 
one  of  its  protective  mechanisms  that  may  actually  oppose  some  gene 
expression  abnormalities  that  cause  neurodegeneration  or  cognitive 
impairments. 
One of the major mechanisms previously discussed is the protective effect of 
EGb 761
® against excess NO. As described before in section 1.2.6.1 EGb 
761
® was able to counteract some of the deleterious effects of NO. Excessive 
NO production can be a result of activation or over expression of enzymes 
which catalyze its formation. 
There  are  3  different  forms  of  these  enzymes  which  are  known  as  NO 
synthases. These are, 
Constitutive endothelial cells NOS [eNOS] 
Inducible macrophage type NOS [iNOS] 
Brain or neuronal NOS [nNOS] [inducible] 
EGb 761
® down regulates iNOS in vitro and ex vivo, the ex vivo effect was 
also  seen  with  nNOS  (Wadsworth  et  al.  2001;Sharma  et  al.  2000). 
Noteworthy here is to mention that traumatic brain injury and acute restraint 
stress have been shown to cause increase in nNOS RNA (de Oliveira et al. 
2000;Rao et al. 1999), pointing out the neuroprotective effect of EGb 761
®.  
As for the constituents of EGb 761
®, GA, GB and BB were able to down-
regulate iNOS in vitro, and GB down-regulated iNOS and nNOS in rat brains 
ex vivo (Sharma et al. 2000). 
The  anti-oxidant  effect  of  EGb  761
®  and  its  flavonoid  fraction  has  been 
previously mentioned [section 1.2.6.1]. What is left to say in this section is Introduction 
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that  EGb  761
®  is  able  to  up-regulate  some  anti-oxidant  enzymes  such  as 
mitochondrial Mn superoxide dismutase and regulatory subunit-1 of gamma-
glutamyl-cysteinyl synthetase [GCS] which is the rate controlling enzyme for 
glutathione synthesis (Gohil et al. 2000). Down-regulation of this enzyme was 
noticed with age in cerebral cortex, hippocampus and cerebellum of rats, and 
this change is correlated with decreases in the gamma GCS activity and the 
GSH content (Liu 2002), encouraging the use of EGb 761
® during aging. 
Moreover Chen et al demonstrated that treating cells in vitro with Ginkgo 
extract induced glutathione peroxidase [GPx] gene expression (Chen et al. 
2001) whereas GB and BB showed no effect. With regards to the fact that 
over-expression  of  GPx  increases  the  resistance  of  PC12  cells  and  rat 
embryonic cultured cortical neurons to Aß-induced damage, this indicates a 
protective role of EGb 761
® against Aß-toxicity and its benefit in AD (Barkats 
et al. 2000).  
EGb  761
®  and  its  constituents  influence  mitochondrial  and  anti-apoptotic 
genes.  EGb  761
®  was  able  to  up-regulate  the  anti-apoptotic  bcl-2  protein. 
Furthermore,  a  two-fold  increase  in  subunit  1  of  NADH  dehydrogenese 
[complex 1] was observed by EGb 761
® and BB in vitro (Tendi et al. 2002). 
BB affects another complex of the respiratory chain; it causes a significant 
increase in the cytochrome c oxidase subunit 3 COX III [complex 4] mRNA, 
this effect was specific to BB and not shared by GB. 
Interestingly, brains from AD patients showed a 50-65 % decrease in mRNA 
levels  of  COX  I  and  III  in  the  middle  temporal  association  neocortex  as 
compared  to  control  brains.  These  outcomes  add  to  the  mitochondrial 
protective effects of EGb 761
® and its indication as a therapy for AD.  
Transthyretin which is known to sequester Aß and decrease amyloid plaque 
formation (Tsuzuki et al. 2000;Schwarzman et al. 1994;Stein et al. 2004), was 
up regulated in mice hippocampus after feeding them for 4 weeks with EGb Introduction 
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761
® (Watanabe et al. 2001). In the same study Watanabe et al were also able 
to  demonstrate  that  mRNAs  of  tyrosine/threonine  phosphatase  1  and 
microtubule–associated tau were both increased by 7 and 4 folds respectively. 
This is quite interesting because microtubule associated tau over expression 
can lead to formation of the neurofibrillary tangles found in the AD brain. On 
the other hand, up regulation of tyrosine/threonine phosphatase 1 could be 
beneficial since hyper-phosphorylated tau isolated from AD patients has been 
shown to be efficiently dephosphorylated by phosphatases (Gong et al. 2000). 
In relation to Aß only one study lately tested the effect of EGb 761
® and its 
constituents  on  Aß  production  by  measuring  the  ß-secretase  which  is 
responsible for the amyloidogenic cleavage of APP leading to formation of 
Aß.  They  concluded  that  neither  EGb  761
®  nor  its  constituents  affect  ß-
secretase mRNA and enzyme activity levels in cultured neurons and in mice 
(Augustin et al. 2008). 
From  the  foregoing  section  it  is  obvious  that  EGb  761
®  and  some  of  its 
constituents  exert  modifications  in  mammalian  gene  expression.  The 
activation or inhibition of genes that maybe involved in diseases such as AD 
should  be  examined.  Although  the  importance  of  Aß  and  tau  in  the 
pathogenesis  of  AD  is  well  known,  a  few  researches  have  been  directed 
towards  the  genes  responsible  for  production  and/or  clearance  of  these 
proteins. Introduction 
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1.2.7 Clinical evidence 
1.2.7.1 EGb 761
® in healthy subjects 
Concerning the clinical efficacy of EGb 761
® many studies were carried out 
on  older  participants  with  cognitive  impairment,  and  fewer  on  healthy 
subjects. Regarding the trials on healthy subjects, a recent review updated to 
January 2007 from 15 randomized clinical trials declares that these studies 
provide no convincing evidence that G. biloba extracts taken either as a single 
dose or over a longer period has a positive effect on any aspect of cognitive 
performance in healthy people under the age of 60 years. 
However,  some  of  the  earlier  single-dose  studies  have  indeed  reported 
positive effects of Ginkgo, but due to weak methodologies such as low sample 
size  their  relevance  is  underestimated  (Hindmarch  1986;Subhan  and 
Hindmarch  1984;Canter  and  Ernst  2007).  Recent  studies  are  very 
contradicting, they reported subjective positive effects (Kennedy et al. 2002) 
unreliable positive results (Elsabagh et al. 2005) and no significant effects of 
EGb 761
® in healthy adults (Jezova et al. 2002). 
As for long-term studies on healthy subjects the evidence is more negative in 
respect to EGb 761
® (Burns et al. 2006;Mattes and Pawlik 2004;Elsabagh et 
al. 2005;Kunkel 1993).The only positive study was by Stough et al. where 5 
of 11 measured outcomes were in favor of Ginkgo (Stough et al. 2001). 
The available trials imply that both short-term and long-term administration 
of Ginkgo in healthy young adults doesn’t appear to enhance memory and/ or 
cognitive functions. 
Nevertheless, it appears that healthy adults over 60 years could benefit from 
EGb 761
®. This observation was made by Mix et al in a 6-week trial with a 
daily dose of 180 mg EGb 761
® (Mix and Crews, Jr. 2002) where the authors 
concluded  that  EGb  761
®  is  efficient  in  enhancing  certain 
neuropsychological/memory  processes  in  healthy  adults  over  60.  In Introduction 
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accordance to this study are the findings of Burns et al that long-term memory 
assessed by associational learning tasks showed improvement with Ginkgo 
over 12 weeks using only 120 mg/day in subjects aged 55 to 79 years (Burns 
et al. 2006). However in the same study there was no difference between the 
EGb 761
® and placebo group in other measured parameters. Another 6 week 
study  applying  120  mg  Ginkgo  daily  also  found  no  effects  on  cognitive 
performance (Solomon et al. 2002).  
The fact that in these 3 trials, using moderate doses [180 mg/kg] for 6 weeks 
showed optimum results (Mix and Crews, Jr. 2002) a lower dose 120 mg/day 
for longer time [12 weeks] showed effect only on long term memory (Burns et 
al. 2006) and low dose [120 mg/day] for short period [ 6 weeks] showed no 
effect (Solomon et al. 2002). These results can lead us to the conclusion that 
Ginkgo should be used for longer periods of time [at least 12 weeks] or in 
doses more than 120 mg/day in order to demonstrate effects in healthy adults 
over 60. 
1.2.7.2 EGb 761
® in demented patients 
Many  clinical  trials  were  preformed  to  assess  the  efficacy  and  safety  of 
Ginkgo biloba for dementia or cognitive decline. Due to the vast number of 
studies  on  this  aspect  with  different  criteria,  diverse  patient  groups  and 
variable time spans it is quite difficult to reach a veraciuos conclusion.  
The most recent meta-analysis by Birks, Grimley Evans and Lee published 
online on 18 April 2007 states that Ginkgo biloba appears to be safe in use 
with no  excess side  effects  compared  with placebo,  and the  evidence that 
Ginkgo  has  predictable  and  clinically  significant  benefit  for  people  with 
dementia  or  cognitive  impairment  is  inconsistent  and  unconvincing.  35 
studies were included in this review, from those only 29 contribute data to the 
meta-analyses, and of these 15 studies contribute very few data. Noteworthy, 
is  the  fact  that,  in  the  feedback  the  review  was  criticized  and  that  the Introduction 
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reviewers  are  in  the  process  of  reconsidering  the  inclusion  criteria.  The 
updated review should be recently online. 
Taking into consideration other meta-analysis, for example one which was 
carried out in 2002 by the same authors who carried out the above mentioned 
review  (Birks  et  al.  2002),  most  are  in  favor  of  Ginkgo  (Oken  et  al. 
1998;Kleijnen  and  Knipschild  1992a;Kleijnen  and  Knipschild  1992b). 
Another example is the meta-analysis carried out in 1992 by Kleinjneen and 
Knipschild which had very stringent criteria. Here only eight of the 40 trials, 
generally conducted for at least 4-8 weeks with 120 mg/day of either an EGb 
761
® product were well performed and of acceptable quality. Interestingly 
seven  of  these  "acceptable"  trials  showed  effects  of  EGb  761
®  that  were 
superior to placebo and significant enough to establish a clinically relevant 
effect  of  the  extracts  for  controlling  symptoms  associated  with  cerebral 
insufficiency. 
The most recent clinical trials which were not included in any of the above 
mentioned meta-analysis are discussed below. 
Mazza el al preformed a 24-week randomized, placebo-controlled, double-
blind  study.  Patients  aged  50–80  years,  suffering  from  mild  to  moderate 
dementia, were allocated into one of the three treatments: Ginkgo biloba [160 
mg daily dose], Donepezil [5 mg daily dose], or placebo group. Their results 
suggest that there is no difference in the efficacy of EGb 761
® and Donepezil 
in  the  treatment  of  mild  to  moderate  Alzheimer’s  dementia  (Mazza  et  al. 
2006). 
Another  randomized,  placebo  controlled  double-blind  study  in  513  out-
patients with uncomplicated dementia of Alzheimer type was carried out for 
26 weeks using 120 mg/day or 240 mg/day EGb 761
®. The authors conclude 
there  is  no  significant  difference  between  placebo  and  Ginkgo.  But  in  a 
subgroup  with  neuropsychiatric  disorders  there  was  a  greater  decline  in Introduction 
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placebo group and better cognitive performance for Ginkgo group (Schneider 
et al. 2005). 
Most  likely,  based  on  this  result  Napryeyenko  et  al  carried  out  another 
randomized,  double-blind,  22-week  trial  using  400  patients  with  dementia 
associated  with  neuropsychiatric  features.  Patients  were  treated  with  EGb 
761
®  [240  mg/day]  or  placebo.  EGb  761
®  was  significantly  superior  to 
placebo with respect to primary and all secondary outcome variables. 
These 3 aforementioned most recent clinical trials were included in the last 
Cochrane meta-analysis [in the process of updating] but with restrictions. For 
example in the Schneider trial the unplanned subgrouping of neuropsychiatric 
syndrome  was  considered  inappropriate  and  therefore  not  taken  into 
consideration! The Napryeyenko study which was restricted to participants 
with  neuropsychiatric  features  of  dementia,  was  not  merged  in  the  meta-
analysis with the reasoning that “the results were strongly in favor of Ginkgo 
and so different statistically from the findings of the non-selective studies”!  
On the other hand, both Napryeyenko and Schneider trials were included in a 
very  recent  meta-analysis  completed  by  the  Institute  for  Quality  and 
Efficiency in Health Care [IQWIG] in Germany. The aim of this research was 
to assess the benefits of long-term treatment with Ginkgo compounds in AD 
compared with a) placebo, or b) a different drug or non-drug treatment option. 
The  authors  concluded  that  a  dose  of  240  mg  daily  shows  advantage  in 
“activities of daily living”. Moreover, indications of a benefit for “cognitive 
function”,  “general  psychopathological  symptoms”,  and  quality  of  life  of 
caregivers” was demonstrated in the high-dose Ginkgo group. However there 
is possibility that the advantage of Ginkgo is only present in patients with 
accompanying psychopathological symptoms. Furthermore, due to diversity 
between the analyzed studies no conclusion could be drawn on the benefits of 
low-dose Ginkgo [120 mg daily].  Introduction 
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Summing up, the fact that a vast number of clinical studies and reviews about 
Ginkgo  are  present  with  major  differences  in  subjects,  time  spans  and 
outcome measures makes it much more difficult to try to reach a satisfactory 
conclusion. However, a reasonable one would be that Ginkgo seems to be safe 
in use with no excess adverse effects compared with placebo. Moreover, there 
is promising evidence of improvement in cognition and function in patients 
with dementia and/or cognitive decline especially those with neuropsychiatric 
features. Aims of the thesis 
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2 Aims of the thesis 
The  fact  that  Ginkgo  biloba  has  been  used  thousands  of  years  ago  in 
traditional medicine makes it difficult to accept that its mechanisms of action 
have not been fully elucidated. This is partly due to the complexity of the 
extract with several components contributing to its actions.  
Nowadays, the standardized extract of Ginkgo biloba leaves EGb 761
® is 
becoming one of the most popular herbal medicine and dietary supplements 
consumed in Europe and the US. The major therapeutic indications for EGb 
761
®  are  associated  with  CNS  disturbances  including  dementia  and  AD. 
Earlier  studies  attempting  to  explicate  the  cellular  and  molecular 
mechanisms behind the actions of EGb 761
® and its constituents pointed out 
its radical scavenging effect. Since ROS is associated with the mitochondria 
and  EGb  761
®  has  proven  to  act  as  an  anti-oxidant,  the  protection  of 
mitochondrial function was subsequently addressed. Previously, our group 
observed mitochondrial protective actions on PC12 cells in vitro.  
Since the goal of the present study was to uncover the mechanisms of action 
of EGb 761
® that are related to cognitive impairment and AD, therefore, the 
in vitro findings on cell culture were extended on animal models in vitro and 
ex  vivo,  as  well  as  in  transgenic  animal  models  for  AD.  In  this  study 
mitochondrial  functions  were  assessed  in  dissociated  brain  cells  by 
measuring viability, ATP levels and mitochondrial membrane potential. 
Influence of EGb 761
® on the mitochondria was evaluated after additional 
external stress; both H2O2 and NO, which play a role during aging and AD, 
were applied. Aims of the thesis 
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The role of age was also addressed in this study by comparing the outcome 
after EGb 761
® treatment in both young and older mice models as well as in 
senescence  accelerated  mouse  model.  However  in  the  senescence 
accelerated mouse model treatment was implemented for 5 months in order 
to evaluate the long-term influence of EGb 761
® on aging.  
Acknowledging  that  EGb  761
®  is  composed  of  several  constituents,  the 
effect of each constituent on mitochondrial functions was studied. Noticing 
from  previously  reported  studies  that  methodologies  employed  and 
incubation schemes contribute to the efficacy of the single constituents of 
EGb 761
®, all the constituents were tested under the same conditions, and 
measuring the same parameters. 
Moreover, two different treatment methods were implemented, either post-
treatment  or  pre-treatment.  The  motive  behind  this  was  not  only  to 
determine the relative activities of the EGb 761
® components but also to find 
out the mechanism of action. Here again the same mitochondrial parameters 
for EGb 761
® were determined for the constituents, namely viability, ATP 
levels and mitochondrial membrane potential. 
The next step was then directed towards one of the major hallmarks of AD; 
the amyloid beta peptide, and the influence of EGb 761
® on its production, 
aggregation and clearance. This was based on 2 reasons, first of all that EGb 
761
®  is  mainly  indicated  for  dementia  and  AD,  and  secondly  because 
recently  researchers  linked  Aß  and  its  precursor  protein  APP  to  the 
mitochondrion.  Moreover,  mitochondrial  accumulation  of  APP  directly 
correlates with mitochondrial dysfunction in various brain regions in AD. 
Consequently transgenic mice over producing human Aß were treated for 21 
days  with  EGb  761
®.  Aß  levels,  relative  mRNA  levels  of  proteins  and Aims of the thesis 
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enzymes  involved in  Aß production and  degradation were  examined and 
compared to a placebo-treated group. 
In conclusion, this study emphasized on exposing the means by which EGb 
761
® and its constituents act, on both the cellular and molecular level. For 
these investigations aging  mice  and  a  transgenic  AD  mouse  model  were 
utilized. Materials and Methods 
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3 Materials and Methods 
3.1 Materials 
3.1.1 Apparatus 
Branson Sonifier, Cell Disruptor B15  Branson Ultrasonics Corp., Danbury 
Centrifuge model Allegra 6R  Beckmann GmbH, Munich 
CO2 B-incubators Heraeus, Type BB 6220  Heraeus Instruments GmbH, Hanau 
Combitips  Eppendorf-Netheler-Hinz-GmbH, 
Hamburg  
Cryo-vial, model Cryo-S,   Greiner, Frickenhausen 
Disposable Pasteur pipettes  Elkay, Ireland, UK 
Fluorescence spectrometer, SLM Aminco Bowman 
Series 2 
SLM instruments, Urbana. USA 
Fluorescence spectrometer, Victor Multi-label counter  Perkin Elmer, Juegesheim 
Fridge [4-8°C], type Glassline KGT 3546  Liebherr-Hausgeraete GmbH, 
Ochsenhausen 
Freezer [-20 °C]  Liebherr-Hausgeraete GmbH, 
Ochsenhausen 
Freezer [-80 °C]  Liebherr-Hausgeraete GmbH, 
Ochsenhausen 
Horizontal slab gel electrophoresis apparatus 10x15 cm  PeqLab Biotechnologies GmbH, 
Erlangen 
Heating Block Unitek HB-130  CLF, Emersacker Germany 
Homogenizer, Potter S  B.Braun-Melsungen, Düsseldorf  
Inverse microscopes, models TMS I04 and TS100  Nikon, Japan  
Ice machine Ziegra  ZIEGRA Frankfurt 
Laminar flow hood  Heraeus Instruments GmbH, Hanau 
Latex examination gloves  Ansell GmbH, Munich 
Magnetic agitator, type Poly 15  Merck Eurolab GmbH, Frankfurt 
Microtiter plates IWAKI, 96 well with flat bottom  Dunn Labortechnik GmbH, Asbach 
Microtiter plate, U-shaped bottom, sterile  Greiner Labortechnik, 
Frickenhausen 
Microfuge R centrifuge  Beckmann GmbH, Munich 
Mini Galaxy A CO2 incubator  RS Biotech, UK 
Minishaker MS2  IKA® Werke GmbH & Co. KG, 
Staufen 
Photometer for microplate model Digiscan  Asys Hightech, Eugendorf 
Pipetus-P
® , Hirschmann  Merck Eurolab GmbH, Frankfurt 
Pipettes model Pipetman  Abimed, Langenfeld 
Pipettes sterile packed  Greiner Labortechnik, 
Frickenhausen 
PP-tubes 15 ml and 50 ml, Cellstar
®  Greiner, Frickenhausen Materials and Methods 
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PCR tubes  Greiner Labortechnik, 
Frickenhausen 
Rotor-Gene 3000 thermo-cycler   Corbett Research, Sydney, Australia 
Thermocycler, GeneAMP PCR-9700  Perkin Elmer Bio Systems, USA 
Transferpette
®   Brand, Merck Eurolab GmbH, 
Frankfurt 
UV Transilllumniator, UVT-20 M/W  Herolab GmbH, Weisloch  
Water bath, type Thermomix 1441  B.Braun-Melsungen, Düsseldorf 
Water bath, type 1003, GFL  Merck Eurolab GmbH, Frankfurt 
Weighing scale model Ab204 and AT261  Mettler, Gießen 
 
 
3.1.2 Chemicals 
 
Acetic acid  Merck, Darmstadt 
Agarose  Merck, Darmstadt 
Bovine Serum Albumin [BSA]  Sigma-Aldrich, Munich 
Calcium chloride dihydrate  Merck, Darmstadt 
Dimethylsulfoxide [DMSO]  Merck, Darmstadt 
Diphenylhexatriene [DPH]  Sigma-Aldrich, Munich 
Di-sodium hydrogen phosphate  Merck, Darmstadt 
Dulbecco’s Modified Eagle Medium  Invitrogen, Karlsruhe 
Ethidium bromide  Sigma-Aldrich, Munich 
Ethanol  Merck, Darmstadt 
Ethylene-diamine-tetraacetic acid  Merck, Darmstadt 
Fetal calf serum [FCS]  Sigma-Aldrich, Munich 
Forene [isofluran]  Abbott GmbH & co., Wiesbaden 
Geneticine sulfate [G418]  Life Technologies, Karlsruhe 
Ginkgo-biloba- Extract [EGb 761
®]  Schwabe, Karlsruhe 
Glucose monohydrate  Merck, Darmstadt 
Guanidine  Merck, Darmstadt 
Hank’s Balanced Salt  Sigma-Aldrich, Munich 
Hydrogen peroxide 30%  Sigma-Aldrich, Munich 
Hydrochloric acid  Merck, Darmstadt 
4-[2-hydroxyethyl]-1-piperazine-ethane-sulfonic acid 
HEPES 
Merck, Darmstadt 
Horse Serum [HS]  Invitrogen, Karlsruhe 
Magnesium Chloride, hexahydrate   Merck, Darmstadt  
Penicillin /Streptomycin- solution (Pen/Strep)  Life technologies, Karlsruhe 
Phosphate buffered saline [PBS]  PAA laboratories GmbH, Cölbe 
Potassium Chloride  Merck, Darmstadt 
Potassium dihydrogen-phosphate  Merck, Darmstadt 
Primers [oligonucleotides] for PCR  MWG, biotech AG Materials and Methods 
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Rhodamine 123  Calbiochem, Darmstadt 
Sodium hydrogen carbonate  Merck, Darmstadt 
Sodium dodecyl sulfate [SDS]  Merck, Darmstadt 
Sodium nitroprusside [SNP]  Sigma-Aldrich, Munich 
Sterilium
® disinfectant  Merck, Darmstadt 
Sucrose   Merck, Darmstadt 
Trimethylammonium Diphenylhexatriene [TMA-DPH]  Sigma-Aldrich, Munich 
Tris[hydroxylmethyl]-aminomethane  Merck, Darmstadt 
Tween 20  Sigma-Aldrich, Munich 
Trypan blue solution  Biochrom AG, Berlin 
 
3.1.3 Buffers and Media 
All  buffers  and  media  were  prepared  in  de-ionized  water  and  pH  was 
adjusted with pH meter before use. The pH meter was calibrated daily prior 
to utilization. 
TAE Buffer [pH 7.4] for DNA gel electrophoresis 
4.84 g Tris 
1.142 ml acetic acid 
1 mM Na EDTA in 1 l de-ionized water 
Medium І [pH 7.35] for dissociated brain cells 
138 mM NaCl 
5.4 mM KCl 
0.17 mM Na2HPO4  
0.22 mM KH2PO4 
5.5 mM Glucose × H2O 
58.4 mM Sucrose 
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Medium П [pH 7.4] for dissociated brain cells 
110 mM NaCl 
5.3 mM KCl 
1.8 mM CaCl2 × 2 H2O 
1 mM MgCl2 × 6 H2O 
25 mM Glucose × H2O 
70 mM Sucrose 
20 mM HEPES 
Hank’s Balanced Salt Solution [HBSS, pH 7.4]  
1 vial of HBSS powder was dissolved in 1 l de-ionized water. 
Supplemented with: 
10 mM HEPES 
1 mM CaCl2 
0.5 mM MgSO4  
Dulbecco’s Modified Eagle Medium [DMEM] for dissociated brain cells 
Supplemented with:  
10 % [V/V] fetal calf serum [FCS] 
5 % [V/V] horse serum [HS] 
Dulbecco’s Modified Eagle Medium [DMEM] for Hek sw cells 
Supplemented with: 
10 % [V/V] FCS Materials and Methods 
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50 units/ml penicillin 
50  g/ml streptomycin 
400  g/ml G418 
MTT solubilization reagent  
90 ml N, N-Dimethyl-formamide  
90 ml Solubilization Solution [Kit] 
27g SDS 
5 M guanidine HCl/ 50 mM Tris HCl [pH 8] 
477.65 g guanidine dissolved in 50 mM Tris HCl 
BSAT-DPBS [pH 7.4] 
Dulbecco’s phosphate buffered saline [10 xs] was diluted with de-ionized 
water- Supplemented with:  
5% BSA 
0.03% Tween-20 
 
Tris-buffered saline [TBS, pH 7.4] 
150 mM NaCl  
25 mM Tris HCl  Materials and Methods 
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3.1.4  Kits 
 
 Bio-Rad DC Protein Assay [Lowry]  Bio Rad, Munich 
 Cell Proliferations Kit I [MTT-Assay]  Roche, Mannheim 
 DNeasy
® Tissue Kit  Qiagen, Hilde 
Master Taq Kit [PCR]  Eppendorf, Hamburg 
Beta-Amyloid [Ab] [1-40] colorimetric ELISA   Invitrogen, Karlsruhe 
Beta-Amyloid [Ab] [1-42] colorimetric ELISA  Invitrogen, Karlsruhe 
ViaLight 
® kit [ATP]  Cambrex, Belgium 
Micro BCA Protein Assay kit  Pierce, Ireland 
Quanti-Tec 
® SYBR
®Green RT-PCR kit   Qiagen, Hilde 
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3.2 Cell culture 
3.2.1 Hek cells 
Hek cells are human embryonic kidney cells. The Hek cells which were used 
in this thesis were transfected with DNA constructs harboring human mutant 
APP  [APP-sw,  K670M/N671L]  gene  inserted  downstream  of  a  CMV 
promoter, using  FUGENE  technique  [Roche  Diagnostics].  The  Hek  cells 
were transfected by Dr. Barbara Steiner, and characterized by Dr. Astrid 
Bonert. The cells  were  cultured in Dulbecco’s  modified  Eagle’s medium 
[DMEM]  supplemented  with  10  %  heat  inactivated  fetal  calf  serum,  50 
units/ml penicillin, 50  g/ml streptomycin, and 400  g/ml G418 at 37°C in a 
humidified incubator containing 5 % CO2. 
3.2.2 Cryopreservation 
Cells were collected in 15 ml Falcon tubes and centrifuged at 1000 rpm for 5 
minutes. Medium was aspirated; cells were re-suspended in 1 ml freezing 
medium and transferred to cryotubes. After storage overnight in a freezing 
box at -80°C the cells were transferred to liquid nitrogen until needed. 
3.2.3 Thawing cells 
The frozen cells were gently thawed in a water bath at 37°C. They were then 
transferred to a falcon tube containing 10 ml warm medium. Cell suspension 
was then centrifuged at 1000 rpm for 5 minutes, medium was aspirated and 
cells were re-suspended in 1 ml fresh medium. The cell suspension was then 
transferred to a Petri-dish containing 10 ml medium and incubated in the 
incubator. 
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3.3 Methods 
3.3.1 Animals and housing 
Mice were housed in cages [Makrolon, type II, Altromin GmbH, Germany]. 
Each cage was supplied with a plastic tube and cellulose sheets. Mice were 
kept at room temperature and constant humidity under a 12 hour dark/light 
cycle. Food [Standard 1320 Maintenance diet rat/mouse, Altromin GmbH, 
Germany]  and  water  ad  libitum  were  supplied  to  all  cages.  Cages  were 
changed  once  weekly,  cleaned  and  disinfected  with  perform.  All 
experiments described in this thesis are in accordance to animal protection 
laws and requirements. Healthy mice only were used for the experiments, 
mice showing any visible skin lesions or tumors were excluded. 
3.3.1.1 NMRI mice [Naval medical research Institute mice] 
The original colony of Swiss mice was brought from Lausanne, Switzerland, 
in 1926 by Clara Lynch. In 1937 introduced to Poiley from Lynch. They 
were inbred by Poiley and known as NIH/PI. At F51 brought to US Naval 
Medical Research Institute and known as NMRI mice. Then introduced to 
the “Bundes-Forschungsanstalt fuer Viruskrankheiten” in 1955. The mice 
were then presented to the Central Institute for Laboratory Breeding in 1958, 
and finally to Winkelmann in 1981 [now Harlan Winkelmann]. The NMRI 
mice were purchased from Harlan Winkelmann. 
3.3.1.2 Senescence accelerated mouse [SAMR1, SAMP8] 
The  senescence-accelerated  mouse  [SAM]  is  a  model  of  accelerated 
senescence  that  was  established  through  phenotypic  selection  from  a 
common genetic pool of AKR/J strain of mice (Takeda et al. 1981). In 1975, 
early senescence was noticed in littermates of AKR/J mice with a shorter life Materials and Methods 
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span. Five of these litters which become senile at an early age were selected 
as the progenitors of the senescence-accelerated-prone mice [SAMP]. Three 
litters with normal aging process were also selected as the progenitors of the 
control  senescence-accelerated-resistant  mice  [SAMR]  (Takeda  et  al. 
1981;Miyamoto 1997). The establishment of the SAM mouse model was 
complete in 1981, including nine major SAMP sub-strains and three major 
SAMR  sub-strains,  each  of  which  exhibits  characteristic  disorders.  The 
SAMP8 model employed in this study is characterized by acquiring age-
related learning and memory deficits and age-dependent deposition of Aß. 
Moreover the life span of SAMP8 mice ranges from 10-17 months which is 
much shorter that of the normally aging SAMR1, which ranges from 19-21 
months (Flood and Morley 1998). 
The author would like to acknowledge Dr. Jan Frank and his coworkers for 
the housing and feeding of the SAM mice. 
 
3.3.1.3 C57BL/6 mice 
The C57BL/6 mouse was developed by C.C. Little in 1921 after mating the 
female N°57 with the male N°52 from a commercial breeding centre in the 
USA  [Miss  Abby  Lathrop].  They  were  introduced  into  the  Jackson 
laboratory in 1948. Then to NIH in 1951 and finally to Charles River in 
1974. C57BL/6J mice were purchased from Charles River laboratories. 
3.3.1.4 Thy1-APP transgenic mice 
Our  transgenic  mice  were  C57Bl/6  mice  with  both  the  Swedish  double 
mutation  [KM670/671NL]  and  the  London  mutation  [V717I].  The  751 
amino acid form of human APP with both mutations was generated under Materials and Methods 
 
  92 
the control of a murine Thy-1 promoter as described by Blanchard and co-
workers  (Blanchard  et  al.  2003).  The  Thy-1  promoter  leads  to  high  and 
selective  expression  in  neurons.  Furthermore,  a  Kozack  element  was 
introduced  into  the  5’-UTR  region  of  the  APP  gene  for  optimization  of 
expression. The 751 amino acid form of APP contains the 56 amino acid 
Kunitz  protease  inhibitor  [KPI]  region  and  has  been  shown  to  result  in 
altered APP processing with a higher yield of Ab levels in cell culture (Ho et 
al.  1996).  Plaque  formation  is  accelerated  with  first  plaques  appearing 
already at an age of 6 months. Materials and Methods 
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3.3.2 Genotyping of transgenic mice 
3.3.2.1 DNA isolation from rodent tails  
DNA was isolated from rodent tails using the DNAeasy tissue kit according 
to  the  supplier’s  manual.  This  is  an  advanced  silica-gel  membrane 
technology for rapid and efficient purification of total cellular DNA. All 
steps  were  conducted  in  aseptic  conditions  and  great  care  was  taken  to 
minimize possible cross-contamination between samples. Briefly, mice were 
weakly anaesthetized by isoflurane inhalation. Tissue samples were obtained 
by tail biopsy and mice were marked either with numbered ear clips or with 
ear piercing for identification. Tail samples were lysed by addition of lysis 
buffer and proteinase K during an overnight incubation in a 55°C water bath. 
Lysate was loaded onto the DNAeasy mini spin column. DNA is selectively 
bound to the DNAeasy membrane as contaminants pass through. DNA was 
then eluted and was ready for use.  
3.3.2.2 PCR  
The DNA elute obtained was used in PCR reactions for detection of human 
APP.  PCR  was  performed  utilizing  MasterTaq  Kit  from  Eppendorf.  The 
PCR components were mixed according to the manufacturer’s instruction to 
contain in an end volume of 25 µl [per probe] the following:  
1 U of Taq-DNA-polymerase 
2 µM of sense-primer 
2 µM of anti-sense-primer  
0.2 mM dNTPs  
1 µl of sample DNA elute Materials and Methods 
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Buffer 
Samples were heated to 94°C for 5 minutes and PCR was done in 35 cycles 
of 1 minute at 94°C, 1 minute at 55°C and 1.5 minutes at 72°C. After the 
reaction, samples were kept at 4°C until gel electrophoresis was done for the 
detection of DNA bands. 
The following primers were used: 
APP genotyping: 
Sense: 5’-GTA GCA GAG GAG GAA GAA GTG-3’ 
Anti-sense: 5’-CAT GAC CTG GGA CAT TCT C-3’ 
Positive controls with APP 751 DNA template and negative controls with 
sterile distilled water were used for controlling the PCR reaction and for 
exclusion of possible contamination of reagents. Materials and Methods 
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3.3.2.3 DNA Gel electrophoresis 
Gels were prepared by boiling 1 g agarose in 100 ml TAE buffer for a short 
interval followed by addition of 8 µl ethidium bromide solution after the gel 
solution has cooled down to approximately 70°C. Gels were cast into a 10 x 
25 cm BioRad sub cell model 96 gel tray with two 51-well combs and left to 
cool down for 1 hour. The gels were then placed in the sub cell chamber 
filled  with  an  appropriate  amount  of  TAE  buffer  to  ensure  complete 
submersion of gels. PCR samples were mixed with 1 µl Blue juice 10 x gel 
loading buffer and loaded onto the gel. The electrophoretic separation was 
accomplished  using  Bio  Rad  Power  Pac  300  set  at  90  Volts  for 
approximately 45 minutes. Gels were then placed on a UV trans-illuminator 
[Herolab] and bands were photographed with a video camera [Kodak] and 
printed for analysis. APP 751 positive controls always gave bands at 492 bp. 
No  other  bands were  detected indicating specificity  of primers. Negative 
controls  with  de-ionized  water  instead  of  DNA  templates  always  gave 
negative results. 
   
Figure 3-1 
DNA gel electrophoresis for Thy-1 APP mice 
PCR products of DNA samples obtained from the rodent tail were separated electrophoretically 
on agarose gel stained with ethidium bromide. Lane 1: positive control obtained from a transgenic 
Thy-1 APP mouse, lane 2: negative control [water], lane 3: no band indicating a sample from a 
non-transgenic mouse and lane 4: band at 492 bp showing a sample from a transgenic Thy-1 APP 
mouse. 
 Materials and Methods 
 
  96 
3.3.3 qRT-PCR 
3.3.3.1 RNA isolation 
Lipid Tissue Protocol
 total RNA was extracted according to the RNeasy 
[Qiagen]. DNA digestion was done with RNase-Free DNase Set [Qiagen]. 
The  concentration  of  isolated  RNA  was  determined  by  measuring  the 
absorbance at 260 nm and the purity was determined by the ratio of 260/280 
nm  in  a  spectrophotometer  [Beckmann  Instruments;  Munich,  Germany]. 
RNA aliquots were stored at –80 °C until PCR analysis.  
Primer sequences  for  real-time RT-PCR experiments were  designed with 
primer 3 software. Primer pairs in table below were obtained from MWG 
Ebersberg, Germany]. Materials and Methods 
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Gene   Name  mRNA 
sequence  Source  Sequence FW  Sequence RV 
Product 
size 
ADAM10  alpha secretase  NM_007399.  primer3  CCATGCTCATGGAAGACAGTT  CCTTCTTCACCATAAATATGTCCA  144bp 
BACE1  beta-secretase  NM_011792.   primer3  GGAGCATGATCATTGGTGGT  ACTCCTTGCAGTCCATCTTGA  144bp 
muAPP 
Murine  amyloid-
precursor protein  NM_007471.  primer3  CCGTTGCCTAGTTGGTGAGT  GCTCTTCTCGCTGCATGTCT  142bp 
NEP  Neprilysin  NM_008604  primer3  CATTTTGACCAGCCTCGACT  GGCAAACTTTGTTCCTGACG  137bp 
IDE 
Insulin  degrading 
enzyme   NM_031156  primer3  GGTTTTCCAAGAGTGCAAGG  TCAGCTGTGAGCACTCCATT  132bp 
ECE-1 
Endothelin 
converting enzyme   NM_199307  primer3  GCCATTTTATACCCGCTCTTC  TCCCATCCTTGTCGTACTCC  119bp 
APPbp1 
APP  binding 
protein 1   NM_144931  primer3  GCTGCCAGGTATTGGATCAT  GCTCGGTTCTTGCCAATACT  108bp 
b-actin  ACTB, actin, beta   NM_001101  primer3  GGATGCAGAAGGAGATCACTG  CGATCCACACGGAGTACTTG  90bp 
Hu APP 
Human  Amyloid 
precursor protein  
 NM_201414  
NM_201413  
NM_000484  primer3  ACCGCTGCTTAGTTGGTGAG  GGTGTGCCAGTGAAGATGAG  113bp Materials and Methods 
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3.3.3.2 Real-time qRT-PCR 
One-step  quantitative  reverse  transcriptase  PCR  was  carried  out  with  the 
Quanti-Tec
®SYBR
®Green  RT-PCR  kit  [Qiagen].  Each  PCR  reaction  [final 
volume  20.0  µl]  contained  0.45  µl  of  the  respective  forward  and  reverse 
primer, 22.5 µl of Quanti-Tec
® SYBR
® Green RT-PCR Master Mix, 0.45 µl 
Quanti-Tec RT-Mix, 18.0 µl of RNA dilution and 3.15 µl of water. 
Real-time PCR amplification was performed in a Rotor-Gene 3000 thermo-
cycler [Corbett Research, Sydney, Australia]. Relative mRNA levels of genes 
were quantified as the ratio between the amount of target gene and the amount 
of a housekeeping gene [beta-actin]. 
The  author  would  like  to  thank  Dr.  Patricia  Huebbe  for  her  assistance  in 
conducting the real-time RT-PCR. 
3.3.4 Preparation of dissociated brain cells 
Mice were sacrificed by decapitation and brains were immediately dissected 
on ice [method modified after Stoll et al (Stoll et al. 1992)]. After removing 
the cerebellum, brains were minced using a scalpel and suspended in ice-cold 
medium I. Tissue was dissociated by triturating through a nylon mesh [210 
µm  pore  diameter]  with  a  Pasteur  pipette.  The  resulting  suspension  was 
filtered by gravity through another nylon mesh [102 µm pore diameter] and 
the  dissociated  cell  aggregates  were  washed  twice  with  20  ml  of  ice-cold 
medium  II  by  centrifugation  [2000  rpm  for  5  mins  at  4°C].  50   l  of  the 
suspension  were  used  for  protein  determination.  The  prepared  dissociated 
brain cells were re-suspended in 6 ml DMEM for the whole cerebrum or in 3 
ml for the hemisphere. The cell suspension was distributed in 48-well plates, 
250 µl per well for measurement of mitochondrial membrane potential, or 50 
µl in 96-well plates for measurement of ATP levels and MTT assay. Plates 
were then incubated for 4 hours at 37°C and 5 % CO2. Vitality of the cells Materials and Methods 
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was tested previously using the Trypan blue exclusion method and was shown 
to be > 90% (Hartmann et al. 1996).  
 
3.3.5 Determination of protein content 
Protein levels were determined using either modified Lowry (LOWRY et al. 
1951)  or  BCA  (Smith  et  al.  1985)  protein  assay  according  to  sample 
compatibility.  Bovine  serum  albumin  [BSA]  was  used  as  protein  standard 
solution and dilutions were prepared using the same buffer or medium used 
for the tested samples. 
3.3.5.1 Lowry Assay 
In the first step of this assay proteins react with copper tartrate in alkaline 
solution.  In  the  second  step,  Folin  reagent  is  added  and  reduced  by  the 
protein-copper-complexes  resulting  in  a  characteristic  blue  color  due  to 
several reduced species. The color shows an absorbance minimum at 405 nm 
and  a  maximum  at  750  nm  (Peterson  1979).  We  used  the  commercially 
available BioRad DC Protein Assay Kit. Briefly, 5 µl of sample replicate were 
mixed with 25µl of reagent A [copper tartrate solution] and 200µl of reagent 
B  [Folin  reagent]  in  a  micro-titer  plate.  If  detergents  were  present  in  the 
samples, reagent A was supplemented with 3 % reagent S. Standards and 
samples were assayed in triplicates. Plates were mixed thoroughly on a plate 
shaker for 15 minutes at room temperature. Absorption was read using the 
ASYS Hi-tech Digiscan microtiter plate reader with a 620 nm filter. Protein 
concentration was calculated from the standard curve. 
3.3.5.2 BCA Assay 
The first step in the BCA assay is the chelation of copper with protein in an 
alkaline environment to form a blue colored complex that absorbs light at 540 
nm. In this reaction, known as the biuret reaction, peptides containing three or 
more amino acid residues form a colored chelate complex with cupric ions in 
an alkaline environment containing sodium potassium tartrate. In the second Materials and Methods 
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step of the color development reaction, bicinchoninic acid [BCA], a highly 
sensitive and selective colorimetric detection reagent reacts with the cuprous 
cation [Cu
1+] that was formed in step 1. The purple-colored reaction product is 
formed by the chelation of two molecules of BCA with one cuprous ion. The 
BCA/copper complex is water-soluble and exhibits a strong linear absorbance 
at 562 nm with increasing protein concentrations. The commercially available 
Pierce
® BCA Protein Assay Kit was used. The working solution was prepared 
by mixing BCA Reagents A and B in the ratio of 50:1 respectively. 25  l of 
each standard or unknown sample replicate was placed into a micro-titer plate 
well and 200 µl of the working solution was added to each well. Standards 
and samples were assayed in triplicates. Plates were mixed thoroughly on a 
plate  shaker  for  30  seconds,  and  then  incubated  for  30  minutes  at  37°C. 
Absorption  was  read  by  means  of  the  ASYS  Hi-tech  Digiscan  micro-titer 
plate reader using a 570 nm filter. The standard curve was used to calculate 
the protein concentrations. 
3.3.6 In vitro treatment schemes 
For  pre-treatment  studies,  DBCs  were  incubated  with  EGb  761
®  or  its 
constituents  and  30  minutes  later  H2O2  or  SNP  was  added.  Plates  were 
incubated for 4 hours at 37°C and 5 % CO2, followed by measurement of 
mitochondrial membrane potential, ATP levels or viability [MTT assay] as 
described below. 
For post treatment studies, DBCs were first stressed with H2O2 or SNP for 30 
minutes, followed by addition of EGb 761
® or its components. Plates were 
incubated  for  4  hours  at  37°C  and  5%  CO2.  Consequently  mitochondrial 
membrane  potential,  ATP  levels  or  viability  [MTT]  were  measured  as 
described below. Materials and Methods 
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3.3.7 Mitochondrial membrane potential 
The mitochondrial membrane potential was measured using the fluorescence 
dye  Rhodamine  123  [Rh-123]  (Baracca  et  al.  2003).  Rh-123  is  a  cationic 
lipophilic  dye  that  accumulates  in  the  mitochondrial  matrix  driven  by  the 
electric gradient following the Nerst equation. The higher the mitochondrial 
membrane potential, the more Rh-123 is taken up into the matrix. 
 
Molecular structure and spectra of Rhodamine 123 
For  the  measurement  of  mitochondrial membrane  potential the dissociated 
brain  cells  that  were  incubated  in  48-well  plates  were  removed  from  the 
incubator  and  centrifuged  at  1500  rpm  for  5  minutes.  The  medium  was 
aspirated carefully and 250 µl HBSS were added to each well. 5µl of Rh-123 
[end concentration of 0.4 µM] was placed in each well and the plates were 
incubated for 15 minutes with the dye on a plate shaker. After the incubation 
time, plates were centrifuged at 1500 rpm for 5 minutes, HBSS was removed 
and again 250 µl HBSS were added. The previous wash step with HBSS was 
repeated  and  finally  the  plate  was  measured  using  Victor
  Multi-label 
Counter at an excitation wavelength of 490 nm and an emission wavelength 
of 535 nm. Materials and Methods 
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3.3.8 Measuring ATP levels 
ATP levels were measured using the Via-Light HT
Ò kit which is based upon 
the bioluminescent measurement of ATP (Crouch et al. 1993).This method 
utilizes an enzyme, luciferase, which catalyses the formation of light from 
ATP and luciferin according to the following reaction: 
 
The  emitted light  is  linearly  related to the  ATP  concentration  and  can  be 
measured using an illuminometer. The dissociated brain cells were incubated 
in 96-well white walled plates for measurement of ATP levels. The plates 
were removed from the incubator and left to cool down to room temperature. 
Cell lysis reagent was added as instructed to each well and after 10 minutes 
ATP monitoring reagent was added. The luminescence was measured directly 
using Victor
 Multi-label Counter. Materials and Methods 
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3.3.9 MTT assay 
The cytotoxicity was measured using the MTT assay kit. This assay which 
measures metabolic activity is based on the cleavage of the yellow tetrazolium 
salt MTT into purple formazan by metabolically active cells. This cellular 
reduction involves the pyridine nucleotide cofactors NADH and NADPH. A 
decrease in the number of living cells results in a decrease of total metabolic 
activity  which  leads  to  a  weaker  color  formation.  For  the  respective 
experiments dissociated brain cells were incubated in 96-well plates. MTT 
reagent was added at a final concentration of 1.0 mg/ml 2 hours before the 
end  of  the  incubation  period.  After incubation the  formazan  crystals  were 
solubilized by adding 100  l of a 20%SDS/50% N, N-dimethly-formamide 
solution (Mosmann 1983). The absorption of the solubilized formazan was 
measured at 570 nm using ASYS Hitech Digiscan microtiter plate reader. 
 
Figure 3-2 
Reduction of MTT reagent to Formazan  Materials and Methods 
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3.3.10 Determination of membrane fluidity 
3.3.10.1 Tissue preparation 
For membrane fluidity measurements, brain hemispheres were homogenized 
in 15 ml buffer [5 mmol/liter Tris-HCl] and centrifuged at 48,000 g for 20 
min. The formed pellet was re-suspended in 20 ml buffer and centrifuged. 
Protein content was determined according to Lowry method. 
3.3.10.2 Fluorescent probes 
1,6-Diphenyl-1,3,5-hexatriene  [DPH]  and  its  cationic  derivative  which 
contains  trimethylammonium  [TMA-DPH]  were  provided  for  the 
measurement of anisotropy. DPH and its derivatives are cylindrically shaped 
molecules  with  absorption  and  fluorescence  emission  transition  dipoles 
aligned  approximately  parallel  to  their  long  molecular  axis.  Consequently, 
their fluorescence polarization is high in the absence of rotational motion and 
is very sensitive to re-orientation of the long axis resulting from interactions 
with  surrounding  lipids.  Intercalation  of  DPH  and  its  derivatives  into 
membranes is accompanied by strong enhancement of their fluorescence; their 
fluorescence is practically negligible in water. DPH is highly lipophilic and 
can  reside  in  the  center  of  the  lipid  bilayer  parallel  to  the  surface.  It  is 
generally assumed to be oriented parallel to the lipid acyl chain axis. 
As for TMA-DPH, due to the cationic substitute it is more water soluble and 
acts as a surface anchor. Staining of cell membranes by TMA-DPH is much 
more rapid than staining by DPH. However, the duration of plasma membrane 
surface staining by TMA-DPH before internalization into the cytoplasm is 
quite prolonged. 
3.3.10.3 Anisotropy measurement 
Membrane pellets were re-suspended accordingly to obtain 300 µg/ml protein. 
100 µl of membrane suspension were incubated for 45 mins at 37 °C with 
1000  µl  buffer,  900µl  of  1:150  DPH  [stock  solution  5mmol/l  in Materials and Methods 
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tetrahydrofuran] or 1:300 TMA-DPH [stock solution 5 mmol/l in dimethyl 
formamide]. The steady-state anisotropy was measured using excitation and 
emission wavelengths of 360 nm and 450 nm [slits 4 nm] respectively. 
The  steady-state  fluorescence  polarization  (Ps)  was  expressed  as  the 
anisotropy (rs) of the probe, using the following equation: 
 rs = 2Ps/3 − Ps 
The  author  would  like  to  thank  Claudia  Jordan  for  her  assistance  in 
performing the membrane fluidity experiments. 
3.3.11 Quantification of Beta Amyloid 
The Biosource Human beta Amyloid [Hu Aß] kits, 1-40 and 1-42 were used 
for the determination of beta amyloid amounts in the tissues. 
Both kits are solid phase sandwich Enzyme Linked Immuno-Sorbent Assays 
[ELISA]. A monoclonal antibody specific for the NH2-terminus of Hu Aß has 
been  coated  onto  the  wells  of  the  microtiter  strips.  Standards,  control 
specimens  and  unknowns  were  pipetted  into  these  wells  and  co-incubated 
with a rabbit antibody specific for the COOH-terminus of either the 1-40 Aß 
sequence or the 1-42 Aß sequence. The bound rabbit antibody is detected by 
the  use  of  a  horseradish  peroxidase-labeled  anti-rabbit  antibody.  After 
removal of excess anti-rabbit antibody, a substrate solution was added, which 
is acted upon by the bound enzyme to produce color. The intensity of the 
colored product is directly proportional to the concentration of Hu Aß present 
in the original specimen. The optical density was measured at 450 nM. Materials and Methods 
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3.3.11.1 Soluble Amyloid beta 
Hek-293 cells 
The Hek-sw cells were cultured in Petri-dishes in the incubator until the plates 
were  approximately  70  %  confluent.  The  medium  was  aspirated  and  new 
medium was added to the cells in the Petri-dishes with EGb 761
® in different 
concentrations.  24  hours  later  the  cell  suspension  was  collected  in  falcon 
tubes and centrifuged at 1000 rpm for 5 minutes. 1 ml from the supernatant 
was transferred to cryotubes and 10 µM PMSF was immediately added. The 
tube was frozen at -80 °C until the ELISA was carried out. 
The cell pellet was re-suspended in PBS buffer and centrifuged at 1000 rpm 
for 5 minutes. PBS was aspirated and the protein content of the cell pellet was 
determined by Lowry’s method. 
Mouse brain tissue 
For the determination of the levels of soluble Aß, the wet mass of the mice 
brain  samples  were  determined.  10x  volume  of  Tris-Buffered  Saline 
supplemented  with  Complete
®  protease  inhibitor  cocktail  was  added  and 
homogenized  using  Potter  S  homogenizer  [10  strokes,  1200  rpm].  The 
homogenate  was  centrifuged  at  15,000  x  g  for  30  minutes  at  4°C.  The 
supernatant  was  collected  and  stored  at  -80°C  until  performing  the  Aß1-40 
ELISA. Materials and Methods 
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3.3.11.2 Total amyloid beta 
Total Aß was extracted from the tissues using 5 M guanidine HCl/ 50 mM 
Tris HCl solution. The mice brain samples were homogenized with Potter S 
homogenizer [10 strokes, 1200 rpm]. The homogenate was mixed at room 
temperature for 4 hours using a plate shaker and stored at -20°C. Directly 
before use, the samples were diluted with the reaction buffer BSAT-DPBS, so 
that guanidine concentration does not exceed 0.1 M. Diluted samples were 
centrifuged at 16,000 x g for 30 minutes at 4°C. ELISA was then preformed. Materials and Methods 
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3.3.12 Ex vivo treatment studies 
Ex vivo studies were carried out in order to test the effect of EGb 761
® after 
oral application. For these studies mice were treated per os daily either with 
EGb 761
® or with the vehicle only for the control groups. The solutions were 
prepared directly before treatment. Mice were weighed daily before treatment 
and were given 100 mg/ kg body weight EGb 761
® or 0.2 % agarose solution. 
Mice were sacrificed 24 hours after the last treatment.  
Study designs 
Study 1 
Testing the effect of EGb 761
® [100 mg/kg] treatment on mitochondrial 
functions in 2 different age groups 
3 and 15 months old NMRI female mice were treated daily for 14 consecutive 
days  with  either  EGb  761
®  [100  mg/kg]  solution  in  agarose  or  with  the 
vehicle alone for the control group. Mice were sacrificed 24 hours after the 
last treatment and dissociated brain cells were prepared. Total number of mice 
tested was 10 mice per group. Mice showing lesions or tumors were excluded 
from the experimental results. 
 
  Control [0.2 %Agarose]  EGb 761
® [100 mg/kg] 
2-3 months  10  10 
15-16 months  10  10 Materials and Methods 
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Study 2 
Testing the effect of EGb 761
® [100 mg/kg body weight] treatment on 
mitochondrial functions in transgenic APP mice and non-transgenic 
littermates 
Tg-APP mice [6 months old] and their corresponding littermates were treated 
daily for 14 consecutive days with either EGb 761
® [100 mg/kg] solution in 
agarose or with the vehicle for the control group. Total number of mice tested 
was 18 transgenic and 18 non-transgenic as shown in the table below. Mice 
were  sacrificed  and  dissociated  brain  cells  were  prepared.  Mice  showing 
lesions or tumors were excluded from the experimental results. 
  Control  EGb 761
® [100mg/kg] 
Tg-APP  9  9 
Non-Tg littermates  9  9 
 Materials and Methods 
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Study 3 
Testing the effect of long-term treatment with EGb 761
® on SAMP8 and 
SAMR1 mice 
Mice were treated for 5 months with western diet pressed in pellets. Western 
diet contains 21% butterfat, 0.15% cholesterol, 35 mg/kg vitamin E and 3000 
IE/Kg vitamin A. However it was devoid of anti-oxidants, flavonoids and 
vitamin C. The amount of EGb 761
® present in the pellets was 1g/ g western 
diet.  Given  that  on  average  basis  one  mouse  consumes  3.5  g/day;  the 
calculated daily intake of EGb 761
® would be 150 mg/ kg body weight. Both 
SAMR1 and the placebo-treated mice received western diet devoid of EGb 
761
®.Total number of mice was 23. 
After  5  months  treatment  mice  were  sacrificed  and  the  mitochondrial 
functions  were  directly  assessed  in  a  hemisphere.  Half  of  the  other 
hemisphere was rapidly frozen for membrane fluidity studies. 
 
  Control  EGb 761
® [100mg/kg] 
SAMR1  10  - 
SAMP8  7  6 Materials and Methods 
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Study 4 
Testing the effect of EGb 761
® [100 mg/kg body weight] on amyloid beta 
levels and gene expression in transgenic mice 
6 months old Tg-APP and their corresponding littermates were treated daily 
per os for 21 consecutive days with either EGb 761
® [100mg/kg body weight] 
solution  in  agarose  or  with  the  vehicle  only  for  the  placebo  group.  Total 
number of mice was 36. Mice were sacrificed. One hemisphere was stored 
directly at -80 °C until further use for the ELISA. The second hemisphere was 
stored in RNAlater solution for 24 hours at room temperature, and then stored 
at -20 °C for RT-PCR. 
 
  Control  EGb 761
® [100mg/kg] 
Tg-APP  9  10 
Non-tg littermates  9  8 
 Materials and Methods 
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3.3.13 Software and statistics 
Microsoft excel was used to calculate mean values from measured duplicates 
or  triplicates.  Calculated  means  were  then  transferred  to  Graphpad  prism 
[version  4.03].  Data  are  represented  as  means  ±  standard  error  of  mean 
[S.E.M]. Statistical analyses were preformed also using the Graphpad prism 
program, p values less than 0.05 were considered significant. For analysis of 
significant correlations between variables, linear regression was calculated. It 
was also assumed that data are sampled from Gaussian populations. Results 
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4 Results 
4.1 Dissociated brain cells: Experimental conditions 
optimization 
In this study mitochondrial functions were tested using dissociated brain cells 
[DBCs] prepared from mice. This model was previously used and described 
by  others.  Vitality  of  the  cells  was  tested  earlier  using  the  Trypan  blue 
exclusion method and was shown to be > 90% (Hartmann et al. 1996). Using 
MTT-Assay  it  was  demonstrated  that  after  4  hours  there  is  no  significant 
decrease in the viability of DBCs. This is first noticed after 8 hours, where 
there  exists  a  25  %  decrease  in  metabolic  activity  of  the  DBCs  which 
indicates an approximate decrease of 25 % in the number of living cells. 
In the current study, the effect of EGb 761
® on mitochondrial functions and its 
ability  to  regenerate  the  mitochondria  were  investigated.  Mitochondrial 
dysfunction  was  achieved  by  implementing  either  oxidative  stress  or 
nitrosative stress. Hydrogen peroxide [H2O2] was used to induce oxidative 
stress and sodium nitroprusside [SNP], a nitric oxide [NO] donor to induce 
nitrosative  stress.  As  markers  for  the  function  of  the  mitochondria, 
mitochondrial membrane potential, ATP levels and metabolic activity of the 
cells [MTT Assay] were determined. 
4.1.1 Optimization of experimental conditions for SNP 
4.1.1.1 Mitochondrial membrane potential 
Sodium  nitroprusside  was  used  to  induce  nitrosative  stress  on  DBCs. 
Mitochondrial  membrane  potential  was  one  of  the  parameters  to  be 
investigated;  therefore  optimization  of  experimental  conditions  for  this 
marker was essential. 
For  establishment  of  experimental  conditions  2-3  months  old  NMRI  mice 
were utilized. Results 
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Figure 4-1 
Time dependent decrease in mitochondrial membrane potential of 
dissociated brain cells with SNP 
Dissociated brain cells were incubated with either 0.5 mM SNP [A] or 2 mM SNP [B] for 15, 30 
and 60 minutes. Mitochondrial membrane potential was then determined. Data are represented as 
percent of control. Data are expressed as means ± S.E.M [n=15-17]. 
 
In order to choose a time frame for our experiments, DBCs were incubated 
with 2 different concentrations of SNP for 15, 30 and 60 minutes. Neither 0.5 
mM nor 2 mM were able to influence the mitochondrial membrane potential 
in this short period [figure 4-1]. 
Consequently, the effect of these 2 concentrations was tested for a longer 
period. The DBCs were incubated for 1, 2, 4 and 6 hours and mitochondrial 
membrane potential was determined. Results 
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Figure 4-2 
Time dependent decrease in mitochondrial membrane potential of 
dissociated brain cells by SNP 
Dissociated brain cells were incubated with either 0.5 mM SNP [A] or 2 mM SNP [B] for 1, 2, 4 
and  6  hours.  Mitochondrial  membrane  potential  was  then  determined.  Data  are  represented  as 
percent  of  control.  Data  are  expressed  as  means  ±  S.E.M  [n=12]  [ANOVA,  ***p<0.001  vs. 
untreated controls]. 
Based on our knowledge that a 25 % decrease in cell viability of DBCs occurs 
within 8 hours, our incubation periods were limited to 6 hours in order to have 
maximum amount of viable cells and mitochondria. As depicted above, 0.5 
mM showed a significant effect at 4 hours and 2 mM SNP after a minimum of 
2 hours. A more pronounced decrease in mitochondrial membrane potential 
was  detected  after  4  hours  with  2  mM  SNP  causing  approximately  24  % 
reduction in mitochondrial membrane potential [figure 4-2]. In light of these 
findings, incubation period was standardized to 4 hours.  
After  choosing  the  time  frame  different  concentrations  of  SNP  were 
examined, starting from 0.5 mM to 3 mM. DBCs were incubated for 4 hours 
with 4 different concentrations of SNP as shown below [figure 4-3]. 
 Results 
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Figure 4-3 
Concentration dependent decrease in mitochondrial membrane potential of 
dissociated brain cells by SNP 
Mitochondrial  membrane  potential  was  measured  after  incubating  dissociated  brain  cells  with 
different concentrations of SNP for 4 hours. Data are represented as percent of control. Data are 
expressed as means ± S.E.M [n=4-7], [ANOVA, ***p<0.001 vs. untreated controls]. 
A  concentration  dependent  depolarization  of  mitochondrial  membrane 
potential was observed. 2 mM SNP was the concentration chosen for our up-
coming experiments. 
4.1.1.2 ATP levels 
The second marker for mitochondrial function used in this study was ATP 
levels. In this experiment, the influence of different concentrations of SNP on 
the amount of ATP levels was tested. As shown in figure 4-4, SNP led to a 
dramatic decrease in ATP levels. Using 2 mM SNP lowered ATP levels by 
approximately 88 %, which is the same concentration causing 24 % decrease 
in mitochondrial membrane potential. This could be due to methodological 
differences,  indicating  that  quantifying  ATP  levels  using  bioluminescence 
assay is a more sensitive method compared to the fluorometric measurement Results 
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of  mitochondrial  membrane  potential  using  Rh  123.  Consequently,  a 
concentration of 0.2 mM SNP was chosen for our further investigations on 
mitochondrial functions, which causes a significant decrease in ATP levels 
but also allows us to see treatment effects of EGb 761
®, if present. 
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Figure 4-4 
Concentration dependent decrease in ATP levels of dissociated brain cells 
by SNP 
Dissociated brain cells were incubated with different concentrations of SNP for 4 hours and ATP 
levels were measured. Data are represented as percent of control. Data are expressed as means ± 
S.E.M [n=6] [ANOVA, ***p<0.001 vs. untreated controls]. 
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4.1.1.3  MTT assay 
The  metabolic  activity  of  the  cells  was  measured  using  the  MTT  assay. 
Different  concentrations  of  SNP  were  examined  to  determine  the  most 
appropriate concentration to use for this assay [figure 4-5]. 0.5 mM of SNP 
was selected to be used for all MTT assays in this study. 
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Figure 4-5 
Concentration dependent decrease in cell viability of dissociated brain cells 
by SNP 
Dissociated brain cells were incubated for 4 hours with different concentrations of SNP and cell 
viability was measured using the MTT assay. Data are represented as percent of control. Data are 
expressed as means ± S.E.M [n=4] [ANOVA, *p<0.05 and ***p<0.001 vs. untreated controls]. 
Concluding,  in  all  the  experiments  preformed  with  SNP  throughout  this 
thesis, the incubation period was kept constant [4 hours] but the concentration 
of SNP was adjusted according to the sensitivity of the assay preformed. A 
minimal concentration of 0.2 mM was applied for ATP assay due to its high 
sensitivity  and  a  much  higher  concentration  of  2  mM  was  used  for  the 
fluorometric determination of mitochondrial membrane potential. The relative 
sensitivities of the different assays preformed with SNP are summarized in the 
table below. Results 
 
  119 
 
  Percentage damage caused by 
different concentrations of SNP [% ± S.D] 
Assay  0.2 mM SNP  0.5 mM SNP  1 mM SNP  2 mM SNP 
MMP  -  74.31 ± 10.8  67.83 ± 13.13  60 ± 9.71 
ATP  52.65 ± 8.00  26.16 ± 2.54  16.63 ± 1.07  11.92 ± 1.32 
MTT  88.69 ± 4.13  81.73 ± 3.06  69.04 ± 6.56  52.81 ± 7.01 
Table 4.1 
Relative sensitivities of different tests to SNP-induced damage 
Dissociated  brain  cells  were  incubated  for  4  hours  with  different  concentrations  of  SNP,  and 
mitochondrial membrane potential [MMP], ATP levels [ATP] and metabolic activity [MTT] were 
determined. The sensitivity of ATP > MTT > MMP. Data are represented as percent of control ± 
Standard deviation. Results 
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4.1.2 Optimization of experimental conditions for H2O2 
In order to test the protective effects of EGb 761
® on the mitochondria, not 
only  nitrosative  stress  was  induced  but  also  oxidative  stress.  In  all  the 
experiments  H2O2  was  used  as  a  source  of  oxidative  stress.  Hence,  the 
experimental conditions for H2O2 were optimized.  
4.1.2.1 Mitochondrial membrane potential 
Different concentrations of H2O2 were applied to the DBCs and mitochondrial 
membrane potential was determined after 4 hours. H2O2 was able to influence 
mitochondrial membrane potential at a concentration of 1 mM but a more 
apparent depolarization was seen at a concentration of 2 mM [Figure 4-6].  
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Figure 4-6 
Concentration dependent decrease in mitochondrial membrane potential of 
dissociated brain cells by H2O2 
Mitochondrial  membrane  potential  was  measured  after  incubating  dissociated  brain  cells  with 
different concentrations of H2O2 for 4 hours. Data are represented as percent of control. Data are 
expressed as means ± S.E.M [n=6] [ANOVA, *p<0.05, ***p<0.001 vs. untreated controls]. 
The 2 mM concentration was tested for shorter periods of time, 1 hour and 2 
hours [figure 4-7]. Incubating the DBCs for 1 hour with H2O2 had no effect on 
mitochondrial  membrane  potential,  but  starting  2  hours  the  effect  was Results 
 
  121 
noticeable.  For  consistency  and  direct  comparison  with  SNP,  the  4  hour 
incubation period was selected.  
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Figure 4-7 
Time dependent decrease in mitochondrial membrane potential of 
dissociated brain cells with 2mM H2O2  
Dissociated brain cells were incubated with 2  mM  H2O2 for 1, 2, and 4 hours. Mitochondrial 
membrane  potential  was  then  measured.  Data  are  represented  as  percent  of  control.  Data  are 
expressed as means ± S.E.M [n=6] [ANOVA, **p<0.01 vs. untreated controls]. 
 Results 
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4.1.2.2 ATP levels 
DBCs were incubated for 4 hours with several concentrations of H2O2 [Figure 
4-8]. The ATP levels were highly influenced by H2O2, a concentration as low 
as  0.4  mM  was  able  to  decrease  the  ATP  levels  significantly.  This 
concentration was used for all future experiments. 
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Figure 4-8 
Concentration dependent decrease in ATP levels of dissociated brain cells 
with H2O2  
Dissociated brain cells were incubated with different concentrations of H2O2 for 4 hours and ATP 
levels were measured. Data are represented as percent of control. Data are expressed as means ± 
S.E.M [n=6-8] [ANOVA, ***p<0.001 vs. untreated controls].  
The discrepancy observed previously in the sensitivities of the ATP assay and 
the  fluorometric  determination  of  mitochondrial  membrane  potential,  was 
confirmed  in  the  above  experiments.  Here  again  extensively  higher 
concentrations  of  H2O2  were  required  to  cause  noticeable  decrease  in 
mitochondrial membrane potential as apparent in the table below. Results 
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  Percentage damage caused by 
different concentrations of H2O2 [% ± SD] 
Test   0.4 mM H2O2  0.5 mM H2O2  1 mM H2O2  2 mM H2O2 
MMP  -  94.11± 10.54  88.85 ± 5.4  82.52 ± 5.91 
ATP  73.05 ± 8.60  55.37 ± 0.82  44.93 ± 1.91  39.78 ± 0.922 
Table 4.2 
Relative sensitivities of different assays to H2O2-induced damage 
Dissociated  blood  cells  were  incubated  for  4  hours  with  different  concentrations  of  SNP  and 
mitochondrial membrane potential [MMP], ATP levels [ATP]] were measured. The sensitivity of 
ATP > MMP. Data are represented as percent of control ± Standard deviation. 
After  the  optimization  of  the  experimental  conditions  for  determining  the 
mitochondrial functions in DBCs, the aforementioned assigned concentrations 
and  the  time  intervals  were  kept  constant  throughout  all  the  following 
experiments. 
 Results 
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4.2 Effects of Ginkgo biloba extract [EGb 761
®] on 
mitochondrial function: Protection against H2O2 -
initiated stress 
EGb  761
®  has  been  widely  used  in  the  treatment  of  geriatric  memory 
disorders  including  vascular  and  neurodegenerative  dementia.  The  major 
intention of this study was to examine extensively the protective properties of 
EGb 761
® and the mechanisms lying behind these effects. Lately, it has been 
proposed that mitochondrial dysfunction plays a key role in aging and age-
related diseases. Therefore, examination of EGb 761
® effects pertaining to 
mitochondrial functions would be plausible. 
One  of  the  major  causes  of  mitochondrial  dysfunction  is  oxidative  stress. 
Oxidative  stress  is  known  to  play  a  key  role  in  aging  and  age-related 
neurodegenerative diseases including Alzheimer’s disease [AD] [see section 
1.1.8]. The effects of EGb 761
® on H2O2 induced mitochondrial damage was 
examined both in vitro and ex vivo. 
4.2.1 In vitro findings 
4.2.1.1 3 months old NMRI mice 
DBCs attained from young adult female NMRI mice ranging between 2-3 
months were incubated for 4 hours with either 2 mM H2O2 for depolarizing 
mitochondrial membrane potential or with 0.4 mM H2O2 for reducing ATP 
levels. After 30 minutes 0.1 mg/ml or 0.5 mg/ml EGb 761
® was added. EGb 
761
® was able to alleviate the decrease in mitochondrial membrane potential 
caused by H2O2 but had no protective effect on the ATP levels [figure 4-9]. 
 Results 
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Figure 4-9 
In vitro protection of mitochondrial functions against H2O2 induced 
oxidative stress in 2-3 months old mice 
Dissociated  brain  cells  were  incubated  for  4  hours  with  2  mM  H2O2  for  determination  of 
mitochondrial membrane potential [A] or with 0.4 mM for the measurement of ATP levels [B]. 
EGb 761
® was added 30 minutes after incubation with H2O2. Data are expressed as means ± S.E.M 
[n=8-9] [*p<0.05, **p<0.01 vs. H2O2, student’s t-test] 
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4.2.1.2 15 months old NMRI mice 
The influence of EGb 761
® in DBCs from older mice was then determined. 
The previous experiment was repeated but instead of obtaining DBCs from 2-
3  months old  mice, they  were prepared from  15-16  months old  mice. 0.1 
mg/ml EGb 761
® was able to slightly improve both mitochondrial membrane 
potential [figure 4-10A] and ATP levels [figure 4-10B]. 
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Figure 4-10 
In vitro protection of mitochondrial functions against H2O2 induced 
oxidative stress in 15-16 months old mice 
Dissociated brain cells prepared from 15-16 months old mice were incubated for 4 hours with 2 
mM H2O2 for mitochondrial membrane potential [A] or with 0.4 mM for ATP levels [B]. EGb 761
® 
was added 30 minutes after incubation with H2O2. Data are expressed as means ± S.E.M [n=13 and 
n=6 for A and B respectively]. [*p<0.05 vs. H2O2, student’s t-test] 
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4.2.2 Ex vivo findings 
After noticing a significant improvement on the mitochondrial functions after 
H2O2 –induced damage in both young and older animals, the ex vivo effects of 
EGb 761
® were analyzed. 
A preliminary test was carried out to examine the influence of oxidative stress 
on the 2 different age groups. Both 2-3 and 15-16 months old mice were 
equally sensitive to H2O2 generated oxidative stress as demonstrated in figure 
4-11. The decrease in mitochondrial membrane potential [figure 4-11A] and 
ATP levels [figure 4-11B] was the same in both age groups. 
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Figure 4-11 
 Effect of H2O2 on the mitochondrial functions of 2 different age groups of 
NMRI mice 
Prepared dissociated brain cells were incubated for 4 hours with H2O2, followed by measuring 
mitochondrial membrane potential [A] and ATP levels [B]. Data are expressed as means ± S.E.M 
[n=8-10] Results 
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Figure 4-12 
14 days treatment of NMRI mice with 100 mg/kg body weight EGb 761
® 
2-3 months old NMRI mice and 15-16 months old mice were treated orally with either 0.2 % 
agarose [control] or with 100 mg/kg body weight EGb 761
® for 14 consecutive days. 24 hours after 
the last treatment mice were sacrificed and Dissociated brain cells were prepared. Dissociated brain 
cells were incubated for 4 hours with H2O2 followed by measurement of mitochondrial membrane 
potential [mmp] and ATP levels 
For the treatment study, the above scheme was implemented. For each age 
group  18  mice  were  used.  9  mice  were  assigned  to  the  control  group, 
receiving a daily treatment of 0.2 % agarose solution and the other 9 mice 
received 100 mg/kg body weight EGb 761
® solution. This is a universally 
applied  dosage  and  has  been  previously  reported  to  reduce  ROS-induced 
apoptosis  and  improve  learning  deficits  in  aged  mice  (Schindowski  et  al. 
2001;Stoll et al. 1996). Mice were treated daily for 14 consecutive days, 24 
hours after the last treatment mice were sacrificed and DBCs were prepared as 
usual.  For  mitochondrial  membrane  potential  measurement  cells  were Results 
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incubated with 2 mM H2O2 and for ATP measurement with 0.4 mM H2O2 for 
4 hours. 
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Figure 4-13 
 Ex vivo protection of mitochondrial membrane potential against H2O2 
induced oxidative stress in different age groups 
2-3 months old [A] and 15-16 months old [B] mice were treated for 14 consecutive days with 100 
mg/kg body weight EGb 761
® or with vehicle only. Dissociated brain cells prepared from the 
treated  mice  were  incubated  for  4  hours  with  2mM  H2O2  and  then  mitochondrial  membrane 
potential  was  measured.  Data  are  expressed  as  means  ±  S.E.M  [n=8-9]  [*p<0.05,  vs.  H2O2, 
unpaired student’s t-test] 
An age dependent sensitivity was observed , only the 15-16 months old group 
showed an improvement in the mitochondrial membrane potential after EGb 
761
® treatment, [figure 4-13B] but no response was observed in the young 
mice [figure 4-13A]. 
Measuring the ATP levels after the H2O2 triggered impairment revealed no 
alterations between the vehicle-treated group and the EGb 761
® treated group 
in both age groups [figure 4-14]. 
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Figure 4-14 
 Ex vivo effect of EGb 761
® on ATP levels against H2O2 induced oxidative 
stress in different age groups 
2-3 months old [A] and 15-16 months old [B] mice were treated for 14 consecutive days with 100 
mg/kg body weight EGb 761
® or with vehicle only. Dissociated brain cells prepared from the 
treated mice were incubated for 4 hours with 0.4 mM H2O2 and then ATP levels measured. Data are 
expressed as means ± S.E.M [n=8-9]  
After examining the effect of EGb 761
® ex vivo in young and older mice and 
noticing a slight protective effect during aging we decided to examine the 
effect of EGb 761
® in a transgenic mouse model mimicking AD. Thy-1 APP 
mice are transgenic; comprising both the double Swedish mutation and the 
London  mutation.  These  mutations  lead  to  higher  yields  of  amyloid  beta 
peptide and consequently plaque formation. Results 
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Figure 4-15 
14 days treatment of Thy-1 APP mice and non-tg littermates with 100 mg/kg 
body weight EGb 761
® 
6 months old Thy-1 APP mice and non-tg littermates were treated orally with either 0.2 % agarose 
[control] or with 100 mg/kg body weight EGb 761
® for 14 consecutive days. 24 hours after the last 
treatment mice were sacrificed and dissociated brain cells were prepared. Dissociated brain cells 
were  incubated  for  4  hours  with  H2O2  followed  by  measurement  of  mitochondrial  membrane 
potential [mmp]  
6 months old wild type [littermates] and Thy-1 APP female mice were both 
treated for 14 consecutive days with EGb 761
® [100 mg/kg body weight] or 
with vehicle only. 24 hours after the last treatment the mice were sacrificed 
and DBCs were prepared. 
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Figure 4-16 
Ex vivo protection of mitochondrial membrane potential against H2O2 
induced oxidative stress in transgenic APP mice and non-tg littermates 
6 months old non.-tg littermates [A] and Thy-1 APP [B] mice were treated for 14 consecutive days 
with 100 mg/kg body weight EGb 761
® or with vehicle only. Dissociated brain cells prepared from 
the treated mice were incubated for 4 hours with 2 mM H2O2 and then mitochondrial membrane 
potential was determined. Data are expressed as means ± S.E.M [n=8-9] [*p<0.05, **p<0.01 vs. 
H2O2, unpaired student’s t-test] 
Mitochondrial membrane potential was measured after incubating the DBCs 
with 2 mM H2O2. As depicted in figure 4-16 both wild type and transgenic 
mice showed higher resistance to H2O2 -induced mitochondrial damage after 
EGb 761
® treatment. It is worth mentioning that the potency of EGb 761
® 
appears to be higher in the transgenic mouse model. The effect observed in 
the wild type mice and was not observed in the NMRI mice could be due to 
the age difference [3 months vs. 6 months] or due to strain difference [NMRI 
vs. C57BL/6]. 
Summing  up  the  previous  section,  EGb  761
®  enhanced  mitochondrial 
membrane potential in vitro against H2O2 -induced damage in both young and 
old NMRI mice and improved ATP levels only in the older mice. Treating the 
same  age  groups  with  EGb  761
®  for  14  consecutive  days  alleviated 
mitochondrial  membrane  potential  of  the  older  group  only.  Unfortunately, 
EGb 761
® was not able to protect neither the young nor the older mice against Results 
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H2O2 -mediated decrease in ATP levels ex vivo. Testing the effects of EGb 
761
® in an AD mouse model ex vivo showed alleviation in the mitochondrial 
membrane potential of wild type mice and the effect was more pronounced in 
transgenic mice.  
4.3 Effects of Ginkgo biloba extract [EGb 761
®] on 
mitochondrial function: Protection against SNP 
induced stress 
SNP which is a well known NO donor was used to exert nitrosative stress. NO 
and its derivative peroxynitrite cause injury to the mitochondria, inhibiting all 
respiratory  chain  complexes.  This  leads  to  reduced  ATP  formation  and 
decreases the mitochondrial membrane potential.  
4.3.1 In vitro findings 
4.3.1.1 3 months old NMRI mice 
2-3  months  old  female  NMRI  mice  were  used  in  this  study.  DBCs  were 
prepared from these mice and were incubated for 4 hours with either 2 mM 
SNP to measure mitochondrial membrane potential [figure 4-17A] or with 0.2 
mM SNP for ATP levels [Figure 4-17B]. EGb 761
® was added 30 minutes 
after incubation with SNP. As illustrated in figure 4-17, EGb 761
® was able to 
protect the mitochondria from the SNP induced damage. Both mitochondrial 
membrane potential and ATP levels were improved after EGb 761
® treatment. 
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Figure 4-17 
In vitro protection of mitochondrial functions against SNP induced 
nitrosative stress in 2-3 months old mice 
Dissociated brain cells were incubated for 4 hours with 2 mM SNP for mitochondrial membrane 
potential [A] or with 0.2 mM for ATP levels [B]. EGb 761
® was added 30 minutes after incubation 
with  SNP.  Data  are  expressed  as  means  ±  S.E.M  [n=11-12]  [*p<0.05,  ***p<0.001  vs.  SNP, 
student’s t-test] 
4.3.1.2 15 months old NMRI mice 
To examine the effect of EGb 761
® on aging, the same in vitro experiment 
was repeated but instead of using 2-3 months old mice, 15-16 months old 
mice were used. EGb 761
® was able to improve the mitochondrial damage 
caused  by  SNP  in  15-16  months old  mice.  A  concentration of  0.1  mg/ml 
showed  a  significant  effect  on  the  ATP  levels  [figure  4-18B]  and  a 
concentration  of 0.5  mg/ml  EGb  761
® was  able  to  enhance  mitochondrial 
membrane potential [figure 4-18A]. 
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Figure 4-18 
In vitro protection of mitochondrial functions against SNP induced 
nitrosative stress in 15-16 months old mice 
Dissociated brain cells were incubated for 4 hours with 2 mM SNP for mitochondrial membrane 
potential [A] or with 0.2 mM for ATP levels [B]. EGb 761
® was added 30 minutes after incubation 
with SNP. Data are expressed as means ± S.E.M [n=7-8] [**p<0.01 vs. SNP, student’s t-test] Results 
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4.3.2 Ex vivo findings 
A treatment study for 2 weeks was carried out to examine the influence of 
EGb 761
® on NO generated mitochondrial dysfunction in both young [2-3 
months old] and 15-16 months old mice. Each age group was divided into a 
control group and an EGb 761
® group. After 14 days treatment the mice were 
sacrificed and DBCs were prepared as usual. The DBCs were then incubated 
for 4 hours with either 2 mM SNP for mitochondrial membrane potential or 
with 0.2 mM SNP for determining ATP levels. 
 
Figure 4-19 
14 days treatment of NMRI mice with 100 mg/kg body weight EGb 761
® 
2-3 months old NMRI mice and 15-16 months old mice were treated orally with either 0.2 % 
agarose [control] or with 100 mg/kg body weight EGb 761
® for 14 consecutive days. 24 hours after 
the last treatment mice were sacrificed and dissociated brain cells were prepared. Dissociated brain 
cells were incubated for 4 hours with SNP followed by measurement of mitochondrial membrane 
potential [mmp] and ATP levels. 
 Results 
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Comparing the effect of NO on the two different age groups indicated that the 
younger mice were more sensitive to nitrosative stress as depicted in figure 4-
20.  This  observation  was  minor  on  the  mitochondrial  membrane  potential 
[figure 4-20A], but was highly pronounced on ATP levels [figure 4-20B]. 
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Figure 4-20 
Effect of NO on the mitochondrial functions of 2 different age groups of 
NMRI mice 
Prepared dissociated brain cells were incubated for 4 hours with SNP, followed by measuring 
mitochondrial membrane potential [A] and ATP levels [B]. Data are expressed as means ± S.E.M 
[n=8-9] [**p<0.01 vs. 2-3 months old mice, student’s unpaired t-test]. 
After  2  weeks  treatment  EGb  761
®  was  able  to  improve  mitochondrial 
membrane potential only in older mice and showed no effect in the younger 
mice [figure 4-21]. Results 
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Figure 4-21 
Ex vivo protection of mitochondrial membrane potential against SNP 
induced stress in different age groups 
2-3 months old [A] and 15-16 months old [B] mice were treated for 14 consecutive days with 100 
mg/kg body weight EGb 761
® or with vehicle only. Dissociated brain cells prepared from the 
treated  mice  were  incubated  for  4  hours  with  2mM  SNP  and  then  mitochondrial  membrane 
potential was determined. Data are expressed as means ± S.E.M [n=8-10] [**p<0.01 vs. vehicle, 
unpaired student’s t-test]. 
However,  comparing  ATP  levels  in  the  EGb  761
®  treated  group  and  the 
placebo  group  after  NO  stress  showed  no  difference  in  both  age  groups 
[figure 4-22] Results 
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Figure 4-22 
Ex vivo effect of EGb 761
® on ATP levels against SNP induced nitrosative 
stress in different age groups 
2-3 months old [A] and 15-16 months old [B] mice were treated for 14 consecutive days with 100 
mg/kg body weight EGb 761
® or with vehicle only. Dissociated brain cells prepared from the 
treated mice were incubated for 4 hours with 0.2mM SNP and then ATP levels were measured. 
Data are expressed as means ± S.E.M [n=8-10]. 
Similar to the experiments done with H2O2, our ex vivo studies with NO were 
extended  by  testing  the  influence  of  EGb  761
®  in  AD  transgenic  mouse 
model. 6 months old female Thy-1 APP and wild type mice were treated for 
14 days with EGb 761
® [100 mg/kg body  weight] or with vehicle. DBCs 
prepared from these mice were stressed for 4 hours with 2 mM SNP and 
mitochondrial membrane potential was then measured. Results 
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Figure 4-23 
14 days treatment of Thy-1 APP mice and non-tg littermates with 100 mg/kg 
body weight EGb 761
® 
6 months old Thy-1 APP mice and non-tg littermates were treated orally with either 0.2 % agarose 
[control] or with 100 mg/kg body weight EGb 761
® for 14 consecutive days. 24 hours after the last 
treatment mice were sacrificed and dissociated brain cells were prepared. Dissociated brain cells 
were  incubated  for  4  hours  with  SNP  followed  by  measurement  of  mitochondrial  membrane 
potential [MMP]. Results 
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Figure 4-24 
Ex vivo protection of mitochondrial membrane potential against SNP 
induced nitrosative stress in transgenic APP mice and non-tg littermates 
Non.-tg littermates [A] and Thy-1 APP [B] mice were treated for 14 consecutive days with 100 
mg/kg body weight EGb 761
® or with vehicle only. Dissociated brain cells prepared from the 
treated  mice  were  incubated  for  4  hours  with  2  mM  SNP  and  then  mitochondrial  membrane 
potential  was  determined.  Data  are  expressed  as  means  ±  S.E.M  [n=8]  [*p<0.05  vs.  vehicle, 
unpaired student’s t-test]. 
Both wild type and transgenic mice were significantly protected against the 
NO-induced stress after EGb 761
® treatment [figure 4-24], here again with a 
more evident effect in the transgenic mice. 
The effect of EGb 761
® on NO-induced damage was similar to that seen with 
H2O2 but slightly more pronounced. Both young and old mice were protected 
in  vitro  against  NO-induced  mitochondrial  damage.  There  was  no  effect 
noticed on ATP levels ex vivo, but mitochondrial membrane potential was 
improved in the older mice group. EGb 761
® was also efficient in the AD 
transgenic mice model. Results 
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4.4 Effects of various components of EGb 761
® on 
mitochondrial function: Protection against SNP 
induced stress 
From the above findings and from previously reported results in the literature, 
EGb 761
® has proven its ability to prevent ROS and RNS induced damage, 
and  protect  the  mitochondria.  However,  the  question  which  component/s 
is/are responsible for these effects is still not answered. Only a few scientists 
tried to answer this question by testing all the different components under the 
same conditions, some tested only the flavonoids others only bilobalide or the 
terpenoids. Comparing these different studies and trying to reach a conclusion 
makes it very difficult due to the methodological differences. In order to reach 
such  conclusions  all  components  should  be  evaluated  under  the  same 
conditions. 
Therefore,  the  impact  of  the  single  components  of  EGb  761
®  on  the 
mitochondrial function was tested, under the same conditions and measuring 
the same parameters.  
EGb 761
® consists of two major groups of substances, the flavonoid fraction 
[24 %] and the terpenoid fraction [6 %]. The flavonoid fraction is primarily 
composed  of  quercetin,  kaempferol  and  isorhamnetin  glycosides  and  the 
terpenoid  fraction  consists  of  ginkgolides  A,  B,  C,  J  and  bilobalide.  The 
components were tested against SNP initiated mitochondrial dysfunction, and 
not H2O2, since the influence of EGb 761
® on NO-generated damage was 
more pronounced. 
4.4.1 In vitro findings  
In  vitro  experiments  with  DBCs  were  preformed  using  two  different 
experimental  procedures.  For  pre-treatment  studies  the  ability  of  the  EGb 
761
®  constituents  to  prevent  occurrence  of  mitochondrial  damage  was Results 
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examined. Here the EGb 761
® constituents were first added, after 30 minutes 
incubation time the DBCs were stressed with NO for 4 hours. 
For  post-treatment  studies  the  ability  of  the  constituents  to  regenerate  the 
mitochondrial functions after nitrosative damage was tested. The DBCs were 
first stressed with NO for 4 hours, 30 minutes after insult the constituents 
were added.  
4.4.1.1 Pre-treatment studies 
In this section, experiments were conducted with the help of DBCs prepared 
from  2-3  months  old  female  NMRI  mice.  Mitochondrial  function  was 
evaluated via 3 different markers. Mitochondrial membrane potential, ATP 
levels and cell viability were determined for each constituent. 
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Figure 4-25 
Protection of the mitochondria against NO insult by pre-treatment with 
Ginkgolide A 
Dissociated brain cells were incubated with Ginkgolide A for 30 minutes. Then SNP was added for 
4  hours.  Mitochondrial  membrane  potential  [A],  ATP  levels  [B]  and  metabolic  activity  were 
determined [C]. Data are expressed as means ± S.E.M [n=5-8] 
The  DBCs  were  first  incubated  with  GA.  30  minutes  later  cells  were 
incubated with 2 mM SNP for mitochondrial membrane potential, 0.2 mM 
SNP for ATP levels and with 0.5 mM SNP for MTT assay. After 4 hours Results 
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mitochondrial  membrane  potential,  ATP  levels  and  MTT  assay  were 
measured. As shown in figure 4-25 pre-treatment with GA had no influence 
on mitochondrial functions. 
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Figure 4-26 
Protection of the mitochondria against NO insult by pre-treatment with 
Ginkgolide B 
Dissociated brain cells were incubated with Ginkgolide B for 30 minutes. Then SNP was added for 
4  hours.  Mitochondrial  membrane  potential  [A],  ATP  levels  [B]  and  metabolic  activity  were 
determined  [C].  Data  are  expressed  as  means  ±  S.E.M  [n=6-8]  [*p<0.05,  **p<0.01  vs.  SNP, 
student’s paired t-test]. 
On the contrary, pre-treatment with GB was able to enhance mitochondrial 
membrane  potential  at  a  concentration  of  0.01  mg/ml  [figure  4-26A]  and 
improve cell viability at a concentration of 0.05 mg/ml [figure 4-26C]. On the 
other hand ATP levels were not affected by the pre-incubation with GB.  Results 
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Figure 4-27 
Protection of the mitochondria against NO insult by pre-treatment with 
Ginkgolide C 
Dissociated brain cells were incubated with Ginkgolide C for 30 minutes. Then SNP was added for 
4  hours.  Mitochondrial  membrane  potential  [A],  ATP  levels  [B]  and  metabolic  activity  were 
determined  [C].  Data  are  expressed  as  means  ±  S.E.M  [n=6-8]  [*p<0.05,  **p<0.01  vs.  SNP, 
student’s paired t-test]. 
Both mitochondrial membrane potential and cell viability were significantly 
improved using 0.01 mg/ml GC [figures 4-27A&C]. Here again ATP levels 
were not improved by pre-treatment with GC [figure B]. Results 
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Figure 4-28 
Protection of the mitochondria against NO insult by pre-treatment with 
Ginkgolide J 
Dissociated brain cells were incubated with Ginkgolide J for 30 minutes. Then SNP was added for 
4  hours.  Mitochondrial  membrane  potential  [A],  ATP  levels  [B]  and  metabolic  activity  were 
determined [C]. Data are expressed as means ± S.E.M [n=5-7]. 
Similar  to  GA,  pre-treatment  with  GJ  had  no  influence  on  mitochondrial 
properties as depicted in figure 4-28. Results 
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Figure 4-29 
Protection of the mitochondria against NO insult by pre-treatment with 
Bilobalide 
Dissociated brain cells were incubated with Bilobalide for 30 minutes. Then SNP was added for 4 
hours.  Mitochondrial  membrane  potential  [A],  ATP  levels  [B]  and  metabolic  activity  were 
determined [C]. Data are expressed as means ± S.E.M [n=5-7] [*p<0.05 vs. SNP, student’s paired t-
test]. 
Pre-treating the DBCs with Bilobalide demonstrated a slight improvement on 
the  mitochondrial  functions.  0.05  mg/ml  showed  a  slight  increase  in 
mitochondrial membrane potential [figure 4-29A] which was not significant, 
but the same concentration was able to enhance cell viability significantly 
[figure 4-29C]. 
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Figure 4-30 
Protection of the mitochondria against NO insult by pre-treatment with 
Flavonoids 
Dissociated brain cells were incubated with Flavonoids for 30 minutes. SNP was added for 4 hours. 
Mitochondrial  membrane  potential  [A],  ATP  levels  [B]  were  measured.  Data  are  expressed  as 
means ± S.E.M [n=6-7] [*p<0.05, **p<0.01 vs. SNP, student’s paired t-test]. 
The flavonoid fraction had a relatively potent effect compared to the other 
single  constituents  and  was  able  to  enhance  mitochondrial  membrane 
potential to nearly control levels [100 %] as illustrated in figure 4-30A. The 
ATP  levels  were  also  significantly  increased  with  a  concentration  of  0.01 
mg/ml [figure 4-30B]. Cell viability for DBCs treated with flavonoids could 
not be measured, due to the interference with the MTT assay reagents. Results 
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0.005 0.01 0.05
GA MTT - - -
MMP - - -
ATP - - -
GB MTT - - *
MMP - ** -
ATP - - -
GC MTT - * -
MMP - ** -
ATP - - -
GJ MTT - - -
MMP - - -
ATP - - -
Bilobalide MTT - - -
MMP - - *
ATP - - -
Flavonoids MTT
MMP - * **
ATP - * -
Pre-treatment
Reagents interference
 
Table 4.3 
Summary of pre-treatment with EGb 761
® single constituents 
Dissociated brain cells were incubated with SNP for 4 hours. The EGb 761
® constituents were 
added  30  minutes  before  [Pre-treatment]  incubation  with  SNP.  Cell  viability  [MTT  assay], 
mitochondrial membrane potential [MMP] and ATP levels were measured. [*p<0.05 and **p<0.01 
vs. SNP, student’s paired t-test]. 
The above table represents an overview of the outcomes of the pre-treatment 
study. In conclusion, it appears that the flavonoid fraction is the most potent, 
followed by GC. Minor protection was noticed by treatment with GB and BB. 
Finally GJ and GA were ineffective. Results 
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4.4.1.2 Post-treatment studies 
In  this  section  the  ability  of  EGb  761
®  constituents  to  regenerate 
mitochondrial  functions  after  nitrosative  stress  was  tested.  DBCs  were 
incubated for 4 hours with SNP; 30 minutes after nitrosative stress EGb 761
® 
components were added. After the 4 hours incubation period mitochondrial 
membrane potential, ATP levels and cell viability were measured. 
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Figure 4-31 
Protective effect of Ginkgolide A on mitochondrial functions after NO 
insult 
Dissociated brain cells were stressed with SNP for 4 hours. 30 minutes after incubation with SNP 
Ginkgolide A was added. Mitochondrial membrane potential [A], ATP levels [B] and metabolic 
activity were determined [C]. Data are expressed as means ± S.E.M [n=6-11] [*p<0.05, **p<0.01 
and ***p<0.001 vs. SNP, student’s paired t-test]. 
In contrast to pre-treatment, post- treatment with GA was able to enhance the 
mitochondrial functions against NO damage. GA in concentrations as low as 
0.005 mg/ml improved cell viability and 0.05 mg/ml improved mitochondrial 
membrane potential and ATP levels [figure 4-31]. 
 
 
 Results 
 
  151 
 
 
0.01
0.05
0
20
40
60
80
100
Ginkgolide B
[mg/ml]
* *
2 mM SNP
R
1
2
3
 
f
l
o
u
r
e
s
c
e
n
c
e
[
%
 
o
f
 
c
o
n
t
r
o
l
]
0.01
0.05
0
20
40
60
80
100
Ginkgolide B
[mg/ml]
0.2 mMSNP
[0.066]
A
T
P
[
%
 
o
f
 
c
o
n
t
r
o
l
]
0.005
0.01
0.05
0
20
40
60
80
100
Ginkgolide B
 [mg/ml]
*** ** **
0.5 mM SNP
M
T
T
[
%
 
o
f
 
c
o
n
t
r
o
l
]
A
B C
Figure 4-32 
Protective effect of Ginkgolide B on mitochondrial functions after NO 
insult 
Dissociated brain cells were stressed with SNP for 4 hours. 30 minutes after incubation with SNP 
Ginkgolide B was added. Mitochondrial membrane potential [A], ATP levels [B] and metabolic 
activity were determined [C]. Data are expressed as means ± S.E.M [n=6-8] [*p<0.05, **p<0.01 
and ***p<0.001 vs. SNP, student’s paired t-test]. 
Post-treatment  with  GB  showed  significantly  higher  cell  viability  at  a 
concentration of 0.005 mg/ml [figure C]. 0.01 mg/ml was able to increase 
mitochondrial membrane potential [figure A], and only slight improvement in 
ATP levels was detected [figure B]. Results 
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Figure 4-33 
Protective effect of Ginkgolide C on mitochondrial functions after NO 
insult 
Dissociated brain cells were stressed with SNP for 4 hours. 30 minutes after incubation with SNP 
Ginkgolide C was added. Mitochondrial membrane potential [A], ATP levels [B] and metabolic 
activity were determined [C]. Data are expressed as means ± S.E.M [n=6-12] [*p<0.05, **p<0.01 
vs. SNP, student’s paired t-test]. 
Ginkgolide C had a weak protective effect on the mitochondria. This effect 
was  only  perceived  on  mitochondrial  membrane  potential  were  a 
concentration of 0.01 mg/ml was able to alleviate the impairment caused by 
NO [figure 4-33]. 
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Figure 4-34 
Protective effect of Ginkgolide J on mitochondrial functions after NO insult 
Dissociated brain cells were stressed with SNP for 4 hours. 30 minutes after incubation with SNP 
Ginkgolide J was added. Mitochondrial membrane potential [A], ATP levels [B] and metabolic 
activity were determined [C]. Data are expressed as means ± S.E.M [n=6-8] [*p<0.05 vs. SNP, 
student’s paired t-test]. 
Mitochondrial dysfunction caused by NO was not reduced by treatment with 
GJ. Slight improvement was observed using 0.05 mg/ml on mitochondrial 
membrane potential [figure 4-34A]. ATP and cell viability were not affected 
[figure 4-34B&C]. Results 
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Figure 4-35 
Protective effect of Bilobalide on mitochondrial functions after NO insult 
Dissociated brain cells were stressed with SNP for 4 hours. 30 minutes after incubation with SNP 
Bilobalide  was  added.  Mitochondrial  membrane  potential  [A],  ATP  levels  [B]  and  metabolic 
activity were determined [C]. Data are expressed as means ± S.E.M [n=6-7] [*p<0.05, **p<0.01 vs. 
SNP, student’s paired t-test. 
The  sesquiterpenoid,  Bilobalide  was  able  to  protect  the  mitochondria  at  a 
concentration  of  0.01  mg/ml.  Mitochondrial  membrane  potential  was 
significantly elevated [figure 4-35A] and cell viability was increased to nearly 
100 % [figure 4-35C]. Unfortunately no effect was seen on ATP levels. 
 Results 
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Figure 4-36 
Protective effect of Flavonoids on mitochondrial functions after NO insult 
Dissociated brain cells were stressed with SNP for 4 hours. 30 minutes after incubation with SNP a 
mixture of the Flavonoids extracted from EGb 761
® was added. Mitochondrial membrane potential 
[A], ATP levels [B] were determined. Data are expressed as means ± S.E.M [n=6-7] [**p<0.01 vs. 
SNP, student’s paired t-test]. 
The Flavonoid fraction of EGb 761
® was also active in post-treatment as it 
was  in  pre-treatment.  It  was  able  to  increase  mitochondrial  membrane 
potential significantly at a concentration of 0.01 mg/ml [figure 4-36A] and 
ATP levels were also significantly increased but at a higher concentration of 
0.05 mg/ml [figure 4-36B]. 
 Results 
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0.005 0.01 0.05
GA MTT *** ** *
MMP - - *
ATP - - *
GB MTT *** ** **
MMP - * *
ATP - - -
GC MTT - - -
MMP - * **
ATP - - -
GJ MTT - - -
MMP - - *
ATP - - -
Bilobalide MTT - * *
MMP - * **
ATP - - -
Flavonoids MTT
MMP - ** **
ATP - - **
Post-treatment
Reagant interference
Concentration mg/ml
 
Table 4.4 
Summary of post-treatment with EGb 761
® single constituents 
Dissociated brain cells were incubated with SNP for 4 hours. The EGb 761
® constituents were 
added  30  minutes  after  [post-treatment]  incubation  with  SNP.  Cell  viability  [MTT  assay], 
mitochondrial membrane potential [MMP] and ATP levels were measured. [*p<0.05, **p<0.01, 
***p<0.001 vs. SNP, student’s paired t-test]. 
The  above  table  summarizes  the  effects  of  post-treatment  with  EGb  761
® 
components. All the EGb 761
® constituents were are able to enhance one or 
more of the measured parameters. It is obvious that the ginkgolides are more 
effective in post-treatment than in pre-treatment. Results 
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4.5 Influence of long-term treatment with EGb 761
® in a 
senescence accelerated mouse model 
With the intention of investigating the influence of a long- term EGb 761
® 
therapy, a 5 months feeding study was preformed. Since 5 months would only 
represent ¼ of the life span of mice, a special mouse model known as SAMP 
[senescence accelerated prone-mice] was utilized. The life span of SAMP8 
mice ranges from 10 to a maximum of 17 months, and they are characterized 
by  acquiring  age-related  learning  and  memory  deficits  and  an  increased 
deposition  of  Aß.  This  makes  this  model  optimal  for  studying  long-term 
effects  of  EGb  761
®  with  only  5  months  feeding,  and  representing  AD 
characteristics. As controls SAMR1 [senescence accelerated resistant-mice] 
were employed, these have a normal life span ranging from 19 to 21 months, 
and undergo normal aging without memory impairments. 
Mitochondrial functions of the SAMP8 and SAMR1 were assessed, and the 
influence of 5 months feeding with EGb 761
® was evaluated. Given that on 
average basis one mouse consumes 3.5 g/day; the calculated daily intake of 
EGb 761
® would be 150 mg/ kg body weight. Both SAMR1 and the placebo-
treated mice received western diet devoid of EGb 761
®. Results 
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Figure 4-37 
Mitochondrial functions of SAMR1 and SAMP8 
The EGb 761
® SAMP8 mice received 5 months food pellets supplemented with EGb 761
® extract, 
while both the placebo SAMP8 and SAMR1 received western diet. Dissociated brain cells were 
prepared from SAMR1 and SAMP8 mice and mitochondrial membrane potential [A] and ATP 
levels  [B]  were  determined.  Data  are  expressed  as  mean  ±  S.E.M  [n=4-6].  [+p<0.05  vs. 
SAMR1,*p<0.05 vs. placebo-treated, student’s unpaired t-test]. 
The SAMP8 exhibited impaired mitochondrial functions as depicted above 
[figure  4-37].  They  have  significantly  lower  mitochondrial  membrane 
potential and ATP levels compared to SAMR1 mice. EGb 761
® enriched diet 
alleviated mitochondrial dysfunction by increasing ATP levels significantly 
and mitochondrial membrane potential slightly.  
In view of the fact that membrane fluidity decreases during aging and since 
SAMP8 mice age rapidly, we thought it would be credible to compare the 
membrane fluidity of SAMR1 and SAMP8. 
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Figure 4-38 
Influence of EGb 761
® on the membrane fluidity in SAMP8 mice  
The EGb 761
® SAMP8 mice received 5 months food pellets supplemented with EGb 761
® extract, 
while both the placebo SAMP8 and SAMR1 received western diet. Anisotropy was measured with 
the help of TMA-DPH [A] and DPH [B] fluorescent probes. Data are represented as mean ± S.E.M 
[n=6-8]. [*p<0.05 vs. placebo-treated, student’s unpaired t-test]. 
There was no difference identified in the fluidity of the membranes obtained 
from SAMR1 and SAMP8 mice. However, EGb 761
® was able to increase 
membrane fluidity in the SAMP8 mice. This observation was made by both 
fluorescent probes [DPH and TMA-DPH]. Results 
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4.6 Effects of EGb 761
® on amyloid beta production 
Genetic, animal modeling and biochemical studies suggest that amyloid beta 
[Aβ] plays a central role in initiating Alzheimer’s disease. Lately, Aβ has 
been reported to contribute to mitochondrial dysfunction in several models. 
Based  on  this  data  and  the  current  findings  that  EGb  761
®  improves 
mitochondrial functions of impaired mitochondria, the influence of EGb 761
® 
on Aβ was examined. 
Aβ is derived from the amyloid precursor protein [APP] by the action of two 
aspartyl proteases [β- and γ-secretases]. APP is first cleaved by β-secretase 
shedding  its  large  ectodomain  and  leaving  a  membrane  bound  C-terminal 
stub. This 99 amino acid long stub is subsequently cleaved by γ-secretase and 
Aβ is released. Depending on the cleavage by γ-secretase, two main forms of 
Aβ, comprising either 40 or 42 amino acid residues, are produced. The longer 
form [Aβ 42] is far more prone to oligomerize and form fibrils than is the 
more abundantly produced Aβ 40 peptide. 
4.6.1 HEK cells with Swedish mutation 
Preliminary experiments were carried out on a cell line model for AD. Hek-
293  cells,  which  are  human  embryonic  kidney  cells  carrying  the  Swedish 
double mutation were employed. This mutation leads to the production of 
large amounts of Aß, comparable to the transgenic mice model [Thy-1 APP] 
which is transfected with both the Swedish and the London mutations. For 
this purpose Hek-Swedish [Hek-sw] cells were selected as a suitable model 
for the preliminary experiments.  
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Figure 4-39 
Effect of different concentrations of EGb 761
® on amyloid beta Aß 1-40 
production in HEK sw cells 
HEK sw cells were incubated for 24 hours with concentrations ranging from 0.5µg/ml to 100 µg/ml 
EGb 761
®. Medium was collected after the 24 hours and Aß 1-40 and Aß 1-42 levels were determined 
using an ELISA kit. Data are expressed as means ± S.E.M [n=3-6] [*p<0.05, **p<0.01 one way 
ANOVA]. 
For testing the influence of EGb 761
® on Aß production, the Hek-sw cells 
were grown in petri dishes. The medium was exchanged and the new medium 
conferred to the cells contained different concentrations of EGb 761
®. Cells 
were harvested and medium was collected 24 hours after incubation with EGb 
761
®. The amount of Aß was determined in the medium and an unexpected 
dramatic increase in the levels of soluble Aß 40 was observed, significant at a 
concentration as low as 0.5 µg/ml [figure 4-39A]. The Aß 42 values were 
slightly increased showing a maximum effect at 1µg/ml EGb 761
®. A typical 
u-shape curve was noticed with both forms of Aß. 
4.6.2 Thy-1 APP transgenic mice 
In order to confirm the above observation with Hek-sw cells and for further 
investigations, a treatment study was carried out in a transgenic mice model 
[Thy-1  APP].  These  mice  are  characterized  by  an  altered  APP  processing 
leading to overproduction of Aß and plaque formation at an age of 6 months.  Results 
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4.6.2.1 Soluble amyloid beta 
Transgenic Thy-1 APP mice and non-transgenic littermates were treated for 
21 days with EGb 761
® [100 mg/kg body weight] or vehicle only. After 21 
days  the  mice  were  sacrificed  and  brains  were  removed  to  determine  Aß 
levels. 
Comparing the Aß levels of tg-APP and non-tg mice, the soluble Aß 40 was 
as expected, produced only in the transgenic mice as shown in figure 4-40B. 
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Figure 4-40 
Amount of soluble amyloid beta [Aß1-40] in vehicle treated non-tg and tg-
APP mice 
Non-tg and tg-APP Mice were treated for 21 days with vehicle [0.2% agarose] for 21 days. ELISA 
was carried out on brain extracts to determine the amount of soluble Aß1-40. The levels of Aß were 
calculated  from  the  standard  curve  [A],  produced  with  the  provided  standard  solution  in  the 
commercially available ELISA kit. Data are expressed as means ± S.E.M [n=8-9] [***p<0.001 vs. 
wild type, student’s unpaired t-test]. Results 
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Figure 4-41 
Effect of 21 days treatment with EGb 761
® on the soluble Aß 1-40 levels in 
Tg-APP mice 
After treating Tg-APP mice for 21 days with EGb 761
® [100 mg/kg], soluble Aß1-40 was determined 
in the brain extracts using ELISA. Data are expressed as means ± S.E.M [n=7-9] [*p<0.05 vs. 
vehicle, unpaired t-test]. 
Verifying our observation with Hek-sw cells, brain extracts from the EGb 
761
®- treated mice exhibited higher levels of soluble Aβ 40 compared to the 
placebo-treated group. 
Note:  The  soluble  levels  of  Aß  42  were  below  the  detection  level  of  the 
commercially available ELISA kit.  
4.6.2.2 Total amyloid beta 
Total Aß, soluble and insoluble was extracted using guanidine tris-buffer. The 
total amount of both Aß 40 and Aß 42 in the transgenic and wild type mice 
was determined and as shown in the figure below, transgenic mice showed 
masses of both Aß 40 and Aß 42. 
Although both Aß 40 and Aß 42 levels were very high in the transgenic mice, 
the amount of Aß 42 was around 20 times more as Aß 40. The transgenic mice 
showed an approximate of 26,000 pg/mg protein Aß 40 [figure 4-42B] while 
the average amount of Aß 42 is 550,000 pg/mg protein [figure 4-42D]. 
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Figure 4-42 
Total Amount of Aß 1-40 and Aß 1-42.in vehicle treated non-tg and tg-APP 
mice 
Non-tg and tg-APP Mice were treated for 21 days with vehicle [0.2% agarose]. ELISA was carried 
out on the guanidine brain extracts and the total amount of Aß 1-40 [A & C] and Aß1-42 [B & D] 
were determined from their corresponding standard curves. Data are expressed as means ± S.E.M 
[n=8-9] [***p<0.001 vs. wild type, student’s unpaired t-test]. Results 
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Figure 4-43 
Correlation between total Aß 1-40 and Aß 1-42 in both placebo and EGb 761
® 
treated mice 
Both tg and non-tg mice were treated for 21 days either with Vehicle only or 100 mg/kg body 
weight EGb 761
®.The amount of Aß 1-40 was plotted against the amount of Aß 1-42 for both placebo 
treated and EGb 761
®-treated mice. Correlation r  p = 0.8952, P<0.0001 for the placebo treated 
group [A], and correlation r p = 0.9141, P<0.0001 for the EGb 761
® treated group [B]. 
Comparing the Aß 40 and Aß 42 levels, it was clear that they highly correlate 
linearly  and  positively  with  each  other,  meaning  a  mouse  exhibiting  high 
levels of Aß 40 has also high levels of Aß 42 [figure 4-43] and vice versa. 
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Figure 4-44 
Effect of 21 days treatment with EGb 761
® on the levels of Aß 1-40 and Aß 1-
42 levels in Tg-APP mice 
Tg-APP mice were treated for 21 days with EGb 761
® [100 mg/kg]. ELISA was carried out on the 
guanidine brain extracts to determine the total amount of Aß 1-40 [A & B] and Aß 1-42[C & D] 
Data are expressed as means ± S.E.M [n=8-9]. 
Observing the amount of Aß 40 [figure 4-44B] it is noticeable that the levels 
vary  greatly  from  one  mouse  to  another  as  depicted  in  the  scatter  plots, 
making it difficult to draw a conclusion. The levels of Aß 42 remained more 
or less constant in both the EGb 761
® treated group and the placebo group 
[figure 4-44D]. 
Even  though  the  above  results  demonstrating  the  effects  of  EGb  761
®  on 
soluble Aß levels are quite perplexing, it has to be taken into account that Aß 
can  be  observed  to  self-assemble  into  fibrils,  protofibrils,  and  oligomeric 
structures and not all of these Aß forms are neurotoxic. Recently, it has been 
highly suggested that an important neurotoxic form of Aß is an oligomer, Results 
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composed of approximately 12 subunits with a molecular weight of 54 kDa. 
Aß 42 is more prone to undergo self assembling into the ß-sheet structure, 
aggregating to form the neurotoxic oligomers. Results 
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4.7 Effects of EGb 761
® on gene expression: RT-PCR 
To find out the mechanism behind the effect of EGb 761
® on Aß production 
in the EGb 761
® treated mice, we quantified its effect on the expression of the 
genes which can play a role in Aß production. 
Since the mice used in the treatment study were transgenic mice carrying a 
mutant  human  amyloid  precursor  protein  [APP]  gene  which  leads  to  over 
production  of  Aß,  the  influence  of  EGb  761
®  on  the  human  APP  gene 
expression after 21 days of treatment was determined. 
As illustrated in the figure below the mutant human APP gene was down 
regulated after EGb 761
® treatment.  
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Figure 4-45 
Effect of treatment with EGb 761
® on human APP gene expression in tg-
APP mice 
Tg-APP  mice were treated for 21 days with EGb 761
® [100 mg/kg] or vehicle only. Relative 
mRNA levels of human APP gene were quantified as the ratio between the amount of target gene 
and the amount of the housekeeping gene beta-actin. Data are expressed as means ± S.E.M [n=8-9] 
[*p<0.05, student’s unpaired t-test]. 
The levels of mRNA of murine APP and APP binding protein [APPbp1] were 
analyzed. Unpredictably, the Thy-1 APP transgenic mice showed an elevated 
amount of murine APP compared to the wild type mice.  Results 
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EGb  761
®  treatment  was  able  to  decrease  the  levels  of  murine  APP 
significantly  [figure  4-46A],  suggesting  that  EGb  761
®  is  able  to  down-
regulate not only the mutant human APP in the transgenic mice but also the 
unexpectedly elevated murine APP. 
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Figure 4-46 
Effect of treatment with EGb 761
® on murine APP and APPbp1 gene 
expression in non-tg and tg-APP mice 
Non-tg and tg-APP mice were treated for 21 days with EGb 761
® [100 mg/kg] or vehicle only. 
Relative mRNA levels of both APP [A] and APPbp1 [B] genes were quantified as the ratio between 
the amount of target gene and the amount of the housekeeping gene beta-actin. Data are expressed 
as means ± S.E.M [n=8-10] [*p<0.05, student’s unpaired t-test]. 
The three major enzymes which are responsible for the cleavage of APP are 
the α-, ß- and γ- secretases. Cleavage of APP through α-secretase followed by 
γ-  secretase  is  a  non-amyloidogenic  pathway  and  doesn’t  lead  to  Aß 
formation.  On  the  contrary,  cleavage  through  ß-secretase  followed  by  γ- 
secretase leads to the amyloidogenic pathway forming both Aß 40 and Aß 42. 
Consequently, the genetic expression of both α-secretase and ß-secretase in 
the placebo- and EGb 761
®-treated mice was compared. 
Although  the  exact  identity  of  α-secretase  is  unclear,  the  most  highly 
suggested  candidate  is  the  metalloprotease  ADAM  10.  Therefore,  the Results 
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expression  of  ADAM-10  was  quantified.  As  shown  in  figure  4-47A, 
comparing  the  placebo-treated  and  EGb  761
®-treated  groups  there  was  no 
difference in the mRNA levels of ADAM-10. 
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Figure 4-47 
Effect of treatment with EGb 761
® on ADAM-10 and BACE-1 gene 
expression in non-tg and tg-APP mice 
Non-tg and tg-APP mice were treated for 21 days with EGb 761
® [100 mg/kg] or vehicle only. 
Relative mRNA levels of both ADAM-10[A] and BACE-1[B] genes were quantified as the ratio 
between the amount of target gene and the amount of the housekeeping gene beta-actin. Data are 
expressed as mean ± S.E.M [n=8-9]. 
The  membrane-bound  aspartyl  protease  BACE-1[ß-site  cleaving  enzyme] 
encoded  on  chromosome  11  is  recognized  as  ß-secretase.  As  represented 
above [figure 4-47B] there was no difference on the BACE-1 gene expression 
between the non-transgenic and the Thy-1 APP transgenic mice. Treatment 
with EGb 761
® didn’t alter the mRNA levels of BACE-1. Results 
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Figure 4-48 
Correlation of Human APP expression with BACE and ADAM expression 
in transgenic mice 
Transgenic mice were treated for 21 days either with Vehicle only or 100 mg/kg body weight EGb 
761
®. The Hu APP gene expression was plotted against ADAM expression for both placebo treated 
[A] and EGb 761
®-treated[B] mice. Correlation r  p = -0.8612, P=0.006 for the placebo treated 
group, and correlation r p =- 0.1698, P=0.6178 for the EGb 761
® treated group. The expression of 
Hu APP was plotted against BACE gene expression for both placebo treated [C] and EGb 761
®-
treated  [D]  mice.  Correlation  r  p  =  -  0.7598,  P=  0.0287  for  the  placebo  treated  group,  and 
correlation r p = -0.3946, P=0.2298 for the EGb 761
® treated group. 
The  mRNA  levels of  HuAPP  were  correlated  with  BACE  and  ADAM  as 
illustrated in figure 4-48. In the Vehicle treated group the higher the Hu APP 
expression  the  lower  were  the  values  of  BACE  and  ADAM  [figure  4-
48A&C],  suggesting  less processing of APP.  Treating  the mice  with  EGb 
761
®  decreased  the  expression  of  the  mutant  APP  without  altering  the 
expression of its cleaving enzymes BACE and ADAM [figure 4-48B&D]. 
Accordingly, the cleavage of APP remained constant while the mutant Hu 
APP was down-regulated by using EGb 761
®.  Results 
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In view of the fact that the mRNAs of the enzymes which are responsible for 
the production of Aß were not altered, the Aß degrading enzymes were then 
taken into consideration. 
Many  proteases  or  peptidases  have  been  reported  with  the  capability  of 
cleaving  Aβ  either  in  vitro  or  in  vivo.  The  most  important  enzymes 
contributing  to  Aß  degradation  are  Neprilysin  [NEP],  Insulin-degrading 
enzyme [IDE] and Endothelin-converting enzyme [ECE]. Two isoforms of 
ECE exist, ECE-1 and ECE-2. Expression of ECE-2 is only 1–2 % as much as 
the more abundant ECE-1 and studies have suggested that ECE-1, but not 
ECE-2, is a possible brain Aβ-degrading enzyme (Eckman et al. 2001). 
Based on this knowledge  the levels of mRNA  of  the aforementioned  Aß-
degrading enzymes, namely, NEP, IDE and ECE-1 were examined. 
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Figure 4-49 
Effect of treatment with EGb 761
® on ECE-1, NEP and IDE mRNA levels 
in non-tg and tg-APP mice 
Non-tg and tg-APP mice were treated for 21 days with EGb 761
® [100 mg/kg] or vehicle only. 
Relative mRNA levels of ECE-1[A], NEP [B] and IDE [C] genes were quantified as the ratio 
between the amount of target gene and the amount of the housekeeping gene beta-actin. Data are 
expressed as means ± S.E.M [n=8-9]. 
Observing the above graphs, one notices that NEP [figure 4-49A] and IDE 
[figure  4-49C]  are  slightly  down  regulated  but  not  significantly  in  the 
transgenic mice compared to the non-transgenic mice; ECE-1 did not show 
the same trend. Results 
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EGb 761
® treatment showed no significant effect on the expression levels of 
the 3 enzymes in both transgenic and non-transgenic mice [figure 4-49]. The 
levels of Aß were correlated with the expression of the Aß degrading enzymes 
in order to see if a relation does actually exist, and whether EGb 761
® can 
influence this relation. 
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Figure 4-50 
Correlation between ECE expression and Aß 1-40 or Aß 1-42 in transgenic 
mice 
Transgenic mice were treated for 21 days either with Vehicle only or 100 mg/kg body weight EGb 
761
®.The amount of Aß 1-40 was plotted against ECE gene expression for both placebo treated[A] 
and EGb 761
®-treated [B] mice . Correlation r  p = - 0.01389, P=0.9740 for the placebo treated 
group, and correlation r p = -0.7188, P=0.0291 for the EGb 761
® treated group. The amount of Aß 1-
42 was plotted against ECE gene expression for both placebo treated[C] and EGb 761
®-treated [D] 
mice. Correlation r  p = 0.1746, P=0.6531 for the placebo treated group, and correlation r  p =- 
0.4463, P=0.1960 for the EGb 761
® treated group. Results 
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Although EGb 761
® didn’t alter the mRNA levels of ECE-1, it affected its 
correlation to Aß. The correlation between the ECE-1 expression and Aß 40 
levels is a negative correlation, signifying that after EGb 761
® treatment, mice 
with a high expression of ECE-1 exhibited high levels of Aß 40 [figure 4-
50B]. There was no significant correlation seen between the levels of Aß 42 
and ECE-1 expression [figure 4-50C&D].  
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Figure 4-51 
Correlation between NEP expression and Aß 1-40 or Aß 1-42 in transgenic 
mice 
Transgenic mice were treated for 21 days either with Vehicle only or 100 mg/kg body weight EGb 
761
®.The amount of Aß 1-40 was plotted against NEP gene expression for both placebo treated[A] 
and EGb 761
®treated mice [B]. Correlation r p = - 0.7681, P=0.1250 for the placebo treated group, 
and correlation r p = -0.8592, P=0.003 for the EGb 761
® treated group. The amount of Aß 1-42 was 
plotted against NEP gene expression for both placebo treated [C] and EGb 761
®-treated mice [D]. 
Correlation r  p = 0.1045, P=0.789 for the placebo treated group, and correlation r  p =- 0.5177, 
P=0.1253 for the EGb 761
® treated group. Results 
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Interestingly, NEP and Aß 40 were also inversely proportional in the EGb 
761
® treated group, even more pronounced than ECE-1 [figure 4-51B]. The 
same trend was seen with Aß 42 but to a lower extent and was not significant 
[figure 4-51D]. 
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Figure 4-52 
 Correlation between IDE expression and Aß 1-40 or Aß 1-42 in transgenic 
mice 
Transgenic mice were treated for 21 days either with Vehicle or 100 mg/kg body weight EGb 
761
®.The amount of Aß 1-40 was plotted against IDE gene expression for both placebo treated [A] 
and EGb 761
®-treated mice[B] . Correlation r p = 0.1672, P=0.6923 for the placebo treated group, 
and correlation r p = -0.7382, P=0.0231 for the EGb 761
® treated group. The amount of Aß 1-42 was 
plotted against IDE gene expression for both placebo treated [C] and EGb 761
®-treated [D] mice. 
Correlation r  p = 0.1366, P=0.726 for the placebo treated group, and correlation r  p =- 0.8106, 
P=0.0045 for the EGb 761
® treated group 
Confirming the previous results the negative correlation seen between the Aß 
levels and the Aß degrading enzymes was also observed with IDE. However 
with  IDE  both  Aß  40  and  Aß  42  demonstrated  a  significant  negative 
correlation. Discussion 
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5 Discussion 
5.1 Mitochondrial protective properties of EGb 761
® 
Malfunction of the power house of the cell, that is to say the mitochondria, 
has been highly implicated to AD [see section 1.1.8]. This has been noticed in 
cell culture, transgenic models and most importantly AD brains. The role of 
EGb 761
® as an anti-oxidant has been previously examined due to its high 
content  of  flavonoids,  and definitely  EGb 761
® has  proven  its scavenging 
activities in in vitro acellular and cellular studies, as well as in vivo studies. 
However, the fact that other herbal extracts rich in flavonoids do not exert the 
same actions as Ginkgo, only confirms that other constituents present in the 
Ginkgo extract contribute profoundly to its actions. This implicates that the 
pharmacological effects are not only limited to the well known anti-oxidant 
property of EGb 761
®. Since ROS is highly related to the mitochondria and 
mainly  originates  from  it,  some  researchers  directed  their  studies  towards 
examining  the  effects  of  EGb  761
®  on  the  mitochondria.  This  was  also 
encouraged as the link between not only AD but also Aß and the mitochondria 
started to emerge. Previously, our group observed mitochondrial protective 
actions on cell culture in vitro (Eckert et al. 2005). Therefore, these in vitro 
findings were extended on animal models in vitro and ex vivo, as well as in 
transgenic animal models for AD. Basic groundwork experiments were first 
carried out in order to find the most suitable concentrations, incubation times 
and schemes. Discussion 
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5.1.1 Protection against oxidative stress 
H2O2  was  applied  here  as  an  external  source  of  oxidative  stress,  and  for 
induction of mitochondrial dysfunction. H2O2 is able to inactivate, aconitase 
enzymes,  succinate
  dehydrogenase  [SDH]  and  alpha-ketoglutarate 
dehydrogenase [KGDH] of the tricarboxylic acid cycle (Nulton-Persson and 
Szweda 2001). Subsequently, this leads to reduction in the NADH level. The 
reduced NADH is insufficient to ensure an optimal rate of respiration and 
may consequently lead to inhibition of complex І. Under these circumstances 
the  ATP  levels  are  greatly  reduced,  which  may  be  insufficient  for  F0F1 
ATPase  to  work  as  a  proton  translocator,  and  thereby  prevents  the 
maintenance of mitochondrial membrane potential (Chinopoulos et al. 1999).  
In addition, H2O2 is rapidly converted into the toxic hydroxyl radical, which 
represents  the  main  ROS  product  responsible  for  lipid  peroxidation.  This 
leads  to  damage  to  some  lipids  such  as  cardiolipin.  Cardiolipin  is  almost 
exclusively found in mitochondrial membranes where it serves specific roles 
in  mitochondrial  structure  and  function.  Cardiolipins  are  associated  with 
cytochrome c oxidase and other mitochondrial electron transport complexes 
and transporters that are required for full electron transport activity (Robinson 
1993).  Therefore,  ROS  induced  lipid  peroxidation  and  protein  oxidation 
causes collapse of the respiratory chain, decreasing both the mitochondrial 
membrane potential and ATP levels [see diagram 5-1]. Discussion 
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Figure 5-1 
Scheme showing mitochondrial damage by H2O2 
Incubating our DBCs with H2O2 led to a decrease of mitochondrial membrane 
potential and drop in ATP levels as expected. in vitro addition of EGb 761
® 
after H2O2 insult, led to enhancement of mitochondrial membrane potential in 
both young and old mice with an enhancement of ATP levels only in the older 
mice. The in vitro radical scavenging activity and mitochondrial protective 
properties  of  EGb  761
®  was  previously  reported  by  several  other  groups. 
Formerly,  PC12  cells  were  protected  against  H2O2-induced  mitochondrial 
impairment by in vitro addition of EGb 761
® (Eckert et al. 2003). 
Moreover, treating the 2 age groups for 14 consecutive days with EGb 761
® 
improved the mitochondrial membrane potential of the older mice only. Since 
decrease  in  mitochondrial  membrane  potential  by  H2O2  is  secondary  to 
reduction in ATP levels as explained above, it is not surprising that EGb 761
® Discussion 
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protection  is  more  pronounced  on  mitochondrial  membrane  potential  than 
ATP levels. 
In order to be able to explain the age-related sensitivity of EGb 761
®, which 
was  observed  both  in  vitro  and  ex  vivo,  the  differences  between  the 
mitochondrial  characteristics  of  the  2  age  groups  should  be  discussed. 
Providentially, these were previously studied. DBCs prepared from 16 months 
old NMRI mice showed higher levels of lipid peroxidation than 2-3 months 
old mice. However, unexpectedly the 16 months old mice were less sensitive 
to in vitro H2O2 induced lipid peroxidation (Leutner et al. 2001). These results 
suggest that the brains of adult mice have an elevated capacity to sequester 
exogenous stimuli. This could be explained by the observation that several 
anti-oxidant enzymes in the older mice group show higher activities. Leutner 
et al reported that the activity of Cu/SOD was elevated in the 16 months old 
mice, GR slightly but not significantly and no difference was noticed in GPx 
levels. 
Another disparity is the finding that both DBCs and isolated mitochondria 
prepared from NMRI mice exhibited lower mitochondrial membrane potential 
during aging, which became significant at an age of 24 months (Hauptmann 
2008). Moreover a decline in other mitochondrial functions such as complex 
activity  and  respiratory  control  ratio  was  also  described  during  aging  of 
NMRI mice (Leuner et al. 2007). 
One may argue that the difference in the mitochondrial properties of the 2 age 
groups, for example the elevated anti-oxidant enzyme activity in the older 
mice, is/are responsible for the observed age-related sensitivity. However, in 
the placebo-treated mice, the mitochondria of both young and old mice groups 
were equally damaged by H2O2. This observation calls off the assumption that 
the  DBCs  prepared  from  the  older  mice  group  are  less  sensitive  to 
mitochondrial damage, and proves that EGb 761
® is more effective in older 
mice.  Discussion 
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In  accordance  to  our  observation,  age  related  mitochondrial  protection  by 
EGb  761
®  has  been  previously  reported.  This  goes  back  to  1995,  when 
Holgado et al observed a decrease in the rates of O2
- in both 4 and 33 months 
old rats after 3 months treatment. However, the scavenging activities of SOD, 
catalase and glutathione peroxidase were increased only in the 33 months old 
rats (Defeudis 1998). In addition, EGb 761
® was able to protect isolated brain 
mitochondria from the influence of complexes Ι, IV and V inhibitors in aged 
mice with no effect in younger mice (Hauptmann 2008). 
Additionally,  lymphocytes  from  24-month-old  NMRI  mice  revealed  a 
significantly higher protection by EGb 761
® than from young mice. ROS-
induced  apoptosis  triggered  by  d-ribose  in  isolated  T-lymphocytes  was 
significantly reduced after 14 days treatment (Schindowski et al. 2001). 
Aging also affected mitochondrial size and structural complexity, this is partly 
responsible  for  mitochondrial  dysfunction  and  mitochondrial  membrane 
potential impairment. Sastre et al. were able to show that treating rats with 
EGb  761
®  prevented  these  age-associated  impairments  in  mitochondrial 
morphology, providing a possible explanation for the observed enhancement 
in mitochondrial membrane potential in our aging mice (Sastre et al. 1998). 
They were also able to show that EGb 761
® protects against the oxidative 
damage to mtDNA, the oxidation of mitochondrial glutathione, and the age-
related increase in peroxide generation by mitochondria. 
From these results it seems that EGb 761
® efficacy is more pronounced on 
mitochondria  that  are  impaired.  Since  many  evidences  link  both 
morphological and functional mitochondrial alterations to AD, the next step 
was to examine the effect of EGb 761
® on mitochondria of an AD model.  
Thy-1 APP mice were utilized as a transgenic mouse model. These mice are 
double mutant carrying both the Swedish double mutation and the London 
mutation. Previous studies demonstrated the elevated Aβ levels in this mouse Discussion 
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model, and Aβ plaques were detected at an age of 6 months (Blanchard et al. 
2003). 
Interestingly,  the  Thy-1  APP  transgenic  mice  were  reported  to  exhibit 
mitochondrial  dysfunction  in  previous  studies.  This  makes  them  a  more 
suitable  AD  model  for  testing  mitochondrial  impairment.  Earlier  results 
comparing  mitochondrial  properties  of  Thy-1  APP  and  wild  type  mice 
reported a decrease in mitochondrial membrane potential and ATP levels at an 
age of 6 months (Hauptmann et al. 2008). In addition, Thy-1 APP mice are 
characterized  by  exhibiting  increased  4-hydroxy-2-nonenal  [HNE]  levels, 
reduced Cu/Zn-SOD activity (Schuessel et al. 2005) and decrease in COX 
activity at an age of 3 months.  
Treating these mice at an age of 6 months with EGb 761
® for 2 weeks didn’t 
alter the basal levels of mitochondrial membrane potential significantly [Data 
not shown]. However the mitochondrial membrane potential of the EGb 761
® 
treated mice in both wild type and transgenic mice were less susceptible than 
the placebo-treated group to H2O2-induced depolarization. A slightly higher 
protection was noticed in the transgenic mice group. These findings fit in our 
aforementioned  observation  that  EGb  761
®  seems  to  be  more  effective  in 
impaired or aged mitochondria as well as mitochondria of AD models. In 
agreement  to  these observations,  EGb  761
®  was  able  to  protect  other  AD 
models. 
Depolarization of mitochondrial membrane potential leads to the release of 
cytochrome c into the cytoplasm, caspase activation, and finally apoptosis 
(Liu et al. 1996). Mitochondrial membrane potential was enhanced by EGb 
761
®  in  our  AD  transgenic  mice  model  which  improves  mitochondrial 
functions. Consequently, this could prevent caspase activation and apoptosis. 
In  fact  Luo  et  al  demonstrated  that  internally  activated  caspase  3  in  AD 
mutant cells and mitochondrion-initiated apoptosis were attenuated by EGb 
761
® (Luo et al. 2002). Discussion 
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Additionally,  ROS  scavenging  activity  of  EGb  761
®  in  AD  models  was 
previously described. For example, treating APPswe/PS1d9 mice for 15 days 
reduced  oxidative  stress  related  to  senile  plaques by  approximately  30  %. 
Smith et al demonstrated that treatment of cells expressing an AD-associated 
double  mutation  or  C.elegans  with  EGb  761
®  significantly  attenuated  the 
basal as well as the induced levels of H2O2-related reactive oxygen species 
[ROS] (Smith and Luo 2003). A summary of EGb 761
® intervention in the 
damage pathway of H2O2 is illustrated below. 
 
Figure 5-2 
Summary of the actions of EGb 761
® on H2O2-initiated damage Discussion 
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5.1.2 Protection against nitrosative stress 
The  association  of  NO  in  many  cellular  toxic  effects  has  been  previously 
reported. NO toxicity has been linked to both mitochondrial damage as well 
as  certain  neurodegenerative  diseases  such  as  AD  [refer  to  section  1.1.7]. 
Therefore influence of EGb 761
® on NO-initiated mitochondrial toxicity was 
tested. SNP was utilized as an NO donor. NO reacts with complex IV and 
causes reversible inhibition of the mitochondrial respiratory chain. Complex 
IV may transiently increase the leakage of superoxide anion from the electron 
transport chain. The toxicity of NO is more likely mediated by its oxidation 
products rather than NO itself. The superoxide formed could then react with 
NO  to  generate  peroxynitrite  which  would  cause  irreversible injury  to  the 
mitochondria. 
Mitochondrial enzymes are particularly vulnerable to attacks by peroxynitrite. 
It  induces  permeabilization  of  the  inner  mitochondrial  membrane  by  the 
opening of the permeability transition pore. This decreases the mitochondrial 
membrane potential and  consequently  causes  cessation of  electron  transfer 
and  ATP  production.  Additionally  peroxynitrite  leads  to  an  irreversible 
inhibition of all the respiratory chain complexes except complex IV, thereby 
decreasing ATP levels and enhancing cell death [refer to figure 5-2]. Discussion 
 
  184 
   
Figure 5-3 
Scheme illustrating mitochondrial damage by SNP [NO] 
To examine EGb 761
®, DBCs were incubated with SNP for 4 hours. EGb 
761
®  was  added  30  minutes  after  the  onset  of  SNP  exposure,  and 
mitochondrial  membrane  potential  and  ATP  levels  were  determined.  EGb 
761
®  was  able  to  enhance  mitochondrial  membrane  potential  at  a 
concentration  of  0.5  mg/ml  significantly  and  ATP  levels  at  a  lower 
concentration [0.1 mg/ml] in both DBCs prepared from 3 and 15 months old 
mice.  
These results are in accordance to previous outcomes reported by Eckert et al 
on PC12 cells. In this cell model ATP levels were stabilized at a concentration 
of 5 µg/ml and mitochondrial membrane potential at 10 µg/ml (Eckert et al. 
2005) showing the same pattern as in DBCs but at lower concentrations as Discussion 
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expected. Since NO leads to inhibition of complex IV as mentioned above, a 
possible mechanism of EGb 761
® could be the stabilization of the activity of 
this enzyme. This would then allow the respiratory chain to function normally 
preventing the decrease in ATP production and consequently mitochondrial 
membrane  potential.  Another  possible  explanation  for  the  mitochondrial 
protection  against  NO  damage  is  that  EGb  761
®  blocks  the  SNP  induced 
protein  kinase  C  activation.  This  is  supported  by  the  findings  that  SNP 
activates protein kinase C in rat primary mixed hippocampal cell cultures and 
causes cell death. It was demonstrated that EGb 761
® was able to prevent the 
SNP-induced events as well as the PKC activation (Bastianetto et al. 2000b). 
After 2 weeks treatment of young and old mice with EGb 761
®, SNP-induced 
mitochondrial dysfunction was partially protected in the older mice with no 
improvement in the younger mice. 
Noteworthy was the observation that the 15 months old placebo-treated mice 
were  less  susceptible  to  SNP  induced  damage  than  the  2-3  months  old 
placebo-treated mice. The ATP levels in the older mice were significantly 
higher  than  the  ATP  levels  in  2-3  months  old  mice.  A  reason  for  this 
difference could be that in  the  15  months  old  NMRI  mice the  activity  of 
Cu/Zn  SOD  is  higher  (Leutner  et  al.  2001).  This  decreases  the  available 
superoxide  for  the  reaction  with  NO,  reducing  the  formation  of  the  more 
deleterious  peroxynitrite.  DBCs  of  the  older  mice  only,  showed  enhanced 
mitochondrial membrane potential after EGb 761
® treatment. This is similar 
to  our  findings  with  H2O2  where  EGb  761
®  treatment  protected  only  the 
mitochondria  from  the  aged  mice  with  no  alteration  of  mitochondrial 
properties in the younger mice. The enhancement of mitochondrial membrane 
potential by EGb 761
® could be due to its ability to increase the scavenging 
activities of SOD, catalase and other anti-oxidant enzymes activities in all the 
brain regions (Naik et al. 2006). This decreases the available NO for further 
reaction with radicals and its conversion into higher nitrogen oxides, which Discussion 
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can  react  with  thiols  as  well  as  primary  and  secondary  amines  causing 
mitochondrial and cellular damage (Pacher et al. 2007). 
Another plausible mechanism could be the ability of EGb 761
® to protect 
COX, which is one of the first targets of NO as mentioned above (Cleeter et 
al. 1994;Shiva et al. 2001). Either EGb 761
® protects complex IV activity 
directly,  or  after  the  2  weeks  treatment  it  may  be  able  to  up-regulate  it. 
Supporting  this  hypothesis,  it  was  demonstrated  that  isolated  brain 
mitochondria from EGb 761
® treated mice were protected from sodium azide 
which  is  a  specific  complex  IV  inhibitor  (Abdel-Kader  et  al.  2007). 
Interestingly this was again only a feature of the older mice and not the young 
ones. Also Chandrasekaran et al reported that a 7 days treatment with EGb 
761
®  prevented  ischemia-induced  reductions  in  COX  III  mRNA 
(Chandrasekaran  et  al.  2001).  Therefore  up-regulation  of  mitochondrial 
complex IV gene expression is another possible mean of protection. 
The question which naturally arises is what makes these mechanisms function 
only in the older mice and not in the young mice? 
As mentioned before EGb 761
® seems to function not on healthy but rather on 
impaired  mitochondria.  Chanderasekan  observations  were  made  on  mice 
where  ischemia  was  induced  and  as  a  consequence  COX  III  mRNA  was 
significantly  decreased  in  their  hippocampal  CA1  cells.  In  contrast  both 
young  and  old  mice  used  in  our  experiments  were  healthy,  but  it  is  well 
known that mitochondrial respiratory chain enzymes are influenced by aging. 
Navarro and Boveris were able to show that the activities of complex I and 
complex IV were decreased by 28–30 % in the brains of 92 week old mice 
compared to 28 week old mice (Navarro and Boveris 2004). Therefore, the 
ability of EGb 761
® to protect the complex in aged mice only, supports the 
assumption  that  EGb  761
®  functions  only  in  damaged  or  impaired 
mitochondria. Discussion 
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Further  on,  the  influence  of  a  14  days  treatment  with  EGb  761
®  on  an 
Alzheimer mouse model demonstrated again its efficacy against NO-induced 
mitochondrial damage.  
Although  mitochondrial  functions  of  both  wild  type  and  transgenic  mice 
models were improved, transgenic mice benefit more from the treatment. This 
finding  supports  the  aforementioned  observation  that  the  mitochondrial 
properties  of  the  EGb  761
®  treated  transgenic  Thy-1  APP  mice  were  less 
susceptible to H2O2-initatied damage. In agreement with these results, EGb 
761
® also significantly reduced the SNP-induced decrease of mitochondrial 
membrane potential in transgenic PC12 cells bearing the Swedish mutation 
[APP-sw].  Eckert  et  al  reported  that  the  mitochondria  of  transgenic  cells 
demonstrated  better  improvement  from  treatment  with  EGb  761
®  than  the 
control cells (Eckert et al. 2005). 
Concluding, knowing the importance of NO and its key role in aging and in 
the pathogenesis of AD, influence of EGb 761
® on NO-initiated damage was 
examined. EGb 761
® improved mitochondrial properties both in vitro and ex 
vivo. However, the ex vivo effects of EGb 761
® were observed only in the 
aging mice and more pronounced in transgenic AD models.  Discussion 
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Figure 5-4 
The actions of EGb 761
® on NO induced mitochondrial damage 
Summary 
EGb  761
®  enhances  mitochondrial  properties  in  general,  but  its  effect  is 
pronounced  in  impaired  or  damaged  mitochondria  specifically.  It  has  the 
ability to directly scavenge deleterious ROS in vitro and indirectly through 
enhancement  of  the  activities  of  the  scavenging  enzymes  in  vivo. 
Additionally, it seems that EGb 761
® protects the mitochondrial respiratory 
chain  complexes,  mainly  complexes  І  and  IV,  which  are  the  2  major 
complexes that are reported to be impaired during aging and AD. Accordingly 
this  would  prevent  further  damage  of  the  mitochondria  and  prevent  the 
activation of the caspase cascade and induction of apoptosis [see diagram 5-
4]. 
Knowing that EGb 761
® is a plant extract composed of several components, 
the  first  question  which  crosses  one’s  mind  would  be,  which  of  its 
components is responsible for the observed mitochondrial effects? Discussion 
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5.2  Effects of various components of EGb 761
® on 
mitochondrial function 
To answer the previous question, mitochondrial functions of in vitro treated 
DBCs were assessed. Two different treatment methods were implemented, 
either post-treatment or pre-treatment. The rational behind this was not only 
to discover which of the EGb 761
® component/s is/are more active but also to 
find out the mechanism of action. In pre-treatment the DBCs were incubated 
for 30 minutes with the single components, then NO was added for another 4 
hours. The purpose of pre-treatment was to test the ability of the EGb 761
® 
constituents to prevent the occurrence of mitochondrial damage.  
For post-treatment studies, the efficacy of the constituents in regenerating the 
mitochondrial functions after NO-insult was addressed. The DBCs were first 
stressed with NO for 4 hours, 30 minutes after insult the constituents were 
added. 
The  idea  of  finding  the  most  active  constituent/s  amongst  the  EGb  761
® 
components  is  not  novel.  However,  to  our  knowledge,  examining  the 
mitochondrial functions of all the components under the same conditions and 
using the same parameters was not previously investigated. 
EGb  761
®  is  a  standardized  extract  composed  of  two  major  groups  of 
substances, the flavonoid fraction [24 %] and the terpenoid fraction [6 %]. 
The terpenoid fraction consists of ginkgolides A, B, C, J and bilobalide.  
GA, GB and GC account for about 3.1 % of EGb 761
®. GA and GC are 
present  in  the  highest  amounts  each  representing  ≥1  %,  GB  is  ≤1  %  and 
GJ≤0.5 %. As for BB, it constitutes around 2.9 % of the extract. Taking into 
account  the  abovementioned  percentages  and  that  EGb  761
®  enhanced 
mitochondrial properties in vitro in our cell model at concentrations starting 
from 0.1 mg/ml, concentrations ranging between 0.005 mg/ml and 0.1 mg/ml 
were tested. Discussion 
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Three different parameters were measured, cell viability using MTT assay, 
mitochondrial membrane potential and ATP levels. Pre-treating DBCs with 
the  different  constituents  exemplified  that  the  flavonoid  fraction  has  the 
highest ability to prevent the occurrence of mitochondrial damage by NO in 
opposition to the other components. The presence of the flavonoids in the 
medium before addition of SNP could prevent the action of NO with free 
radicals  and  superoxide  anions  to  form  higher  nitrogen  oxides  that  cause 
immediate  damage  to  the  cells.  This  is  most  likely  due  to  its  radical 
scavenging activity which was previously reported by several other groups. 
In accordance to these observations is that pre-treating cerebellar granule cells 
with the total flavonoid component of EGb 761
® and a mixture of flavonoids 
and terpenes protected them from oxidative damage and apoptosis induced by 
hydroxyl radicals (Xin et al. 2000). However in the same study by Xin et al, 
total terpenes of EGb 761
® did not protect against cytotoxicity. Nevertheless, 
this  can’t  be  directly  compared  to  our  findings  due  to  the  fact  that  the 
mechanism of mitochondrial dysfunction induced by H2O2 is quite different 
than  that  induced  by  NO.  The  major  common  injury  to  the  mitochondria 
would be increased ROS. Moreover the total terpenes were not examined in 
our study, but every ginkgolide was tested alone. 
In  our  pre-treatment  assay,  GC  and  GB  showed  moderate  mitochondrial 
protection with no effects on ATP levels. BB demonstrated slight protection 
at the highest tested concentration, and GA and GJ had no effect at all in the 
pre-treatment study. 
Similar to our results with BB and GB were the findings of Rapin et al. They 
demonstrated that pre-treatment of rat hippocampal neurons with GB and BB 
increased cell viability that was induced by AAPH, which is a peroxyl radical 
generator. GB was protective at a concentration as low as 0.2 µg/ml while BB 
was protective at a higher concentration of 1µg/ml (Rapin et al. 1998). The 
same tendency was noticed in our experiments, where GB was significantly Discussion 
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effective  at  a  concentration  of  0.01  mg/ml  while  BB  at  also  5x  the 
concentration i.e. 0.05 mg/ml. Interestingly, they were also able to confirm 
the effects of GB after oral treatment. Unfortunately, the rest of the EGb 761
® 
components were not tested by Rapin et al.  
In cell culture system, Song et al were able to show that pre-treatment of 
PC12 cells with BB prevented NO-induced neurotoxicity. They also noticed 
an increase in the activities of SOD and catalase by BB. This drove them to 
draw the conclusion that the increase in the anti-oxidant enzymes activities is 
one of the contributing mechanisms to BB protective activity (Song et al. 
2000).  
Although only slight mitochondrial improvement was noticed on NO-induced 
damage by pre-treating DBCs with BB, it seems from other reports that BB 
indeed protects the mitochondria. As proposed by Song et al this could be due 
to  enhancing  the  activities  of  the  anti-oxidant  enzymes  and  thereby 
scavenging the superoxide anion and preventing or decreasing the formation 
of higher nitrogen oxides. Another possible protective mechanism could be 
the protection of the activities of the respiratory chain. Since peroxynitrite 
causes deactivation of complexes I, II, III and IV it is probable that the actions 
of BB are due to enhancement of the activities of complexes I and III as 
observed earlier in isolated rat mitochondria (Janssens et al. 1999). 
Due to the lack of data on the other terpenes, the improvement of cell viability 
and  mitochondrial  membrane  potential  by  GC  can’t  be  supported  by  any 
previous reports. However, in an acellular model it was shown that BB, GB, 
GC  and  GJ  but  not  GA  possess  radical  scavenging  activities  and  that the 
reaction of BB with superoxide is slow compared to GB and GC (Scholtyssek 
et al. 1997). In the present pre-treatment experiments, GC and GB were also 
more efficient than BB in preventing the NO-initiated mitochondrial damage; 
this  could  be  explained  by  their  scavenging  activities  as  proposed  by 
Scholtyssek et al. Moreover GA was also ineffective in our study. However in Discussion 
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contrast to Scholtysseks’ findings no improvement at all was noticed by GJ. 
Yet  again,  the  activity  of  the  EGb  761
®  constituents  against  NO-induced 
damage is not only attributed to their radical scavenging activities and indeed 
other mechanisms play a role here. 
Apparently,  intrinsic  differences  between  cell  models,  methodologies 
employed and incubation schemes seem to contribute to the efficacy of the 
single constituents of EGb 761
®. Discussion 
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Therefore, in addition to the above treatment scheme we implemented another 
study design. In the second study DBCs were also utilized but they were first 
stressed  with  SNP  and  after  30  minutes  incubation  time,  EGb  761
® 
components  were  added.  Here  the  presence  of  NO  for  30  minutes  before 
treatment  is  enough  to  cause  substantial  damage.  To  our  surprise,  the 
observations made in post-treatment were totally different than those made in 
the pre-treatment study. For example, mitochondrial membrane potential was 
enhanced by all terpenes and flavonoids, of course with different potencies. 
Although  here  GA  was  the  least  effective  in  increasing  mitochondrial 
membrane potential, it improved cell viability at a very low concentration. 
GA also increased ATP levels being the only terpene beside the flavonoid 
fraction that affected the ATP levels. 
These observations are in accordance with previous findings using PC12 cells. 
In this cell model mitochondrial membrane potential was improved after NO-
induced depolarization by the post-treatment with every single constituent. 
Similar  to  our  study  in  DBCs,  GA  showed  the  least  enhancement  on 
mitochondrial  membrane  potential  (Abdel-Kader  et  al.  2007).  The 
components  of  EGb  761
®  showed  a  more  pronounced  effect  on  the 
mitochondria  in  PC12  cells  than  in  dissociated  brain  cells.  This  could  be 
related to basic differences between the cell models and/or the fact that PC12 
cells  were  incubated  for  longer  time  periods  with  the  single  components. 
Unfortunately, the other mitochondrial parameters were not measured in PC 
12 cells, making it difficult for a direct comparison. 
A previous study preformed by Bastianetto et al asserted the influence of EGb 
761
® constituents on cell viability in hippocampal cells after pre-exposure to 
SNP. Some but not all of their findings were in agreement with ours. They 
demonstrated  that  the  flavonoid  fraction  CP  205  [25  µg/ml]  rescues 
hippocampal  cells  when  applied  2  h  after  a  pre-exposure  to  SNP.  These 
results are in consent to our observations, where 10 µg/ml flavonoids were Discussion 
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able  to enhance  mitochondrial  membrane  potential.  Also  ATP  levels  were 
significantly increased at a concentration of 50 µg/ml after pre-exposure to 
SNP.  Bastianetto  et al  measured  cell viability  by  MTT  assay  and  another 
colorimetric assay known as the NR assay. However, in our experiments we 
noticed  that  the  flavonoid  fraction  interferes  with the  MTT  reagents.  This 
prevented us from measuring cell viability for the flavonoid fraction to rule 
out any biased results. 
In contrast to our findings they reported that the BB and GB [concentrations 
ranging between 1-5µg/ml] didn’t enhance cell viability after SNP insult. In 
our experiment BB was effective at a higher concentration of 10µg/ml, which 
was not tested by Bastianetto et al. However we saw enhancement in cell 
viability using 5 µg/ml BB, which was not effective in Bastianettos’ study. An 
explanation to this difference could be due to the fact that they stressed with 1 
mM SNP and we exposed our cells to 0.5 mM SNP for MTT measurement. 
On the other hand, they incubated their cells for 2 hours only with SNP while 
in our study the cells were incubated for 4 hours. Alternative reasons would 
be either the cell models utilized or the solvents used for dissolving the GB; 
ethanol vs. DMSO (Bastianetto et al. 2000b). 
It  therefore  seems  that  the  activity  of  the  EGb  761
®  constituents  can  be 
influenced by several factors, such as cell model, method for induction of 
mitochondrial damage and treatment schemes. These discrepancies were also 
noticed by others. Ahlemeyer et al detected these differences in an experiment 
to assert the anti-apoptotic properties of the ginkgolides. They reported that 
GJ reduced apoptotic damage of chick embryonic neurons, but not of neurons 
derived from neonatal rat hippocampus. Additionally, in mixed neuronal/glial 
cultures  from  neonatal  rat  hippocampus  GB  had  protective  effects  after 
staurosporine treatment, but not after serum deprivation. Although both serum 
deprivation  and  staurosporine lead  to  increased  ROS,  the  results  were  not 
similar.  The  ability  of  GB  to  enhance  the  activities  of  SOD  and  Catalase Discussion 
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(Ozturk  et  al.  2006)  could  explain  the  protective  effect  of  GB  in  our 
experiment  against  NO-induced  toxicity  as  well  as  against  staurosporine 
induced apoptosis. These assumptions are based on the findings of Pong et al 
(Pong et  al. 2001)  that  staurosporine induced  apoptosis  and  mitochondrial 
dysfunction could be attenuated by synthetic SOD and Catalase mimetics.  
Ahlemeyer et al also demonstrated that BB reduces apoptotic damage under 
both conditions, indicating that other mechanisms aside from its capability of 
increasing  anti-oxidant  enzyme  activity  are  involved  in  its  anti-apoptotic 
activity (Ahlemeyer et al. 1999). Another probable mechanism for enhancing 
cell survival by BB in the serum deprived medium could be the increase of 
neurotrophic  factor  and  or  growth  factor  as  noted  by  Zheng  et  al  in  rat 
astrocytes  (Zheng  et  al.  2000).  Morover,  chloride  conductance  has  been 
observed to be affected by bilobalide and the ginkgolides through modulating 
of  receptor-gated  chloride  channels,  this  may  indirectly  also  improve 
mitochondrial function (Klein et al. 2003;Chatterjee et al. 2003) 
The  anti-apoptotic  activity  of  BB  was  also  demonstrated  by  several  other 
mechanisms such as reduced ROS-induced elevation of Bax and activation of 
caspase 3 (Zhou and Zhu 2000). 
Summary 
Briefly, from the literature and our data one may conclude that the EGb 761
® 
constituents exhibit different protective activities on the mitochondria. Not 
only the mechanism of action of the flavonoid fraction is different than that of 
the  terpenes,  but  also  there  exists  major  differences  in  the  actions  of  the 
ginkgolides.  The  observation  that  the  single  ginkgolides  exhibit  dissimilar 
influence on the 3 measured mitochondrial parameters under exactly the same 
conditions and using the same cellular model suggests that they act according 
to different mechanisms. Although radical scavenging activity and increasing 
anti-oxidant enzyme activities seem to play a big role here for the protective Discussion 
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effect  of  the  constituents,  it  is  clear  that  other  anti-apoptotic  and 
mitochondrial stabilization mechanisms contribute to the protective actions of 
EGb 761
®.  
Owing to the presence of flavonoids in several plant extracts and their early 
discovery,  one  has  to  acknowledge  that  their  pharmacological  actions  and 
mechanisms are comparatively investigated. As for the EGb 761
® terpenoids, 
they are exclusively found in Ginkgo and are recently gaining more attention. 
For this reason they are still not thoroughly investigated. However, the most 
researched  are  BB  and  GB,  and  as  discussed  above  they  both  exhibit 
beneficial actions on mitochondria but under different conditions indicating 
different  mechanisms  of  actions.  As  for  the  other  EGb  761
®  terpenes, 
although  most  reveal  promising  results,  they  should  be  more  extensively 
studied taking into consideration methodologies applied, cell models used and 
incubation schemes. 
In  this  study  all  the  EGb  761
®  components  were  studied  under  the  same 
conditions and using 2 different incubation schemes in order to elucidate their 
efficacy. However one has to take into consideration during interpretation that 
DBCs were treated in vitro with the single constituents. Therefore, treating 
animals with the constituents in vivo could reveal other findings.  
In light of our findings and the currently present literature we conceive that 
the EGb 761
® constituents act in a complementary manner. That is to say, 
both  the  flavonoid  and  the  terpenoid  fractions  are  able  to  protect  the 
mitochondria however in different approaches. Looking at EGb 761
® effects 
on the mitochondria it seems that it works both anti-apoptotic and radical 
scavenging. However, each constituent seems to address a different target in 
the mitochondria, harmonizing together to achieve the full effect of the whole 
extract. Discussion 
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For example, the ability of BB to increase the activities of the respiratory 
chain complexes I and III, the enhancement of SOD, Catalase and GPx by 
GB, the anti-oxidant effect of flavonoids etc. all add to the mechanisms of 
action of EGb 761
®. This gives EGb 761
® its unique polyvalent action, which 
is buildup from the sum of the actions of every single component.  
 
Figure 5-5 
Targets and actions of the different components of EGb 761
® Discussion 
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5.3 Long-term effects of EGb 761
® in senescence 
accelerated mouse model 
Since EGb 761
® proved to be effective in impaired and aging mitochondria, 
its  effect  on  mitochondria  of  the  senescence  accelerated  mouse  model 
[SAMP8] was tested. Not only the life span of these mice is much shorter than 
their controls [senescence accelerated resistant mice] SAMR1 but they also 
exhibit increased oxidative stress, age-related learning and memory deficits, 
anxiety, and age-dependent deposition of Aß (Butterfield and Poon 2005). It 
has  been  previously  demonstrated  that  the  abnormal  expression  of  Aß 
contributes  to  the  cognitive  decline  and  the  oxidative  stress  observed  in 
SAMP8 mice (Kumar et al. 2000;Morley et al. 2002;Poon et al. 2004). These 
characteristics  make  SAMP8  mice  a  good  model  for  studying  age-related 
memory deficits with high relevance to AD.  
In the current work, mitochondrial functions were observed to be lower in the 
SAMP8 mice compared to the SAMR1 mice. Both mitochondrial membrane 
potential and ATP levels were lower in the SAMP8 mice. In accordance to 
these  findings  Xu  et  al  were  recently  able  to  observe  that  platelet 
mitochondrial  membrane  potential  of  SAMP8  was  lower  than  SAMR1, 
moreover hippocampal and platelets ATP levels were significantly lower in 
SAMP8 mice. Several other work groups have also reported mitochondrial 
dysfunction  in  SAMP8  mice.  Nakahara  et  al  studied  oxidative 
phosphorylation in the livers of SAMP8 and SAMR1 mice. They found that 
the respiratory control ratio decreased during aging in SAMP8 mice, and it 
was estimated that by 18 months of age, there was insufficient ATP synthesis 
for  normal  cell  metabolism.  They  also  observed  that  the  amount  of  the 
apoptotic  regulating  protein  Bcl-x  in  the  liver  mitochondria  was  slightly 
decreased  in  SAMP8  mice  (Nakahara  et  al.  1998).  Nishikawa  et  al. 
demonstrated a higher oxidation/reduction reaction [redox] state and higher 
activity of mitochondrial respiration with a lower respiration control ratio in Discussion 
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the mitochondrial fractions from the brains of 2-month-old SAMP8 males as 
compared to SAMR1 mice (Nishikawa et al. 1998). In the electron transport 
system, decreased activities of Complex I and Complex III were observed 
(Fujibayashi et al. 1998).They also observed a small but significantly greater 
amount of multiple mitochondrial DNA deletions in SAMP8 mice brains at 4 
and 8 weeks of age. Moreover, the activities of Mn-SOD (Kurokawa et al. 
2001),  GPx  (Okatani  et  al.  2002)  and  catalase  (Sato  et  al.  1996)  are  all 
reduced in SAMP8 mice. 
Long-term treatment with EGb 761
® for 5 months enhanced mitochondrial 
membrane  potential  slightly  and  ATP  levels  significantly.  Several 
characteristics of EGb 761
® may contribute to this effect. For example the 
ability of EGb 761
® to protect complexes I and III may play a role here. 
Another possible mechanism is the capability of EGb 761
® to enhance the 
activities of anti-oxidant enzymes such as catalase or SOD which are known 
to be decreased in the SAMP8 mice. 
Another factor which plays a role during aging is membrane fluidity. Reduced 
fluidity  of  brain  membranes  during  aging  has  been  previously  described. 
Abnormal neural membrane phospholipids metabolism, increased cholesterol 
to phospholipids ratios and enhanced lipid peroxidation can all contribute to 
alterations  in  membrane  fluidity.  Interestingly,  Stoll  et  al  previously 
demonstrated  that  EGb  761
®  treatment  improved  short-term  memory  and 
increased  membrane  fluidity  in  aged  mice,  therefore  this  parameter  was 
assessed in the SAM  mouse model after EGb 761
® treatment (Stoll et al. 
1996). 
Comparing the membrane fluidity of the SAMR1 and SAMP8 mice brains, no 
difference was noticed in the membrane fluidity at 6 months of age. However 
the  fluidity  of  the  membranes  was  increased  in  the  EGb  761
®  fed  group 
compared  to  the  placebo  group.  Previous  studies  indicated  memory 
enhancement with increased fluidity, and nootropics such as piracetam were Discussion 
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observed to increase membrane fluidity and cognition (Muller et al. 1997). 
For  example  reduced  fluidity  of  rat  hippocampal  membranes  impaired 
memory (Hong 1995;Clarke et al. 1999) whereas increased fluidity improved 
memory (Scheuer et al. 1999). Moreover, anisotropy studies have additionally 
demonstrated abnormal membrane fluidity in hippocampal synaptosomes of 
AD patients (Eckert et al. 2000), and it has been suggested that increasing 
membrane fluidity decreases the amyloidogenic processing of APP to form 
Aß.  
The  findings  in  the  current  work  indicate  that  EGb  761
®  enhances 
mitochondrial  functions  in  aged  [SAMP8]  and  AD  [Thy-1  APP]  models. 
Recently, mitochondrial accumulation of Aβ and its precursor protein APP 
has  been  reported.  Also,  mitochondrial  accumulation  of  APP  directly 
correlates with mitochondrial dysfunction in various brain regions in AD. The 
data  on  mitochondrial  APP  and  Aβ  complement  growing  literature  that 
mitochondria may interact with factors involved in Aβ metabolism and that 
mitochondria,  APP,  and  Aβ  metabolism  might  be  interconnected  in  the 
cascade,  leading  to  neuro-degeneration  and  dementia.  Whether  Aβ  causes 
mitochondrial  dysfunction,  or  aging  leads  to  induction  of  mitochondrial 
dysfunction by increasing production of ROS and accumulation of Aβ, which 
in a viscous manner reinforces further mitochondrial impairment, is still a 
matter of debate. Taking into account the association of Aß and mitochondrial 
dysfunction, and that membrane fluidity plays a major role in APP processing, 
the first question which rationally arises, are the EGb 761
® observed effects 
linked in any way to Aß formation, aggregation, and/or clearance?  Discussion 
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5.4  The role of EGb 761
® on Aß levels 
Aβ is one of the major pathological hallmarks for AD, and recently it has been 
acknowledged  that  it  plays  an  essential  role  in  initiating  mitochondrial 
dysfunction and apoptosis (Casley et al. 2002;Khan et al. 2000;Manczak et al. 
2006). 
Aβ is derived from its precursor protein APP [Amyloid Precursor Protein]. 
APP can be cleaved by 2 alternative pathways, either the non-amyloidogenic 
pathway by the action of alpha secretase or the amyloidogenic pathways by 
yielding Aß. The alpha secretase pathway forms an extracellular soluble N-
terminus [APPα], and a membrane bound c- terminal fragment [C-83]. In the 
amyloidogenic pathway, APP is cleaved by two aspartyl proteases [β- and γ-
secretases].  APP  is  first  cleaved  by  β-secretase  forming  an  extracellular 
soluble  APPß,  and  leaving  a  membrane  bound  C-terminal  stub  [C-99]. 
According to the position where the γ-secretase cleaves the C-99 fragment 
either the Aß 40 is formed or the Aß 42. The longer form [Aβ 42] is far more 
prone to oligomerize and form fibrils than the more abundantly produced Aβ 
40 peptide. 
Recently, the precursor protein of Aβ [APP] was found to be associated in the 
mitochondrial  compartment  of  the  cortex  and  hippocampus  of  an  AD 
transgenic  mouse  model  [Tg  2576]  that  over-expresses  Swedish  APP 
(Anandatheerthavarada et al. 2003). Interestingly, APP was further associated 
with mitochondria in samples from the brains of individuals with AD, but not 
with mitochondria in samples from non-demented subjects (Devi et al. 2006). 
In light of the above reported Aβ associated mitochondrial impairment and 
our  recent  findings  that  EGb  761
®  showed  enhancement  of  mitochondrial 
functions during aging and more importantly in Alzheimer disease models, 
the influence of EGb 761
® on Aβ was examined. Discussion 
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A  cell  line  model  for  AD  was  utilized  for  the  preliminary  experiments. 
Human embryonic kidney cells [Hek-293] stably transfected with the Swedish 
double mutation were employed. APPsw mutation leads to an increase in β-
secretase  activity  in  cell  culture  (Haass  et  al.  1995),  increasing  vastly  the 
amount  of  Aβ  produced  by  these  cells.  This  cellular  model  is  therefore 
appropriate  for  mimicking  familial  AD,  similar  to  our  tg-APP  mice. 
Expectedly,  the  Hek-sw  cells  show  mitochondrial  dysfunction  such  as 
decreased mitochondrial membrane potential and lower ATP levels compared 
to their untransfected controls (Keil et al. 2004). 
Fortunately, the distribution of intracellular and secreted Aβ 40 and Aβ 42 in 
APPsw HEK cells were previously studied by Dr. Astrid Bonert. Hek-sw cells 
secrete  large  amounts  of  both  Aβ  40  and  Aβ  42  compared  to  their  non-
transgenic controls. However, the levels of secreted Aβ 40 are much higher 
than Aβ 42. The Intracellular, insoluble Aβ 40 and Aβ 42 are elevated in 
comparison  to  soluble  Aβ  40  and  Aβ  42  in  APPsw  HEK  cells.  The 
intracellular, insoluble Aβ 42 was only detected in the Swedish transfected 
Hek cells, neither in the Hek wild type nor in the Hek control cells (Bonert 
2006). Concluding we may state that in APPsw HEK cells, the ratio of Aβ 40 
and Aβ 42 is shifted in favor of intracellular, insoluble Aβ 42 and that the 
accumulation of insoluble Aβ species intracellularly is exclusively found in 
APPsw HEK cells. 
In this study, extracellular, soluble Aβ 40 and Aβ 42 were assessed in the 
Hek-sw cells after EGb 761
® treatment. The cells were treated for 24 hours 
with  different  concentrations  of  EGb  761
®  and  the  soluble  Aβ  was  then 
determined. Unpredictably, extreme elevation in the Aβ 40 levels, reaching 
200 %, was noticed already at the lowest applied EGb 761
® concentration. 
Comparatively the extracellular soluble Aβ 42 also increased after treatment 
with EGb 761
® but to a much lower extent. Discussion 
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Although  the  extracellular  location  of  AD  plaques  initially  led  to  the 
assumption that toxicity results from extracellular attack of neurons by Aβ, 
but Aβ has also been shown to exist intracellular in cell cultures and in rat 
brain tissue. There is evidence that intracellular, nonfibrillar Aβ oligomers 
cause  cytotoxicity  in  human  neurons  that  strongly  exceeds  that  of 
extracellular  Aβ  species.  Moreover,  Kienlen-Campard  et  al.  observed  that 
although  APP  processing  leads  to  production  of  extracellular  Aβ  40  and 
soluble APP, these extracellular derivatives did not induce neuronal death. On 
the other hand, neurons underwent apoptosis as soon as they accumulated 
intracellular Aβ 42 (Kienlen-Campard et al. 2002). 
This  was  also  the  case  in  the  employed  Hek-sw  cell  model.  Where  the 
findings that intracellular, insoluble Aβ 42 is present only in the Swedish 
transfected  Hek  cells  which  demonstrate  decreased  cell  viability  and  ATP 
levels confirm that intracellular, insoluble Aβ 42 is a pathogenic and toxic 
form (Keil et al. 2004;Marques et al. 2003b). 
A  possible  explanation  for  the  vast  increase  in  the  extracellular  soluble 
secreted Aß 40 could be that EGb 761
® shifts the processing of APP towards 
the non-toxic Aß 40 rather than the Aß 42. However this does not explain the 
moderate  increase  in  the  extracellular  soluble  Aß  42  after  EGb  761
® 
treatment. Another possible clarification could be that EGb 761
® prevents the 
accumulation of intracellular soluble Aß, leading to its secretion rather than 
aggregation  to  form  deleterious  forms.  In  accordance  to  this  assumption 
Longpre et al were able to show that EGb 761
® inhibits Aβ 40 fibril formation 
(Longpre et al. 2006) and Yao et al observed that EGb 761
® inhibits Aβ 42 
oligomers formation in vitro, presumably dimers and tetramers of Aβ 42 (Yao 
et al. 2001). This was confirmed in a neuroblastoma cellular system stably 
transfected with the Swedish mutation similar to our cell line. An aggregated 
Aβ  band  at  a  molecular  mass  between  7  and  21  kDa  [dimers  or  higher 
oligomers] found in the control cells, was absent in the medium recovered Discussion 
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from cells treated with EGb 761
® (Luo et al. 2002). A very important study in 
transgenic C.elegans reported not only a decrease in the Aβ oligomers by EGb 
761
® but concurs totally with our results and postulation by also observing an 
increase in the monomeric Aβ after EGb 761
® treatment (Wu et al. 2006). Wu 
et al were also able to show that not only EGb 761
® but also its terpenoid 
fraction,  mainly  GA,  inhibited  Aß  oligomerization  as  well  as  Aß-induced 
paralysis in the transgenic C.elegans. Interestingly, in our observations, from 
the EGb 761
® terpeniods, mainly GA enhanced cell viability and ATP levels 
after NO-induced mitochondrial insult. It was also previously reported that 
NO production is increased in transgenic models with high Aß secretion (Keil 
et  al.  2004;Law  et  al.  2001).Therefore  it  seems  that  the  mitochondrial 
protective  properties  of  EGb  761
®  are  indeed  associated  with  both  Aß 
production and/or oligomerization. 
From  the  above  mentioned  literature  findings  and  the  observations  on  Aß 
production in Hek-sw cells, an assumption was made that EGb 761
® inhibits 
Aβ oligomerization, leading to an increase in the non-toxic Aβ monomers and 
reduction in amyloid deposits. It also seems that EGb 761
® directly secretes 
these  small  soluble  Aβ,  preventing  them  from  accumulating  and  thereby 
aggregating intracellularly. 
To confirm this hypothesis and to assess if these in vitro observations are 
consistent in vivo, Tg-APP mice were treated for 21 days with 100 mg/kg 
body weight with EGb 761
® and the Aß levels in brain homogenates were 
evaluated after the treatment period. 
As expected evaluating the transgenic mice model, they expressed very high 
amounts of human Aß both the 40 and the 42 forms. The total Aß 42 was 
around  20  times  more  than  Aß  40.  The  transgenic  mice  showed  an 
approximate of 26,000 pg/mg protein Aß 40 while the average amount of Aß 
42 is 550,000 pg/mg protein. Correlating these results one notices that the 
correlation is highly significant; meaning a mouse with high levels of Aß 40 Discussion 
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has also high levels of Aß 42. Assessing the amount of soluble Aß levels, the 
levels were much lower than the total Aß levels, with average amount of 11 
pg/mg protein Aß 40 and soluble Aß 42 was undetectable at all. This is in 
agreement with the findings of Blanchard et al. Studying the Thy-1 APP 751 
mice model, they stated that once plaques were present, the majority of Aß 
peptide was insoluble (Blanchard et al. 2003). In our study the tg-APP mice 
were 6- months old, which is the age, were they start developing Aß deposits. 
In the cortex of 6 months old transgenic Thy-1 APP 751 mouse model the 
total Aß 42 present is much greater than Aß 40 present. However, all the Aß 
42 is in the insoluble form, and although the soluble Aß 40 was detectable, its 
amount  can  be  considered  minor  compared  to  the  total  Aß  40  [11  pg/mg 
soluble vs. 26,000 pg/mg total]. 
Measuring the amount of soluble Aß 40 after 21 days treatment with EGb 
761
®, a significant increase was observed which concurs with our finding in 
Hek-sw cells. Since no soluble Aß 42 was quantifiable in the tg-APP mice 
model,  it  was  not  possible  to  measure  the  effect  of  EGb  761
®  on  this 
parameter.  
Looking at the total amounts of both Aß 40 and Aß 42, EGb 761
® treatment 
did not alter their level in the brains of the Thy-1 APP mice. This supports 
that EGb 761
® decreases the aggregation of Aβ, since the total amount of Aβ 
remains  the  same,  meaning  that  the  increase  in  the  soluble  Aβ  form  is 
compensated  some  how  by  a  decrease  in  another  form.  However,  in 
opposition to this hypothesis one may argue that the soluble Aβ 40 represents 
only a very small fraction of the total Aβ in our mice model, and a significant 
increase in its value would not influence the total level of Aβ 40.  
The supposition that EGb 761
® decreases Aß aggregation is in accordance 
with the recent findings that treating a transgenic mouse model for 1 month 
with  EGb 761
®  reduced the level  of the  Aß oligomers  (Tchantchou  et al. 
2007). On the contrary, Stackmann et al reported that neither the soluble nor Discussion 
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the insoluble Aß levels were changed after treating Tg2576 transgenic mice 
with EGb 761
® although they noticed an enhancement in cognition in the EGb 
761
® treated group (Stackman et al. 2003). This may be due to the difference 
in the transgenic mice models used, or the feeding schemes implemented. 
In  Thy-1  APP  mice  it  was  previously  reported  that  the  C-99  fragment  is 
highly  expressed  (Blanchard  et  al.  2003).  Cleavage of  this  stub by  the  γ-
secretase forms either the Aß 40 or the Aß 42 fragment. The London mutation 
present in Thy-1 APP mice increases the proportion of Aß 42 by 50–90 % 
(Suzuki et al. 1994), by shifting the balance of γ-secretase cleavage slightly 
toward the 42 over the 40 cleavage site. Since EGb 761
® treatment increased 
the soluble Aß 40 and had no effect on the Aß 42 forms in the Thy-1 APP 
mice, another possible clarification for the observations made could be that 
EGb 761
® treatment shifts the C-99 cleavage towards the formation of Aß 40.  
There are several studies demonstrating that higher levels of Aß 40 directly 
interferes with Aß 42 aggregation by delaying the Aß 42- mediated nucleation 
step  at  an  early  stage  in  the  fibrillogenesis  process  (Snyder  et  al. 
1994;Hasegawa et al. 1999;Zou et al. 2003). Interestingly, mice expressing 
high levels of Aβ 40 in the absence of human APP over expression did not 
develop overt amyloid pathology. In contrast, mice expressing lower levels of 
Aβ 42 accumulate insoluble Aβ 42 and accumulate Aβ deposits. 
Also the Aß 42/40 ratio plays a very important role and if EGb 761
® is able to 
increase the soluble Aß 40 thereby lowering the ratio this is beneficial and 
could be a contributing mechanism of action of EGb 761
®. The importance of 
the ratio of Aß 42/ Aß 40 has been demonstrated in animals. In transgenic 
mice where Aβ 40 production has been achieved using a viral vector, the 
increase in Aβ 40 inhibited Aβ 42-linked amyloidosis and death (Kim et al. 
2007). This demonstrated that even in the presence of increased total Aβ, a 
shift in Aβ length distribution toward shorter lengths reduces amyloidosis and 
toxicity. Discussion 
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With  regards  to  the  observations  in  both  transgenic  models,  EGb  761
® 
treatment enhanced the levels of soluble Aß 40. This maybe due to a shift in 
the splicing of the C-99 fragment towards more production of soluble Aß 40 
rather than the formation of deleterious Aß 42. In the Hek-sw cells EGb 761
® 
not only enhanced the secreted soluble Aß 40 but also increased the secreted 
soluble Aß 42. From the current observations and literature findings it was 
concluded that EGb 761
® enhances the clearance of the soluble Aß to prevent 
its intracellular accumulation and consequently its aggregation. This was not 
evident  in  our  Tg-APP  mouse  model  due  to  the  absence  of  intracellular 
soluble Aß 42, besides the alteration on distribution of soluble Aß might not 
be detectable by ELISA on brain homogenates prepared without perfusion. 
However, recently it was reported that EGb 761
® favors the clearance of Aß 
via  regulating the  expression of  RAGE and  LRP-1 during  brain ischemia. 
RAGE is thought to be a primary transporter of Aß across BBB into the brain 
from the systemic circulation, while LRP-1 mediates the transport of Aß out 
of the brain (Yan et al. 2008). 
Noticing  the  influence  of  EGb  761
®  on  Aß  peptide,  its  effect  on  Aß 
production and breakdown was studied on the genomic level.  Discussion 
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5.5 Effects of EGb 761
® on gene expression  
The Thy-1 APP mice employed in our study are transgenic mice encoding 
human  APP-751  with  Swedish  double  mutation  plus  London  mutation 
regulated  by  the  neuronal  murine  Thy-1  promoter.  This  leads  to  an  over 
expression of the mutated human APP and consequently enhanced Aß levels.  
Measuring the mRNA levels of the mutant Hu APP after EGb 761
® treatment, 
a  significant  down  regulation  was  observed.  Moreover,  EGb  761
®  down 
regulated all forms of APP, not only the mutant human APP but also mouse 
APP and APP binding protein. The decrease in APP expression as well as 
protein level in rat brain after EGb 761
® treatment was previously reported 
(Yao  et  al.  2004;Gong  et  al.  2005).  On  the  other  hand,  Colciaghi  et  al 
demonstrated no change in APP levels after EGb 761
® treatment in 2 months 
old  rats  (Colciaghi  et  al.  2004).  This  discrepancy  could  be  due  to  the 
difference in treatment periods, in the last study where no effect was observed 
the  rats  were  treated  for  5  days  only.  As  for  the  other  reported  studies 
treatment  periods  were  28  weeks  and  2  months.  Another  possible  reason 
could be that the effect of EGb 761
® is observed only at an older age, where 
in the experiments by Yao and Gong the rats were older than the 2 months old 
rats used by Colciaghi et al.  
In accordance to our finding, only very recently APP was reported to be down 
regulated in another transgenic mouse model. Augustin et al reported that 
human APP protein levels in Tg2576 mice were decreased after 16 months 
treatment with EGb 761
®. However, in contrast to our observations Augustin 
et al noticed no down regulation in human APP in the mice treated only for 1 
month.  Additionally,  no  changes  were  detected  in  mouse  APP  or  APPbp 
(Augustin  et  al.  2008).  The  variation  to  our  findings  could  be  due  to  the 
different  transgenic  mouse  model  implemented.  This  is  also  likely  since 
Stackmann et al reported that neither the soluble nor the insoluble Aß levels Discussion 
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were  changed  after  treating  Tg  2576  transgenic  mice  [which  is  the  same 
mouse model implemented by Augustin et al] with EGb 761
® and in Thy-1 
APP mice it was demonstrated that soluble Aβ 40 increased after EGb 761
® 
treatment. Tg 2576 mice have the Swedish double mutation while Thy-1 APP 
mice implemented in our study have both the Swedish mutation as well as the 
London  mutation.  Comparing  the  forms  of  Aβ  in  both  mice  strains,  one 
notices that in the Thy-1 APP mice the total amount of Aβ 42 is much higher 
than the Aβ 40 as expected, while in the Tg 2576 mice exactly the opposite is 
reported, that is to say the Aß 40 is greater than Aß 42 (Stackman et al. 2003). 
Collectively, EGb 761
® decreased the source of Aβ, namely APP, in Thy-1 
APP  mice  as  well  as  increased  the  soluble  form  of  Aβ  40.  Our  earlier 
hypothesis before measuring APP levels was that EGb 761
® may shift the 
cleavage of C-99 fragment towards Aβ 40 formation and may prevent the 
accumulation and hence aggregation of Aß. After noticing a decrease in the 
APP levels, another possible supposition could be that EGb 761
® enhances 
the cleavage of APP by the β- secretase and γ-secretase which would increase 
the levels of Aβ. To rule out this assumption, the expressions of the secretases 
[BACE-1 and ADAM-10] were quantified in the EGb 761
® treated Thy-1 
APP mice. Due to the complexity of γ-secretase complex its expression was 
not quantified. 
Confirming  the  previously  reported  data,  the  EGb  761
®  treatment  did  not 
change the expression of either BACE or ADAM-10. This is in accordance 
with the reported data that ADAM-10 and ADAM-17 protein levels were not 
altered in rats after EGb 761
® treatment (Colciaghi et al. 2004). The recent 
findings  of  Augustin  et  al  concur  with  our  observations,  where  BACE-1 
mRNA levels and enzyme activity as well as ADAM-10 mRNA and protein 
levels were unchanged in Tg2576 mice after EGb 761
® treatment (Augustin et 
al.  2008;Augustin  et  al.  2009).  Interestingly,  there  existed  an  inverse 
relationship between the Hu APP and the levels of both BACE and ADAM in Discussion 
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the  placebo  group,  that  didn’t  exist  anymore  after  EGb  761
®  treatment. 
Indicating when the levels of BACE and ADAM in the mouse brain were low 
the amount of Hu APP present was high, obviously due to less processing and 
vice versa. In the EGb 761
® treated mice this relationship did not exist any 
more since EGb 761
® treatment decreases the levels of Hu APP and does not 
alter  the  levels  of  the  β-secretase  or  α-secretase.  Therefore,  EGb  761
® 
treatment  decreases  APP  levels  but  does  not  increase  its  processing. 
Accordingly, the first assumption that EGb 761
® may shift the cleavage of C-
99  fragment  towards  Aβ  40  formation  and  prevents  its  accumulation  and 
aggregation  still  seems  the  most  reasonable  justification.  In  addition  EGb 
761
® decreases the availability of APP for further formation of Aß. 
In  order  to  form  a  complete  picture  of  EGb  761
®  intervention  in  Aβ 
production and trafficking, the Aß degrading enzymes were then taken into 
consideration. 
The 3 major enzymes that have been reported with Aß metabolizing activities 
are IDE, NEP and ECE. The expression levels of IDE, NEP and ECE were 
unaltered by EGb 761
® treatment. Therefore it seems that EGb 761
® does not 
influence the breakdown or cleavage of Aβ protein. There are no previous 
data  in  the  literature  addressing  this  issue,  however  very  recently  a  study 
confirmed the observations with NEP, where Tg 2576 mice showed unaltered 
expression levels of NEP after both short-term and long-term treatment with 
EGb 761
® (Augustin et al. 2008). 
Associating the levels of Aβ with NEP, IDE and ECE-1, one notices that only 
in the EGb 761
® treated group, NEP, ECE-1 and IDE correlate significantly 
and negatively with Aβ 40. Additionally, IDE is also negatively proportional 
to  Aβ  42  in  the  EGb  761
®  treated  group  only.  Although  an  inverse 
relationship between Aß levels and the degrading enzymes was previously 
reported, this was not the case in our placebo-treated mice. For example, an 
inverse relationship was observed between NEP mRNA levels and both Aß Discussion 
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plaques  and  Aß  levels  (Wang  et  al.  2006).  In  this  study,  the  negative 
correlation was noticed only in the EGb 761
® treated mice although the levels 
of  the  enzymes  and  the  total  Aβ  levels  were  not  altered  by  EGb  761
® 
treatment. The correlation was significant and more pronounced between Aβ 
40 and the enzymes in the EGb 761
® treated mice. Although no correlation 
exists  in  the  placebo  treated  group,  a  statistical  comparison  between  the 
correlations of the placebo-treated and the EGb 761
® treated mice does not 
yield significant difference. Nevertheless, the p values are 0.054, 0.065 and 
0.075  for  the  correlations  NEP/Aß  40,  IDE/Aß  40  and  IDE/  Aß  42 
respectively.  Owing  to  the  small  sample  size,  care  must  be  taken  in 
interpreting these correlations; however EGb 761
® may possibly affect the 
relationship between some of the Aß degrading enzymes and Aß protein. A 
hypothesis which would require further verification is that although EGb 761
® 
doesn’t alter the mRNA levels of NEP, IDE or ECE in the transgenic mice, 
EGb 761
® may alter their activities without altering their expression. Since it 
has been reported that these enzymes cleave mainly Aβ monomers, and EGb 
761
®  either  increases  these  monomers  and/or  prevents  their  aggregation. 
Therefore one may expect that the activities of these enzymes increase after 
EGb 761
® treatment due to the presence of more monomers. Consequently, 
the  mice  which  express  more  enzymes,  their  activities  would  be  more 
enhanced by EGb 761
® treatment than mice expressing lower RNA levels. 
For example, a mouse expressing high levels of NEP would show higher NEP 
activity due to the increase in Aß monomers after EGb 761
® treatment. This 
would increase the cleavage of Aß, decrease its value and therefore a negative 
correlation  would  exist.  However  this  hypothesis  needs  to  be  verified  by 
measuring  the  activities  of  these  enzymes  before  and  after  EGb  761
® 
treatment. 
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Conclusion: 
EGb 761
® decreases the availability of APP for processing into Aß. Further 
splicing  of  the  already  present  C-99  fragment  by  γ-secretase  is  continued, 
however with a tendency of forming more Aß 40 than Aß 42.  EGb 761
® also 
seems to prevent the further aggregation of Aß monomers, and may enhance 
its  clearance  by  enhancing  its  secretion.  This  maybe  augmented  by  the 
regulation of both  RAGE  and  LRP-1  expression levels  (Yan  et al. 2008). 
Enhancement of the activities of the Aß degrading enzymes could be another 
possible clearance mechanism which requires further verification. 
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Figure 5-6 
Summary of the effects of EGb 761
® on Aß Summary 
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6 Summary 
The utilization of Ginkgo biloba in medicinal practice dates back to 1505 
A.D. Ironically, the mechanisms of action of Ginkgo are not fully clarified till 
now. Nowadays, Ginkgo biloba leaf extracts are mainly indicated for mild to 
moderate cerebrovascular insufficiency and different forms of dementia. The 
fact  that  it  is  an  herbal  extract  composed  of  several  different  components 
indeed  adds  to  the  intricacy  of  finding  its  mechanisms  of  actions. 
Indisputably, many scientists tried to elucidate the mechanisms of actions of 
Ginkgo. The first step to achieve this goal was to standardize the leaf extract. 
The standardized Ginkgo leaf extract contains 22-27 % flavonol glycosides, 
2.8-3.4 % of ginkgolide A, B and C, as well as approximately 2.6-3.2 % 
bilobalide  and  below  5  ppm  ginkgolic  acids.  A  widespread  standardized 
Ginkgo extract is the EGb 761, which was utilized in the current work. 
One of the earliest proposed mechanisms is the ability of the Ginkgo extract 
to  act  as  an  anti-oxidant,  which  could  be  explained  by  its  high  flavonoid 
contents. However, without doubt EGb 761 encompasses other characteristics 
which distinguish it from other herbal extracts that are also rich in flavonoids. 
Since free radicals and reactive oxygen species are highly associated with the 
mitochondrial  functions,  examination  of  the  effect  of  EGb  761  on 
mitochondrial functions was lately addressed. Moreover, this was encouraged 
as the link between Alzheimer’s disease [AD] and the mitochondria started to 
emerge. Previously, our group observed mitochondrial protective actions of 
EGb  761 on cell  culture in vitro.  Furthermore,  anti-apoptotic  effects  were 
previously described for EGb 761. 
However, only very few studies addressed the single constituents and their 
effect on mitochondrial functions. Flavonoids were studied in several other 
plant extracts and their radical scavenging activity is unquestionable, but EGb 
761  has  anti-apoptotic  actions  which  may  be  attributed  to  its  terpenoid Summary 
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fraction.  Exclusively  found  in  the  Ginkgo  plant,  are  the  ginkgolides  and 
therefore  their  actions  are  not  yet  fully  elucidated.  Moreover,  those  who 
attempted to address these constituents concentrated on one or two candidates, 
for example bilobalide or ginkgolide B and ignored the rest. Unfortunately, 
this led to incomplete results, and one couldn’t compare the relative activities 
of all EGb 761 components in order to state whether all the components are 
effective or not. 
Therefore, the first goal of the current work was to try to identify the relative 
mitochondrial activities of the single components of EGb 761 using the same 
model as well as identical parameters and conditions. Dissociated brain cells 
prepared from mice were chosen as a suitable in vitro model for this study and 
mitochondrial  functions  were  assessed  using  MTT  viability  test, 
mitochondrial membrane potential and ATP levels. Moreover, two different 
treatment schemes as well as external stress were applied to the cells. 
However, before testing the different constituents in vitro, the effect of the 
whole extract EGb 761 was examined as a reference. This was performed not 
only in vitro in DBCs prepared from young and old mice, but also ex vivo 
after a 14 days treatment with EGb 761 in young, old and APP transgenic 
mice.  Here  again  external  stress  was  applied  and  mitochondrial  functions 
were evaluated by measuring the above mentioned parameters. 
The current work was able to confirm that EGb 761 enhances mitochondrial 
properties in general, but its effect is pronounced in impaired, aged and/or 
damaged mitochondria specifically. Looking at its different components, it 
appears that they act in a complementary manner. That is to say, both the 
flavonoid and the terpenoid fractions are able to protect the mitochondria but 
in different approaches. Not only the mechanism of action of the flavonoid 
fraction  is  different  than  that  of  the  terpenes,  but  also  there  exists  major 
differences  in  the  actions  of  the  terpenes.  Furthermore,  according  to  the 
conditions  and  treatment  schemes  their  relative  activities  differed Summary 
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significantly. For example, in the first scheme pre-treatment with ginkgolide 
A  did  not  alter  any  of  the  measured  mitochondrial  parameters.  However, 
surprisingly  in  post-treatment  ginkgolide  A  was  able  to  enhance 
mitochondrial membrane potential, ATP levels and cell viability after nitric 
oxide  [NO]  induced  insult.  Both  pre-  and  post-treatment  studies  gave  the 
impression that the flavonoid fraction is the most protective fraction against 
NO induced mitochondrial insult. The ginkgolides appear to be more efficient 
in regenerating the mitochondria after damage than in scavenging the radicals. 
In the applied cell model ginkgolide J was the least effective, albeit its ability 
to increase mitochondrial membrane potential in post-treatment. In the present 
study  the  components  of  EGb  761  acted  in  a  complementary  matter,  to 
achieve the observed effects of the EGb 761 extract.  
Although these results are promising and give an indication of the relative 
efficacy of the single constituents in protecting the mitochondria, it should be 
taken into consideration that this work although carried on mice brain cells, 
was in vitro. An in vivo study could unveil even more promising and precise 
outcomes  concerning  the  mechanisms  of  action  of  EGb  761  and  its 
constituents. 
In the current work, it was observed that EGb 761 is more effective in aged 
mice or transgenic mice. Therefore a long-term assessment of EGb 761 in 
aging mice was carried out. To evaluate the long-term effects of EGb 761 on 
mitochondrial  function  during  aging,  a  special  mouse  model  was  chosen. 
Senescence accelerated prone mice [SAMP8] which age rapidly acquiring age 
related cognitive impairment, accumulation of oxidative stress and deposition 
of  amyloid  beta  [Aß]  as  well  as  senescence  accelerated  resistant  mice 
[SAMR1] were selected. SAMP8 mice were fed with EGb 761 for 5 months 
or placebo and membrane fluidity, which is another important parameter that 
plays a role in aging and cognition, was evaluated in addition to mitochondrial 
functions. The mitochondrial membrane potential and ATP levels were found Summary 
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to be lower in the SAMP8 mice compared to the SAMR1 mice and EGb 761 
treatment  was  able  to  alleviate  the  mitochondrial  dysfunction.  Moreover, 
membrane  fluidity  was  increased  after  EGb  761  treatment.  Increasing 
membrane  fluidity  was  previously  linked  to  memory  enhancements  and 
improving cognition. In addition, decreased membrane fluidity was reported 
in  hippocampal  synaptosomes  in  AD  brains,  which  could  be  related  to 
decreasing the amyloidogenic processing of APP and thereby the formation of 
Aß. 
The  focus  of  the  project  was  then  directed  towards  the  link  between  the 
protective properties of EGb 761 in relation to AD and in particular to Aß. 
This  was  based  on  the  findings  that  EGb  761  enhances  mitochondrial 
properties and membrane fluidity and knowing that recent research relates 
both of these parameters to APP processing and Aß formation. 
Consequently, Aß production in transgenic Hek-sw cells was assessed after in 
vitro treatment with EGb 761. Noticing an unexpected increase in the levels 
of extracellular soluble Aß after EGb 761 treatment, the in vivo influence of 
EGb  761  was  examined  in  a  transgenic  mice  model.  Tg-APP  mice  over-
express mutant human APP and accordingly develop high levels of Aß. Tg-
APP mice were treated for 21 days with EGb 761 followed by evaluation of 
Aß  levels  in  their  brains.  Moreover,  the  influence  of  EGb  761  on  Aß 
production and breakdown was studied on the genomic level, by evaluating 
the mRNA levels of the genes involved in making and breaking Aß. 
The increase in the levels of soluble Aß 40 was confirmed in the EGb 761 
treated mice. However the total Aß level was not altered compared to the 
placebo group. Interestingly, the mRNa levels of APP decreased significantly 
after EGb 761 treatment, but the levels of the Aß degrading enzymes [NEP, 
IDE and ECE-1] were not altered after treatment. Nevertheless a negative 
relationship occurred between the Aß levels and the mRNA levels of the Aß 
degrading enzymes in the EGb 761 treated mice only. Summary 
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From these observations together with present data in the literature one may 
presume that EGb 761 decreases the availability of APP for further processing 
into Aß. The C-99 fragment is cleaved with a tendency of forming more Aß 
40.  The  clearance  of  Aß  is  enhanced  by  EGb  761  thereby  preventing  its 
accumulation and further aggregation. This may be either via regulating the 
transport of Aß in and out of the brain, through the RAGE and LRP. Another 
possible clearance mechanism which requires further confirmation could be 
the ability of EGb 761 to enhance the activities of the Aß degrading enzymes. 
In conclusion, the current project contributed the following to research in the 
field of AD prevention and treatment with EGb 761: [1] EGb 761 improves 
mitochondrial abnormalities which occur during aging and AD development. 
[2] The constituents of EGb 761 act in a complementary manner achieving 
together the full effect of the extract. [3] Long-term treatment with EGb 761 
is  beneficial  in  preventing  age-related  mitochondrial  abnormalities  and 
increases  membrane  fluidity.  [4]  APP  processing  and  Aß  formation  and 
aggregation,  which  play  a  major  role  in  AD,  are  influenced  by  EGb  761 
treatment in transgenic models. 
 Zusammenfassung 
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7 Zusammenfassung 
Die  frühesten  Aufzeichnungen  über  die  medizinische  Verwendung  von 
Ginkgo  biloba gehen  auf das  Jahr 1505  n.Chr.  zurück.  Trotzdem  sind  die 
Wirkmechanismen  des  Ginkgos  bis  heute  noch  nicht  vollständig  geklärt. 
Heutzutage  werden  Extrakte  aus  Ginkgo-biloba-Blättern  hauptsächlich  zur 
Behandlung  von  leichten  bis  moderaten  Hirnleistungsstörungen  und 
verschiedenen  Formen  der  Demenz  eingesetzt.  Die  Tatsache,  dass  es  sich 
hierbei um einen pflanzlichen Extrakt, bestehend aus vielen verschiedenen 
Komponenten,  handelt,  erschwert  die  Aufklärung  der  Wirkmechanismen 
erheblich.  Zweifelsohne  wurden  zahlreiche  Versuche  unternommen,  diese 
Mechanismen  wissenschaftlich  zu  ergründen.  Eine  wesentliche 
Voraussetzung  hierfür  war  die  Standardisierung  des  Extrakts  aus  den 
getrockneten  Blättern.  Der  in  dieser  Arbeit  verwendete,  weit  verbreitete 
standardisierte Ginkgoextrakt EGb 761 enthält 22-27 % Flavonolglykoside, 
2.8-3.4 % Ginkgolide A, B und C, sowie 2.6-3.2 % Bilobalid und weniger als 
5 ppm Ginkgolsäuren. 
Einer  der  ersten  Ansätze  zur  Aufklärung  des  Mechanismus  des 
Ginkgoextrakts  beschreibt  seine  anti-oxidativen  Eigenschaften,  was 
hauptsächlich  dem  hohen  Flavonoidgehalt  zugeschrieben  werden  kann. 
Allerdings weist EGb 761 zweifellos darüber hinaus weitere Eigenschaften 
auf,  welche  ihn  von  anderen  pflanzlichen  Extrakten  mit  ebenfalls  hohem 
Flavonoidgehalt unterscheiden. Mitochondriale Funktionen stehen in engem 
Zusammenhang  mit  der  Bildung  von  freien  Radikalen  und  reaktiven 
Sauerstoffspezies. In diesem Zusammenhang deuten erste Erkenntnisse auf 
eine Schlüsselfunktion der Mitochondrien in der Pathogenese der Alzheimer-
Demenz. Vor diesem Hintergrund rückte in letzter Zeit die Wirkung des EGb 
761 auf die mitochondrialen Funktionen zunehmend in den Mittelpunkt des 
Interesses. Eine mitochondrien-protektive Wirkung von EGb 761 konnte von Zusammenfassung 
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unserer  Arbeitsgruppe  bereits  in  in  vitro  Zellversuchen  gezeigt  werden. 
Ebenso wurden anti-apoptotische Effekte für EGb 761 beschrieben. 
Allerdings beschäftigten sich nur sehr wenige Studien mit der Wirkung der 
Einzelkomponenten  auf  die  mitochondriale  Funktion.  Die  Radikalfänger-
Eigenschaften  der  Flavonoide,  bereits  in  zahlreichen  anderen  pflanzlichen 
Extrakten untersucht, stehen außer Frage. EGb 761 weist jedoch auch anti-
apoptotische  Eigenschaften  auf,  die  auf  die  Terpenfraktion  zurückgeführt 
werden können. Ginkgolide, deren Wirkung noch nicht vollständig aufgeklärt 
ist,  sind  ausschließlich  in  Ginkgo  vorzufinden.  Bisherige  Studien  zu 
Ginkgoliden konzentrierten sich weitestgehend auf ein oder zwei Substanzen, 
wie beispielsweise das Bilobalid oder Ginkgolid B. Dies führte einerseits zu 
unvollständigen Ergebnissen und machte es auf der anderen Seite unmöglich 
die Wirkpotenz aller EGb 761 Komponenten eindeutig zu belegen. 
Die  hier  vorliegende  Arbeit  hatte  somit  als  primäres  Ziel,  die  relativen 
mitochondrialen Schutzeffekte der Einzelkomponenten des EGb 761 Extrakts 
unter Verwendung eines einheitlichen Modells sowie einheitlicher Parameter 
und Bedingungen zu bestimmen. Dissoziierte Hirnzellen von Mäusen wurden 
als geeignetes in vitro Modell für diese Studie gewählt. Die mitochondrialen 
Funktionen  wurden  anhand  des  MTT-Viabilitätstests,  des  mitochondrialen 
Membranpotentials sowie des ATP-Spiegels ausgewertet. Hierzu wurden die 
Zellen  mit  den  Einzelkomponenten  in  zwei  unterschiedlichen  Dosierungen 
inkubiert sowie externem Stress ausgesetzt.  
Im Vorfeld zu den in vitro Tests der Einzelkomponenten wurde die Wirkung 
des  Gesamtextrakts  EGb  761  als  Referenz  bestimmt.  Untersuchungen  mit 
dem Gesamtextrakt wurden nicht nur in vitro an dissoziierten Hirnzellen von 
jungen  und  alten  Mäusen  sondern  auch  ex  vivo  nach  einer  14-tägigen 
Behandlung mit EGb 761 von jungen und alten Mäusen sowie von transgenen 
Mäusen  für  mutierten  humanen  Amyloid  Precursor  Protein  durchgeführt. Zusammenfassung 
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Auch  hier  wurde  externer  Stress  angewandt  und  die  mitochondrialen 
Funktionen anhand der oben beschriebenen Parameter erfasst. 
Im Allgemeinen konnte die vorliegende Arbeit die positive Wirkung des EGb 
761  auf  die  mitochondrialen  Funktionen  belegen,  wobei  der  Effekt  in 
gestörten und/oder älteren Mitochondrien deutlicher sichtbar war. Bei näherer 
Betrachtung der unterschiedlichen Komponenten scheint es sich hierbei um 
eine  komplementäre  Wirkung  zu  handeln.  So  vermögen  sowohl  die 
Flavonoid-  als  auch  die  Terpenfraktion  eine  protektive  Wirkung  auf 
Mitochondrien  auszuüben,  allerdings  auf  unterschiedlicher  Weise.  So 
unterscheiden sich nicht nur der Wirkungsmechanismus der Flavonoidfraktion 
von  dem  der  Terpene,  sondern  auch  die  Wirkungen  der  Terpene 
untereinander.  Darüber  hinaus  wurden  signifikant  unterschiedliche  relative 
Aktivitäten  in  Abhängigkeit  von  Dosierung  und  Versuchsbedingungen 
festgestellt.  So  führte  bei  der  ersten  Dosierung  eine  Vorbehandlung  mit 
ginkgolide  A  zu  keiner  Änderung  der  mitochondrialen  Parameter, 
wohingegen  eine  Nachbehandlung  mit  ginkgolide  A  das  mitochondriale 
Membranpotential, die ATP-Spiegel und die Zellviabilität nach nitrosativer 
Stress  [NO]  erhöhte.  Sowohl  die  Vor-  als  auch  Nachbehandlungsstudien 
weisen auf eine stärkere protektive Wirkung der Flavonoidfraktion bei NO 
induziertem, mitochondrialem Sress hin. Ginkgolide hingegen erweisen sich 
in  der  Regenerierung  von  Mitochondrien  als  effizienter  als  in  der 
Neutralisation  von  freien  Radikalen.  In  dem  angewandten  Zellmodell  war 
ginkgolide J, trotz seiner Fähigkeit das mitochondriale Membranpotential bei 
Nachbehandlung  zu  erhöhen,  am  schwächsten  wirksam.  Die  in  der 
vorliegenden Studie beobachteten Effekte des EGb 761 Extrakts sind daher 
auf eine komplementäre Wirkung der Einzelkomponenten zurückzuführen. 
Obwohl es sich hierbei um vielversprechende Ergebnisse handelt, die auf eine 
relative  Wirksamkeit  der  Einzelkomponenten  bei  der  Protektion  von 
Mitochondrien hindeuten, sollte man bedenken, dass diese Versuche in vitro Zusammenfassung 
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an Mäusehirnzellen durchgeführt wurden. Eine in vivo Studie könnte noch 
vielversprechendere  und  präzisere  Ergebnisse  hinsichtlich  der 
Wirkmechanismen von EGb 761 und seiner Einzelkomponeten liefern. 
Im Rahmen der vorliegenden Arbeit wurde eine höhere Wirksamkeit von EGb 
761 in älteren Mäusen oder den transgenen Mäusen beobachtet. Vor diesem 
Hintergrund wurde eine Langzeitstudie mit EGb 761 an alternden Mäusen 
durchgeführt. Um die Langzeitwirkung des EGb 761 auf die mitochondriale 
Funktion während des Alterungsprozesses zu evaluieren, wurde ein spezielles 
Mausmodell  ausgewählt.  SAMP-8  Mäuse  [senescence  accelerated  prone 
mice], die eine schnelle Alterung mit entsprechend altersbedingten kognitiven 
Beeinträchtigungen, erhöhtem oxidativem Stress und Ablagerungen von Aß 
zeigen, sowie Seneszenz resistente SAMR1-Mäuse [senescence accelerated 
resistant mice] wurden in die Studie mit einbezogen. SAMP-8 Mäuse wurden 
für  5  Monate  mit  EGb  761  oder  Placebo  gefüttert.  Zusätzlich  zu  den 
mitochondrialen Funktionen wurde auch die Membranfluidität bewertet, die 
als  weiterer  wichtiger  Parameter  eine  große  Rolle  bei  Alterungs-  und 
Wahrnehmungsprozessen spielt. Im Vergleich zu SAMR-1 Mäusen waren in 
SAMP-8 Mäusen das mitochondriale Membranpotential und die ATP-Spiegel 
niedriger.  Die  Behandlung  mit  EGb  761  konnte  diese  mitochondrialen 
Funktionsstörungen  lindern.  Des  Weiteren  wurde  eine  höhere 
Membranfluidität nach EGb 761 Behandlung festgestellt, was entsprechend 
früherer  Erkenntnisse  in  direktem  Zusammenhang  mit  einer  verbesserten 
Gedächtnis-  und  Wahrnehmungsleistung  steht.  Eine  erniedrigte 
Membranfluidität  in  hippocampalen  Synaptosomen  von  AD  Hirnen  wurde 
von unsere Arbeitsgruppe vor einiger Zeit berichtet, die auf eine reduzierte 
amyloidogene Prozessierung von APP und eine damit erhöhte Bildung von 
Aß zurückzuführen ist. Der weitere Fokus der vorliegenden Arbeit richtete 
sich daher auf den Zusammenhang zwischen den protektiven Eigenschaften 
des EGb 761 unter besonderer Berücksichtigung von Aß. Als Basis dienten Zusammenfassung 
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die  Erkenntnisse  über  die  positiven  Wirkungen  des  EGb  761  auf  die 
Membranfluidität  und  die  mitochondrialen  Funktionen  sowie  bereits 
vorliegende Forschungsergebnisse, die diese beiden Parameter mit der APP-
Prozessierung und Aß Bildung korrelierten.  
Infolgedessen  wurde  die  Aß  Bildung  in  transgenen  Hek-sw  Zellen  nach 
Inkubation mit EGb 761 in vitro evaluiert. Basierend auf dem unerwarteten 
Anstieg des extrazellulären löslichen Aß nach Inkubation mit EGb 761, wurde 
der in vivo Einfluss von EGb 761 im transgenen Mausmodel untersucht. Tg-
APP  Mäuse  exprimieren  mutantes  humanes  APP  im  Überschuss  und 
entwickeln  damit  hohe  Spiegel  an  Aß.  Im  Anschluss  an  eine  21-tägige 
Behandlung von Tg-APP Mäusen mit EGb 761 wurden die Aß Spiegel im 
Hirn  bestimmt.  Zusätzlich  wurde  der  Einfluss  von  EGb  761  auf  die 
Produktion und den Abbau von Aß auf Gen-Ebene untersucht. Hierzu wurden 
die mRNA-Spiegel der Gene, die an dessen Bildung und Beseitigung beteiligt 
sind, evaluiert.  
Die Erhöhung des löslichen Aß 40-Spiegels konnte in EGb 761 behandelten 
Mäusen  bestätigt  werden.  Hingegen  wurde  der  Gesamt-Aß-Spiegel  im 
Vergleich zur Placebogruppe nicht verändert. Interessanterweise wurden die 
mRNA-Spiegel  von  APP  erheblich  reduziert,  während  der  Spiegel  der  Aß 
abbauenden  Enzyme  [NEP,  IDE  and  ECE-1]  nach  der  Behandlung 
unverändert blieb. Nichtsdestotrotz wurde lediglich in EGb 761 behandelten 
Mäusen ein umgekehrt proportionaler Zusammenhang zwischen den Aß- und 
mRNA-Spiegeln festgestellt.  
Auf  der  Basis  dieser  Beobachtungen  und  vorhandener  Literaturdaten  kann 
man argumentieren, dass EGb 761 die Verfügbarkeit von APP für die weitere 
Prozessierung zu Aß verringert. Nach Abspaltung des C-99 Fragment kommt 
es tendenziell zu einer verstärkten Bildung von Aß 40. Die Eliminierung von 
Aß  und  die  damit  einhergehende  Verringerung  seiner  Akkumulation  und 
weiteren Aggregation werden durch EGb 761 begünstigt. Dies kann einmal Zusammenfassung 
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durch die Regulierung des Transports von Aß in und aus dem Gehirn mittels 
RAGE und LRP erreicht werden. Ein weiterer Eliminierungsmechanismus, 
der allerdings noch bestätigt werden muss, könnte auf der Fähigkeit von EGb 
761 beruhen, die Aktivität von Aß abbauenden Enzymen zu stimulieren.  
Zusammenfassend hat die vorliegende Arbeit mit folgenden Erkenntnissen für 
die Forschung auf dem Gebiet der AD Prävention und Behandlung mit EGb 
761 beigetragen: [1] EGb 761 verbessert mitochondriale Funktionsstörungen, 
die  während  des  Alterungsprozesses  und  einer  möglichen  Alzheimer 
Erkrankung  auftreten.  [2]  Die  Gesamtwirkung  des  Extrakts  ist  auf  eine 
komplementäre  Wirkung  der  Einzelkomponenten  zurückzuführen.  [3]  Eine 
Langzeit-Behandlung mit EGb 761 ist für die Prävention von altersbedingten 
mitochondrialen  Abnormalitäten  sowie  für  die  Erhöhung  der 
Membranfluidität vorteilhaft. [4] APP-Prozessierung sowie Aß Bildung und 
Aggregation,  welche  eine  wesentliche  Rolle  in  der  Alzheimer  Demenz 
spielen,  können  durch  Behandlung  mit  EGb  761  in  transgenen  Maus-und 
Zellmodellen beeinflusst werden. References 
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Language Proficiency 
·  Arabic: Mother tongue 
·  English: Fluent 
·  German: Fluent spoken and good written 
·  French: Fair 
 
Personal Interests 
·  Traveling 
·  Hiking 
·  Gym 
·  Reading 
·  Badminton 
 
Personal Information 
·  Date of Birth: 2/4/1980 
·  Nationality: Egyptian 
·  Place of Birth: Cairo, Egypt Appendix 
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